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1 Abstract 
Abstract 
Primary open angle glaucoma, a neurodegenerative disease of the optic nerve (ON), is 
one of the leading cause of blindness worldwide (Quigley 1996). In progression of the 
disease the optic nerve head (ONH) undergoes marked structural extracellular matrix 
changes (ECM), which lead to its permanent deformation and can contribute to the 
degeneration of ON axons. The changes in ECM in the ONH correlate with an increased 
reactivity of astrocytes. An intraocular pressure (IOP), which is too high for the health of 
the ON axons, was identified as the major risk factor for the development for the POAG 
(Collaborative-Normal-Tension-Glaucoma-Study-Group, 1998; The AGIS 
Investigators2000; Gordon et al. 2002; Lichter et al., 2001; Johnson et al., 2002; Kass et 
al. 2002; Leske et al., 2003). In POAG the homeostatic balance of different growth 
factors, affecting the resistance of the outflow pathway is altered (Inatani et al. 2001, Min 
et al. 2006, Ochiai & Ochiai 2002, Ozcan et al. 2004, Picht et al. 2001, Tripathi et al. 
1994, Trivedi et al. 2011). In the last years, the Connective Tissue Growth Factor (CTGF) 
came into focus as a lens-specific overexpression of CTGF in the mice results in an 
elevated IOP and a significant progressive loss of retinal ganglion cell (RGC) axons over 
time (Junglas et al., 2012). CTGF is a member of matricellular regulatory proteins and 
downstream mediator of Transforming Growth Factor β2, and is involved in many 
different functions, like migration, adhesion, differentiation and ECM production. By its 
modular organization CTGF can arrange various interactions with different growth 
factors, integrins and ECM proteins. In this study we investigated the involvement of 
CTGF during eye development and the pathology of POAG. The effect of alterations in 
substratum stiffness on an increased astrocyte reactivity and the implication of possible 
mechanosensors was analyzed. The final aspect of the study was to develop siRNA 
coated NP for specific delivery to the AH outflow pathway tissue and cells. 
During eye development CTGF is expressed in various eye structures. In early 
embryonic development an expression in the outer and inner layer of the optic cup as 
well as the lens vesicle was observed. In the following embryonic and postnatal 
developmental stages, CTGF expression was detected in tissues of the anterior eye 
segment like corneal endothelium, epithelium and stroma, in the TM and ciliary body. In 
the posterior eye segment an expression could be found in the retina, choroidea, sclera, 
ONH and dura mater. During the development of the eye CTGF expression showed 
tissue specific changes in the cornea, the ciliary body, the retina, the ONH and the dura 
mater, whereas the expression the TM remained constantly high. The characterization 
of the CTGF expressing cells types revealed that the trabecular meshwork cells, Müller 
cells, amacrine cells, ON astrocytes and endothelial cells of the SC and of the retinal and 
choroidal vasculature, were the source of the CTGF signal. An important role for CTGF 
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in the correct formation of astrocytic morphology in the retina and the ONH could be 
shown in CTGF conditional knockdown mice. 
Beside the involvement of CTGF in developmental processes a correlation between 
CTGF expression and pathological changes in the murine glaucoma model was 
observed. An increased astrocyte reactivity was associated with an enhanced CTGF 
synthesis in the ONH related to the chronic elevated IOP, whereas none of those 
changes were observed in the adjacent parts of the ON. Interestingly, cultured murine 
ON astrocytes could sense changes in stiffness of the surrounding ECM causing the 
same changes like in the in vivo glaucoma model. The analysis of mechanosensitive ion 
channels showed a broad spectrum of expression changes dependent on the substratum 
stiffness, but the most promising changes were seen in Caveolin expression. An 
enhanced Caveolin synthesis in ON astrocytes was detected on increasing substratum 
stiffness and after treatment with CTGF and TGF-β2 in vitro and in the ONH of the murine 
glaucoma model.  
Layer-by-layer coated NPs were designed and successfully delivered by anterior 
chamber perfusion to the outflow pathway tissues of porcine and human eyes. CD44 
was identified as an ideal target for HA coated NPs, as CD44 is permanently present in 
cultured HTM cells, in the anterior chamber angle of murine and human donor eyes. The 
implication of CD44 in POAG could be shown by the enhanced expression in 
glaucomatous SC cells and the anterior chamber angle of human glaucomatous donor 
eyes. Finally, siRNA coated NP’s could successfully reduce CTGF synthesis in HTM 
cells in vitro.  
We observed that CTGF is highly expressed in various ocular structures and we 
conclude that CTGF plays an essential role in the formation of astrocyte structures during 
development. Further we state that astrocyte reactivity induced by increasing stiffness of 
their surrounding matrix lead to increased levels of CTGF, which in turn contribute to the 
changes in ECM observed in POAG. Furthermore, the results of this study indicate that 
siRNA delivery to the AH outflow pathway tissue and cells based on HA-coated NPs 
could have a great potential in treatment of POAG.  
 
 
 
 
 
3 1. Introduction 
1. Introduction 
Glaucoma, a neurodegenerative disease of the optic nerve (ON), is one of the leading 
causes of blindness worldwide (Quigley 1996). Within the heterogenous group of disease 
the Primary Open Angle Glaucoma (POAG) is the most common form (Tham et al. 2014). 
An intraocular pressure (IOP), which is too high for the health of the ON axons, was 
identified as the major risk factor for the development of POAG (1998, 2000, Gordon et 
al. 2002, Johnson et al. 2002, Kass et al. 2002, Leske et al. 2003, Lichter et al. 2001) In 
recent years, the Connective Tissue Growth Factor (CTGF) came into focus as a lens-
specific overexpression of CTGF in mice results in an elevated IOP and a significant 
progressive loss of Retinal Ganglion Cell (RGC) axons over time (Junglas et al. 2012)). 
These investigations point out that CTGF is a crucial player in the pathogenesis of POAG 
and can function as point of action to develop therapeutic approaches for treatment to 
reduce IOP in POAG. CTGF (also known as CCN2) is a member of matricellular regula-
tory proteins, which also includes Cyr61, NOV, WISP1, WISP2 and WISP3 (Bork 1993, 
Dockrell et al. 2009, Moussad & Brigstock 2000, Perbal 2004) The several proteins of 
this family have a 40-60% sequence homology and are characterized by four highly con-
served domains. Module 1 is an insulin-like growth factor (IGF) – binding domain, module 
2 is a von Willebrand type C domain (Bork, 1993), module 3 is a thrombospondin – 1 
domain and module 4 is a C-terminal domain containing a putative cysteine knot (Groten-
dorst et al. 1996) . The CCN proteins are associated with the ECM and are involved in 
many biological processes, like adhesion, proliferation, differentiation, apoptosis, pro-
duction of the ECM, migration and angiogenesis (Brigstock 2003) . CTGF acts primarily 
on the expression of ECM proteins and the organization of the actin cytoskeleton 
(Heusinger-Ribeiro et al. 2001)  and can arrange various interactions with growth factors, 
integrins and ECM components (Abreu et al. 2002, Bork 1993, Bornstein 2001, Lau & 
Lam 1999) . By its modular organization CTGF can arrange various interactions with 
different growth factors, integrins and ECM proteins (Abreu et al. 2002, Dudley et al. 
1995, Furuta & Hogan 1998, Jena et al. 1997, Luo et al. 1995, Sanford et al. 1997, 
Wawersik et al. 1999). Since CTGF has a broad range of functions within the cellular 
arrangement, it is of huge interest to identify it defined role in development and mainte-
nance of ocular structures in order, to exclude side effects of potential CTGF reducing 
POAG treatments. 
1.1. Mouse eye development 
1.1.1. Embryonic mouse eye development 
For an ideal function of the eye, particularly of the retina, which transduces the light into 
electrical signals, the individual tissues in the eye follow a defined morphogenesis and 
development to ensure an optimal function. The development of the mouse eye starts 
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shortly after gastrulation, identifiable by first visible signs of the eye field (Adelmann HB 
1929, Li et al. 1997, Wilson & Houart 2004).The eye primordium is defined in the medial 
anterior neural plate, comprising all progenitors of neural-derived eye structures (Li et al. 
1997, Wilson & Houart 2004, Zaghloul et al. 2005).As a first step of eye morphogenesis, 
the walls of the diencephalon evert at E 8.5-9.0, to form the optic vesicles resulting in a 
close contact with the surface ectoderm, to generate the lens placode (Spemann H.H. 
1901) (Figure 1-1 A, B). The optic vesicle forms the lens vesicle and the bilayered optic 
cup (Pei & Rhodin 1970) (Figure 1-1 C). The presumptive corneal epithelium, remaining 
a 1-2 cell layer until birth, is formed by the overlying surface ectoderm (Figure 1-2 A). 
The distal optic vesicle becomes the inner layer of the optic cup, the future neural retina 
and the proximal optic vesicle becomes the retinal pigmented epithelium (RPE). The 
layers of the optic cup are connected to the diencephalon by the optic stalk (Figure 1-1 
C).  
 
 
Figure 1-1: Schematic representation of vertebrate eye development. (A) Forming of the optic vesicle. (B) Generation 
of presumptive RPE, neural retina, optic stalk and lens placode. (C) Forming of the optic cup and lens vesicle. (D-E) 
Maturation of the optic cup. Lens vesicle becomes a robust structure. Optic stalk gives rise to the optic nerve and surface 
ectoderm gives rise to the cornea epithelium.: C: cornea; L: lens; LP: lens placode; LV: lens vesicle; MS: mesenchyme; 
NR: neural retina; ON: optic nerve; OS: optic stalk; OV: optic vesicle; RPE: retinal pigment epithelium; S: sclera; SE: 
surface ectoderm. (Adapted and modified from Adler and Canto-Soler, Molecular mechanisms of optic nerve vesicle 
development: Complexities, ambiguities and controversies) 
Forming the presumptive corneal stroma and endothelium, the neural crest-derived 
mesenchymal cells start to migrate between the surface ectoderm and the lens vesicle 
(Figure 1-2 B). Mesenchymal cells differentiate into corneal stroma keratocytes, which 
synthesize specialized extracellular matrix (ECM), like collagen and a variety of 
proteoglycans resulting in the transparence of the cornea (Figure 1-2 C). The formation 
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of the iris and the ciliary body starts with growing of the edge of the optic cup into the 
cavity between corneal endothelium and lens along the anterior lens surface.  
 
Figure 1-2: Initial steps of corneal development. (A) Forming of presumptive epithelium by the overlying surface 
ectoderm. (B) Mesenchymal cells migrate between the surface ectoderm and lens vesicle. (C) Mesenchymal cells 
differentiate to form the corneal endothelium and stroma. (Adapted from Zavala et al., 2013). 
The origins of iris and ciliary body are mesenchymal cells migrating into the anterior eye. 
The anterior and posterior chamber are constituted by the initial formation of the iris, 
which separates the cavity between lens and cornea. At the final stages of embryonic 
development, a distinct demarcation between developing iris and cornea and the 
formation of the ciliary body gives rise to the first appearance of the iridocorneal angle, 
between the iris root and the cornea (Figure 1-3 A, small angle recess depicted with a). 
Within the iridocorneal angle, the trabecular meshwork (TM) and the Schlemm’s canal 
(SC) develop in the postnatal period of eye development. The future location of the TM 
is already present at the later stages of embryonic development (Figure 1-3 A, arrow). 
 
1.1.2. Postnatal mouse eye development 
1.1.2.1. Postnatal development of the anterior eye structures 
In contrast to the human eye, the mouse eye is not completely developed at birth. The 
different eye structures are already existing, but lids are still closed, while iris, ciliary 
body, cornea, retina and TM are still immature (GYLLENSTEN & HELLSTROM 1954, 
Smith et al. 2001).Therefore, the maturation of the individual tissues take place during 
postnatal development.(Baulmann et al. 2002, 2002, Smith et al. 2001). The cornea is 
the outermost tissue of the eye. At birth, the three layers of the cornea are well defined. 
The corneal epithelium, providing the barrier to the external environment and protecting 
the eye from infectious agents, is 1-2 cell layers thick and proliferates rapidly within the 
first two weeks to form a 5-6 cell layered epithelium. The corneal stroma, composing 
90% of corneal thickness, exhibits the key component for corneal transparency with its 
collagenous lamellae orientated parallel to the corneal surface. It decreases in cell 
density during postnatal development. The corneal endothelium, a monolayer of 
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endothelial cells, forms the surface to the anterior chamber and is essential for hydration 
and nutrient supply from the aqueous humor (AH) for the corneal stroma. The specialized 
basement membrane of the corneal endothelium, the Descement’s membrane is first 
evident within the first days after birth.  
In comparison to the cornea, the other structures of the anterior eye segments undergo 
their main morphogenesis during the postnatal development. At birth the first appearance 
of the iridocorneal angle with densely packed mesenchyme and elongated and less 
rounded cells is determined. Some of the cells start to form the iris stroma and 
synthesizes pigment, which makes them distinguishable from the future TM (Figure 1-3 
B; depicted with arrow). By formation of the ciliary body, the iris and the ciliary body are 
separated and can be well defined within the first four days after birth (Figure 1-3 B, 
ciliary processes depicted with arrow; Figure 1-3 C; Smith et al., 2001). From postnatal 
day 2 (P2) to P4, the mesenchyme of the future TM is densely packed (Figure 1-3 C) 
(Smith et al. 2001). Within the dense mass of mesenchymal cells, the cells elongate in 
the region of the developing TM and small spaces are filled with extracellular fibers, 
which are orientated into lamellae and beams.  
 
Figure 1-3: Development of iridocorneal angel in mice. (A) At E16.5, a small angle recess is present (a) and the 
location of the future TM is visible (arrow). (B) At P0, the mesenchyme of iris and TM is distinguishable (arrow) and the 
ciliary body starts to form (arrowhead). (C) At P4, a long angle recess can be recognized, and iris and ciliary body are 
well formed. TM is depicted with arrows. (D) At P8, in the region of the TM the cells are more elongated and small spaces 
are filled with extracellular fibers (TM depicted with arrow). (Adapted from (Smith et al. 2001)).  
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For proper maturation of the TM the intertrabecular spaces must be opened up, involving 
morphogenesis of the mesenchyme mass, without cell death and atrophy (Figure 1-4 A; 
TM depicted with arrow; (Smith et al. 2001)). For generation of the SC the scleral blood 
vessels next to the iridocorneal angle combine to form the SC, which is in close contact 
to the TM. By P14, the SC (Figure 1-4 A; SC depicted with arrow) appears as a small 
lumen lined with endothelial cells (Figure 1-4 A; vascular structures depicted with 
arrowhead), followed by the presence of abundant giant vacuoles at P18. Finally, by P21 
the iridocorneal angle is fully developed. To increase the intertrabecular spaces the 
remodeling of ECM in the TM continues in the following weeks and is completed around 
seven weeks after birth.  (Figure 1-4) (Smith et al. 2001).  
 
Figure 1-4: Postnatal development and remodeling of iridocorneal angel in mice. (A) At P14, the SC (arrow) is 
evident and contains vascular structures (arrowhead). The developing ciliary muscle is present (open arrow) and a deep 
angle recess can be observed (a). (B) At P21, the development of structures of the iridocorneal angle is completed. The 
SC extends from the posterior ciliary body to the end of Descement’s membrane (arrow). (Adapted from Smith et al., 
2001). 
1.1.2.2. Postnatal development of the retina 
The mouse retina exhibits an immature retinal vasculature and a persistent hyaloid 
vessel at birth (GYLLENSTEN & HELLSTROM 1954). Angiogenesis in the mouse retina 
occurs within the first three weeks after birth, starting with the radial outgrowth of vessels 
of the ON at P1 to form the superficial plexus. In this initial outgrowth, the retinal vessels 
follow the astrocyte network, which also spread from the ON (Jiang et al. 1995, Ling et 
al. 1989, Stone & Dreher 1987). The vertical sprouting of superficial capillaries generates 
the deep plexus from P7 to P12, located in the outer plexiform layer (OPL) and the 
intermediate plexus from P12 to P15, resident in the inner plexiform layer (IPL). The 
mature retina is a neuronal network with a stratified organization, composed of 
specialized sensory and projective neurons (Figure 1-5 A). In the process of retinal 
neurogenesis retinal progenitor cells run through symmetric and asymmetric cell division. 
RGC, horizontal interneurons, cone photoreceptors and amacrine cells are generated 
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during the early neuronal differentiation, followed by a second differentiation wave, 
producing rod photoreceptors, bipolar interneurons and Müller glia cells. The stratified 
composition of the retina is well organized, as the sensory neurons, like cone and rod 
photoreceptors are arranged in the outer nuclear layer (ONL) and the horizontal, bipolar 
and amacrine interneurons in the inner nuclear layer (INL) (Figure 1-5 B). RGC, 
functioning as projective neurons, are located in the ganglion cell layer (GCL) (Figure 1-
5 B). In the OPL and IPL the synaptic connections are formed (Figure 1-5 B). Additionally, 
the specialized radial glia, the Müller glia cells structure and control the retinal 
environment (Figure 1-5 B). They span the entire neural retina, and together with 
astrocytes form the inner limiting membrane (ILM), the innermost boundary of the retina, 
and the outer limiting membrane (OLM), by creating junctional complexes with 
photoreceptors. The Müller cells provide support for the retinal neurons, by removing 
metabolites, and maintaining the inner retinal-blood barrier and regulating the blood flow 
(Choi & Kim 2008, Metea & Newman 2006, Tout et al. 1993, Tsacopoulos & Magistretti 
1996).  
 
Figure 1-5: Stratified organization of the Retina. (A) The retina can be divided into different layers. ILM: inner limiting 
membrane; NFL: nerve fiber layer; GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer 
plexiform layer; ONL: outer nuclear layer; OLM: outer limiting membrane; PL: photoreceptor layer; RPE: retinal pigmented 
layer (Adapted and modified from (Willermain et al. 2014)). (B) Schema of retinal cell types. (Adapted and modified from 
(Gramage et al. 2014)). 
 
1.1.3. Signaling pathways in eye development 
The accurate morphogenesis of the eye is based on many different, intricately engaging 
processes. For this precise progression, a predefined interaction of transcription factors 
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and signaling pathways is obvious. A breakdown of this interaction results in false 
development of different eye tissues, which could lead to various developmental 
disorders and reduced visual function or even to blindness. A multitude of studies could 
identify several transcription factors expressed during eye development and essential for 
its morphogenesis. The signaling pathways of retinoic acid (RA), fibroblast growth factors 
(FGFs), sonic hedgehog (Shh), WNTs and the, transforming growth factor β (TGF-β) 
superfamily are known to be involved in the interaction between the neuroepithelium, the 
surface ectoderm and the extraocular mesenchyme (Ashery-Padan & Gruss 2001, Chow 
& Lang 2001, Dudley et al. 1995, Furuta & Hogan 1998, Gehring & Ikeo 1999, Jena et 
al. 1997, Luo et al. 1995, Lupo et al. 2005, Martinez-Morales et al. 2005, Sasagawa et 
al. 2002, van Raay & Vetter 2004, Wawersik et al. 1999). One of the key regulators of 
the eye development is Pax6, a member of the paired box family of transcription factors, 
which is necessary for eye formation (Ashery-Padan & Gruss 2001, Chow & Lang 2001, 
Gehring & Ikeo 1999). Pax6 is essential for the establishment of lens progenitor cells 
and the multipotency of retinal progenitor cells during the early stages of development 
(Cvekl & Duncan 2007, Marquardt et al. 2001). In later stages, Pax6 regulates the 
development of the anterior chamber, the lacrimal gland and the neuroretina (Cvekl & 
Tamm 2004, Makarenkova et al. 2000, Marquardt & Gruss 2002). Different matricellular 
proteins and growth factors are co-expressed with Pax6, the co-localization and 
interaction with TGF-β leads to the hypothesis that the activity of Pax6 is controlled by 
TGF-β signaling (Shubham & Mishra 2012). TGF-β itself is directly involved in the 
morphogenesis of the eye, since homozygous TGF-β knockout mice show a reduced 
corneal stromal layer and a hypercellularity of the posterior chamber (Saika et al. 2001, 
Sanford et al. 1997). Similarity in the developmental defects of both homozygous TGF-
β and heterozygous Pax6 knockout mice confirms the hypothesis that Pax6 activity 
during eye formation can be controlled by TGF-β signaling (Baulmann et al. 2002, 
Collinson et al. 2001, Saika et al. 2001, Sanford et al. 1997). Another group of proteins 
involved in the morphogenesis of the eye are the bone morphogenic proteins (BMPs), 
belonging to the TGF-β superfamily. Mice with a BMP-4 or BMP-7 deficiency show 
impaired lens induction and formation (Dudley et al. 1995, Furuta & Hogan 1998, Jena 
et al. 1997, Luo et al. 1995, Wawersik et al. 1999).  
 
The important role of CTGF during skeletal development was demonstrated in CTGF 
deficient mice, which show multiple skeletal defects, like expanded hypertrophic zones 
of long bones (Ivkovic et al. 2003). CTGF can arrange interactions with different growth 
factors, which are essential for the development of the eye (Abreu et al. 2002, Dudley et 
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al. 1995, Furuta & Hogan 1998, Jena et al. 1997, Luo et al. 1995, Sanford et al. 1997, 
Wawersik et al. 1999). 
 
 
Figure 1-6: Protein structure of CTGF and interaction partners. The CTGF protein is characterized by four highly 
conserved domains and can arrange various interactions with different proteins. IGBP: insulin-like growth factor binding 
domain; VWC: von Willebrand factor-C repeat domain; TSP1: thrombospondin type 1 repeat module; CT: C-terminal 
cystine knot; VEGF: vascular endothelial growth factor; TGFβ: transforming growth factor β; BMP4: bone morphogenic 
protein 4; DCN: decorin. 
The binding of CTGF to BMPs or TGFβ, causes the inhibition of BMP and enhancement 
of TGF-β signaling (Abreu et al. 2002). Additional to the interaction with growth factors 
implicated in differentiation and morphogenesis, CTGF can coalesce interactions with 
vascular endothelial growth factor (VEGF), which is essential for angiogenesis during 
development (Ferrara et al. 1996). CTGF forms VEGF-CTGF complexes, leading to an 
inhibition of VEGF induced angiogenesis and in contrast VEGF can induce CTGF (He et 
al. 2003, Inoki et al. 2002, Jang et al. 2004, Kuiper et al. 2007, Suzuma et al. 2000). The 
interaction of CTGF with different factors essential for eye formation leads to the 
hypothesis that CTGF may play a role during the development of the mouse eye. Little 
is known about the expression pattern of CTGF during the development of the eye and 
its role in the early and later stages of the morphogenesis. The expression of CTGF was 
already shown in pericytes, endothelial cells and tip cells of the superficial plexus in 
CTGFp-GFP mice, which express GFP under the CTGF promotor (Pi et al. 2011) during 
development. The role of CTGF during the development of the superficial plexus, was 
shown by blocking CTGF with a specific antibody, which results in a reduced 
development (Pi et al. 2011). The exact distribution pattern and function of CTGF during 
embryonic and postnatal mouse eye development is still unclear, therefore it was of huge 
interest to analyze the CTGF promotor activity during embryonic and postnatal 
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development and in the adult eye. CTGFLacZ+/-mice, which express β-galactosidase under 
the control of the CTGF promotor were used for histological and immunohistochemical 
studies. Since the embryonic lethality of a CTGF knockout, CTGFCoin/Coin;CAGGCre-ER 
mice, which allow a conditional deletion of CTGF via the Cre-loxP system were used to 
study the effect of CTGF deficiency on eye development.  
 
1.2. The pathology of POAG 
1.2.1. The trabecular meshwork and aqueous humor outflow  
1.2.1.1. Structure and function of the trabecular meshwork 
Under normal conditions the IOP is in a steady state, as the outflow rate across the TM 
is equal to the production of aqueous humor (AH) by the ciliary body epithelium, lining 
the ciliary processes (Tamm 2009). The AH is a clear fluid, which fills the anterior and 
posterior chamber and provides nutrition for avascular structures, such as cornea and 
lens. Additionally, the AH is necessary for removing excretory products from metabolism, 
transporting neurotransmitter, stabilizing the ocular structure and contributes to the 
regulation of the homeostasis. The main drainage system is the conventional or 
trabecular outflow pathway, including the TM (corneo-scleral meshwork and the 
juxtacanalicular connective tissue (JCT)), the endothelial lining of SC, the collector 
channels and the aqueous veins (Figure 1-7 B).  
 
 
Figure 1-7: Schematic representation of TM components and AH drainage. (A) Three layers of TM (shown in cutaway 
views): uveal, corneoscleral, and juxtacanalicular layer. (B) Schematic representation of different AH outflow pathways. 
(Adapted from: (A) Shield and Kriegelstein, 1993 (B (Crawley et al. 2012)) 
 
The TM is enclosed in the internal scleral sulcus, a slight groove in the region of the 
corneo-scleral limbus (Figure 1-7 A). The TM is assembled from connective tissue 
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beams and lamellae, of densely packed collagen and elastic fibers, covered with TM 
cells (Marshall et al. 1991a, 1991b). The inner layer of the TM, the uveal meshwork 
consists of three layers of connective tissue beams and TM cells, with irregular 
intertrabecular fenestrations (Lütjen-Drecoll et al. 1981, Lütjen-Drecoll 1999, Lutjen-
Drecoll E 1994, 2001, Tamm 2009) The corneo-scleral TM is similarly constructed, 
composed of 8-15 layers of perforated sheets of fibers, also covered by TM cells, with 
intertrabecular spaces becoming smaller closer to the SC. The lamellae and beams in 
the uveal and corneo-scleral TM are built up by densely packed collagen, mostly collagen 
type I and III and elastic fibers (Marshall et al. 1991a). The cells in the inner portions of 
the TM function mostly as phagocytic pre-filters, removing cellular debris.  The outermost 
portion, the JCT represents almost all resistance to aqueous humor outflow, therefore 
the intertrabecular spaces become smaller (Figure 1-7 A) (Lütjen-Drecoll et al. 1981, 
Lütjen-Drecoll 1999, Lutjen-Drecoll E 1994, 2001, Tamm 2009)). In the JCT the 
discontinuous distribution of several layers of JCT cells are embedded in loose 
connective tissue. The ECM in the outflow pathway is constituted of several different 
components like laminin, type IV collagen, perlecan and fibronectin (Fuchshofer et al. 
2006, Tamm 2009, Tawara et al. 1989, Ueda et al. 2002). The arrangement of the JCT 
cells and the ECM fibrils presents an irregular network. The ground substance in this 
network is constituted of proteoglycans and hyaluron (Gong et al. 1992, Lütjen-Drecoll 
et al. 1990, Tawara et al. 1989). As the SC is the proximate structure in the AH drainage 
system, the JCT cells are in contact to the endothelial cells lining the inner wall of SC 
(Grierson et al. 1979, Grierson & Lee 1974, 1978, Lütjen-Drecoll et al. 1981, Lütjen-
Drecoll 1999). The AH is transported though the inner wall of SC by giant vacuoles and 
transendothelial pores (Braakman et al. 2015, Johnson 2006). Finally, the AH is drained 
to several collector channels, which are connected to the lumen of the SC. While the 
structure of the human TM and SC is similar to that in mice, the porcine outflow pathway 
differs by formation of an angular aqueous plexus (McMenamin & Steptoe 1991).  
1.2.1.2. Pathological changes in the trabecular outflow pathway 
In the pathogenesis of POAG no macroscopic changes are observed in the TM and SC 
confine it from other forms of glaucoma. Indeed, in POAG structural changes are 
observed in the TM, especially in the JCT, affecting the normal outflow pathway of AH, 
and creating an increased resistance and finally an elevation in IOP (Acott & Kelley 2008, 
Gordon et al. 2002, Johnson 2006, Leske et al. 2003). A characteristic sign of POAG is 
the increased fibrillar ECM in the JCT (Tektas & Lütjen-Drecoll 2009). The nature of this 
so called sheath-derived (SD) material has not been identified, but there is evidence that 
collagen type VI and FN are included (Hann et al. 2001, Lütjen-Drecoll et al. 1989, Lütjen-
Drecoll 1999). It is thought that this accumulation of ECM contributes to the increased 
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outflow resistance in glaucoma. In addition to the alterations in ECM organization and 
structure, the outflow resistance is influenced by the actomyosin contractility of TM cells 
(Tian et al. 2000, Wiederholt et al. 2000). 
TGF-β2, the predominant isoform of transforming growth factor β in the eye seems to be 
involved in the pathogenesis of POAG. TGF-β2, present in the normal AH, was shown 
by many studies to be elevated in the AH of POAG patients (Inatani et al. 2001, Min et 
al. 2006, Ochiai & Ochiai 2002, Ozcan et al. 2004, Picht et al. 2001, Tripathi et al. 1994, 
Trivedi et al. 2011). TGF-β2 causes ECM remodeling and organization, by an increased 
synthesis and a reduced degradation of ECM components. For instance, the synthesis 
of plasminogen activator inhibitor-1 (PAI-1) is induced by TGF-β2, leading to a reduced 
activity of the matrix metalloproteinase 2 (MMP2) (Fuchshofer et al. 2003). In recent 
years, the downstream mediator of TGF-β2, CTGF was implicated in the pathological 
changes occurring in the TM and SC in POAG. Analysis of CTGF levels in the AH of 
glaucoma patients, revealed a slight increase in POAG (Browne et al. 2011). 
Interestingly, another study detected highly increased levels of CTGF in the AH of POAG 
patients (Fahmy IA). Furthermore, enhanced levels were detected in SC cells of 
glaucomatous donors (Overby et al. 2014). The implication of CTGF in the ECM 
reorganization and actin cytoskeleton arrangement supports the assumption that it is 
involved in the processes observed in the TM and SC in POAG. This assumption can be 
confirmed as TM cells cultured on stiffer substratum manifest higher levels of CTGF, 
furthermore CTGF modulate the actin cytoskeleton of TM cells and the effect of TGFβ2 
on the ECM is mediate by CTGF (Junglas et al. 2009, Junglas et al. 2012, Raghunathan 
et al. 2013). Intriguingly, the lens specific overexpression of CTGF in mice results in an 
elevated IOP and a significant progressive loss of RGC axons over time (Junglas et al. 
2012).  
Therefore, CTGF can function as the ideal point of action for therapeutic treatment 
strategies, as a reduction would cause a distinct effect on the dysregulation in the tissue 
of the outflow pathway tissue and thus may regulate the IOP.  
1.2.2. The optic nerve head and the Lamina cribrosa 
1.2.2.1. Structure of the optic nerve head and the Lamina cribrosa 
The optic nerve head (ONH) is a light site in the sclera in the posterior eye (Figure 1-8 
A) (Bellezza et al. 2000), where the axons of the RGCs leave the eye. Besides the axons 
of the RGCs, the ON contains astrocytes, mircoglia, oligodendrocytes, blood vessels and 
depending on the species Lamina cribrosa (LC) cells. In humans, a prominent structure 
within the ONH is the Lamina cribrosa (LC; Lamina cribrosa sclerae), a sieve-like plate 
of connective tissue and elastic fibers, which are lined by astrocytes (Figure 1-8 B) 
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(Hernandez et al. 2008). In addition to astrocytes, the LC cells, a GFAP negative unique 
cell type within the ONH, are also located in the LC (Hernandez et al. 1988). 
 
 
Figure 1-8: Vertical section of human ONH and 3D-representation of LC. (A) Vertical section of the ONH divided into 
its different parts. (B) 3-D representation of LC, depicting different constituents of connective tissue in different regions. 
SNFL: surface nerve fiber Layer; PLR: prelaminar region; LCR: lamina cribrosa region; RLR: retrolaminar region. (Adapted 
from: (A (Hayreh 2011); Ischemic Optic Neuropathies) (B (Sigal IA et al. 2009))  
Astrocytes, lining the connective tissue plates in the LC in primates and forming the glial 
tubes in mice are the important common element of both structures. Type 1B astrocytes 
are the major cell type in the ONH and are accountable for ECM macromolecule 
synthesis in the LC (Hernandez et al. 1991, Pena et al. 1996, Ye et al. 1994). In general, 
astrocytes have a widely spread field of function. They are responsible for maintaining 
the structural rigidity, regulating blood flow, releasing neurotransmitter, modulating 
synaptic function and plasticity, keeping the extracellular environment and are involved 
in scarring and repair processes (Haydon 2001, Iadecola & Nedergaard 2007, Magistretti 
2006, Nedergaard et al. 2003, Newman 2003, Rossi et al. 2007, Takano et al. 2006, 
Ullian et al. 2001)). Within the LC they provide a supporting function to the surrounding 
axons, by their connections to the connective tissue and the surrounding blood vessels 
(Hernandez et al. 2008).  
1.2.2.2. The structure of the optic nerve head in mice 
In comparison to the human optic nerve head, in mice, a dense meshwork built up by 
astrocytes missing the connective tissue plates and with only low expression of ECM 
components, like collagen can be found. Because of the formation of glial tubes, 
illustrating a honeycomb structure where the axons of the RGCs pass through, this 
structure is called the glial lamina (Figure 1-9) (Fujita et al. 2000, Howell et al. 2007, May 
& Lütjen-Drecoll 2002, Morcos & Chan-Ling 2000, Sun et al. 2009). In addition to the 
mostly absence of ECM, the transition zone between unmyelinated and myelinated 
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region is directly behind the LC in primates, but more posteriorly in mice (Oyama et al. 
2006, Sun et al. 2009). 
 
Figure 1-9: Section through a glial lamina of mouse ONH. (A) Honeycomb structure of the glial lamina constituted of 
astrocytes (red). Axons are counterstained with green (neurofilament). (B) Astrocytes (red) network forming glial tubes. 
(Adapted from Lye-Barthel et al., 2013). 
1.2.2.3. Pathological changes in the optic nerve head and the Lamina cribrosa 
The characteristic sign of POAG is the irreversible and progressive loss of axons of the 
RGCs. This significant damage is suggested to occur mostly at the level of the LC in the 
ONH (Hayreh 1978, Quigley et al. 1992). The distinct structural changes occurring in the 
LC lead to the permanent deformation, called excavation or cupping, differentiating it 
from other optic neuropathies (Figure 1-10) (Quigley 1983).  
 
Figure 1-10: The ONH of healthy and glaucomatous patients. (A) The healthy, normal appearance of the ONH. (B) 
Typical changes in the ONH of glaucomatous patients, with tissue loss and cupping of the ONH. (Adapted from: (Quigley 
2011)). 
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Thereby, it is hypothesized that a disruption of the retrograde and anterograde transport 
of neurotrophins is generated by axonal compression, which results in the death of RGC 
cells (Pease et al. 2000, Quigley et al. 2000). In the glaucomatous ONH a wide variety 
of structural changes in the ECM and in the major cell type, the astrocytes arise in 
response to elevated IOP (Fukuchi et al. 1992, Fukuchi et al. 1994, Gong et al. 1997, 
Hernandez et al. 1990, Hernandez 1992, Hernandez et al. 1994, Morrison et al. 1989, 
Morrison et al. 1990, Pena et al. 1996, Pena et al. 1998, Pena et al. 1999, Quigley 1983, 
Quigley et al. 1991). The ECM of the LC is dramatically reorganized, such as abnormal 
deposition of elastin, increased levels of collagen type IV and the connective tissue 
sheath around the capillaries in the prelaminar region are thickened (Hernandez 1992, 
Hernandez et al. 1994, Pena et al. 1998, Pena et al. 2001, Tektas et al. 2010). In 
summary, these changes include variations in both quality and quantity of ECM 
components (Hernandez 2000, Hernandez et al. 2002, Pena et al. 2001). Molecular 
signaling mechanisms contributing to or involved in these processes are not known yet, 
but increased amounts of TGF-β2 were detected in the ONH of glaucomatous patients 
(Pena et al. 1999, Zode et al. 2011). As astrocytes and LC cells assemble the LC it is 
likely that one or both cell types are contributing to structural changes developing in the 
LC (Hernandez 2000). There is evidence that reactive astrocytes are the major source 
of growth factors and ECM component upregulation, as it was shown that TGF-β2 is 
extensively localized to reactive astrocytes in the glaucomatous ONH (Pena et al. 2001). 
Furthermore, previous studies of our group and others could show that TGF-β2 leads to 
an increase in ECM protein level in ONH astrocytes, and that this effect is dependent on 
its downstream mediator CTGF (Fuchshofer et al. 2005, Neumann et al. 2008, Zode et 
al. 2011). In the glaucomatous ONH, a change in astrocyte morphology occurs, indicated 
by cellular hypertrophy, increased GFAP immunoreactivity, rounded cell bodies with 
retracted cell processes and a migration from the core of the cribriform plates into the 
nerve bundles (Varela & Hernandez 1997). These changes are associated with 
alterations in gene expression (Liu & Neufeld 2000, Neufeld et al. 1997, Yan et al. 2000) 
These reactive changes, including migration, hypertrophy, upregulation of GFAP and 
gliosis are observed in human glaucoma and animal models of glaucoma (Hernandez 
2000, Lye-Barthel et al. 2013, Morrison et al. 1990, Quigley et al. 1991, Sun et al. 2010, 
Sun & Jakobs 2012). Similar results could be shown for LC cells which react to the TGF-
β2 treatment with increased ECM expression and synthesis (Kirwan et al. 2005, Kirwan 
et al. 2009, Zode et al. 2011)  
1.2.2.4. Pathological changes in the peripapillary sclera 
In addition, to the alteration occurring in the ONH, implications of the peripapillary sclera, 
the part of the sclera around the ONH, in the pathogenesis of the POAG are existing. In 
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general, the sclera, built up by different collagen types, elastic fibrils and proteoglycans, 
constitutes three quarters of human ocular circumference (Rada et al. 2006). The 
structure of the peripapillary sclera differs in the arrangement of collagen and elastic 
fibrils, as they are oriented circumferentially around the ONH. By this formation, a 
mechanical reinforcement against the stress in this region can be provided (Gelman et 
al. 2010, Girard et al. 2009b, Girard et al. 2009a, Hernandez et al. 1987, Pijanka et al. 
2012, Quigley et al. 1991, Yan et al. 2000). As corneal hysteresis and myopia, both linked 
to the thinning of sclera are glaucoma risk factors, there is strong evidence that the 
composition of the sclera is a crucial component of glaucoma development (Boland & 
Quigley 2007, Congdon et al. 2006). Increased scleral stiffness was shown in human 
glaucoma and experimental glaucoma models, in monkey and mice (Coudrillier et al. 
2012, Downs et al. 2008, Hommer et al. 2008, Nguyen et al. 2013). Furthermore, scleral 
cross-linking is associated with greater RGC and axon loss (Kimball et al. 2014). As the 
astrocytes in the ONH stay in close contact with their processes to the peripapillary sclera 
and are sensitive to mechanical stress, it can be suggested that the mechanical behavior 
of the sclera influences the stress and deformation of the LC and that this mechanical 
stress is sensed by astrocytes, causing changes occurring in the ONH and its astrocytes 
(Coudrillier et al. 2012, Coudrillier et al. 2013, Girard et al. 2009b, Girard et al. 2009a, 
Hernandez 2000, Norman et al. 2011, Rogers et al. 2012, Sigal et al. 2005, Sigal et al. 
2011).  
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2. Aim of the study 
The aim of the study is to investigate the involvement of CTGF in eye development and 
the pathology of POAG. The expression of CTGF during eye development and in the 
adult eye will be investigated in different ocular tissues. Furthermore, the CTGF 
expressing cell types will be identified. It is also of interest to clarify the involvement of 
CTGF in the ONH pathology of POAG. Therefore, the correlation between CTGF 
expression changes and astrocyte reactivity in the ON and ONH will be examined related 
to mechanical stress in vivo and by increasing substratum stiffness in vitro. Additionally, 
possible mechanosensing proteins will be investigated. Furthermore, an aim of this study 
is to develop siRNA coated layer-by-layer nanoparticles as a new tool to reduce CTGF 
in the AH outflow pathway tissue and cells. 
The following experiments were carried out to achieve these aims: 
• Analysis of CTGF promotor activity in CTGFLacZ+/- mice during development and 
in the adult eye 
• Identification of CTGF expressing ocular cell types in CTGFLacZ+/- mice during 
development and in the adult eye 
• Analysis of CTGF and GFAP levels in the ON and ONH of 1-month and 2-month-
old βB1-CTGF1 mice 
• Analysis of the effect of increasing substratum stiffness on CTGF levels and 
reactivity in murine ON astrocytes in vitro 
• Analysis of the effect of increasing substratum stiffness on Trp-channel and 
Caveolin1 expression in murine ON astrocytes 
• Analysis of Caveolin1 expression in murine ON astrocytes after CTGF and TGF-
β2 treatment, and in the ON and ONH of βB1-CTGF mice 
• Evaluation of CD44 prevalence in HTM cells after CTGF and TGF-β2 treatment, 
in the outflow pathway structures of βB1-CTGF mice and glaucomatous and 
healthy human donor eyes 
• Analysis of nanoparticle distribution after perfusion of porcine and human eyes 
with different nanoparticles 
• Evaluation of CTGF knockdown after transfection with siRNA coated 
nanoparticles in HTM cells 
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• Generation and confirmation of a conditional, inducible CTGF knockout 
• Analysis of the influence of conditional CTGF knockout on eye morphology 
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3. Material and methods 
3.1. Materials 
3.1.1. Reagents 
Reagents Source of supply 
2,4,6-Tri(dimethylaminomethyl) phenol 
(DPM-30) 
Roth, Karlsruhe, Germany 
0.05 % Trypsin/EDTA  
 
PAA The Cell Culture Company, Pasching, 
Austria 
2-Mercaptoethanol  
 
Roth, Karlsruhe, Germany  
 
Acetic acid, glacial  
 
Merck, Darmstadt, Germany  
 
Acetone  
 
Merck, Darmstadt, Germany  
 
Albumin Fraction V (BSA)  
 
Roth, Karlsruhe, Germany  
 
Agarose  
 
Biozym Scientific, Oldendorf, Germany  
 
AK10 plasticizer silicone oil Wacker Chemie, Munich, Germany 
Ammonium persulfate (APS), 10% 
(w/v)  
 
Roth, Karlsruhe, Germany  
 
Aminopropyl-triethoxysilane (APTES) Sigma-Aldrich, Taufkirchen, Germany 
Astrocyte growth supplement (AGS)  
 
Sciencell, Carlsbad, USA  
 
BC Assay Reagent A+B  
 
Interchim, Wörgl, Österreich  
 
BC Assay Reagent 1+2  
 
Roth, Karlsruhe, Germany  
 
CDP-Star  
 
Roche, Penzberg, Germany  
 
Chloroform  
 
Roth, Karlsruhe, Germany  
  
Coomassie®Brillant Blue R-250  
 
Sigma-Aldrich, Taufkirchen, Germany  
 
Connective tissue growth factor  
 
Self purification  
 
Connective tissue growth factor  
 
Prospec, Rehovot, Israel  
 
Connective tissue growth factor  
 
EMP, Ingolstadt, Germany 
cross linker 210 Evonik Hanse GmbH, Gesthach, Germany 
Desoxynukleosid-Triphosphate 
(dNTPs)  
 
Qiagen, Hilden, Germany  
 
Dimethylsulfoxid (DMSO)  
 
Roth, Karlsruhe, Germany  
 
Divinyl tetramethyl disiloxane Evonik Hanse GmbH, Gesthach, Germany 
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DL-Dithiothreitol (DTT)  
 
Sigma-Aldrich, Taufkirchen, Germany  
 
Dulbecco’s Modified Eagle Medium 
(DMEM) F12  
PAA The Cell Culture Company, Pasching, 
Austria 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
PAA The Cell Culture Company, Pasching, 
Austria 
EDTA  
 
 
Roth, Karlsruhe, Germany  
Ethanol 100%  
 
Roth, Karlsruhe, Germany  
 
Ethidiumbromide  
 
Serva, Heidelberg, Germany  
 
Fetal calve serum (FCS)  
 
Biochrom AG, Berlin, Germany  
 
Fluorescent Mounting Medium  
 
DakoCytomation, Hamburg, Germany  
 
Formaldehyde  
 
Roth, Karlsruhe, Germany  
Epon Serva, Heidelberg, Germany 
Gelatine  
 
Sigma-Aldrich, Taufkirchen, Germany  
 
Glutaraldehyde, 25% in water  
 
Serva, Heidelberg, Germany  
 
Glycerine Roth, Karlsruhe, Germany 
Glycin  
 
Merck, Darmstadt, Germany  
 
Guanidin HCl  
 
Roth, Karlsruhe, Germany  
 
Hydrochloric acid (37%)  
 
Merck, Darmstadt, Germany  
 
Isoflurane  
 
Baxter, Heidelberg, Germany  
 
Isopropanol  
 
Roth, Karlsruhe, Germany  
 
Ketamine  
 
Wirtschaftsgenossenschaft Deutscher 
Tierärzte (WDT), Garbsen, Germany  
 
Luminata Forte, Western HRP  
 
Millipore Cooperation, Billerica, USA  
 
Magnesium chloride (50 mM)  
 
Bioline, Luckenwalde, Germany 
Methanol  
 
Merck, Darmstadt, Germany  
 
methylhydrosiloxane-dimethylsiloxane 
AB116655 cross linker 
ABCR GmbH, Karlsruhe, Germany 
Milk powder (MM)  
 
Roth, Karlsruhe, Germany  
 
N,N,N`,N`,-Tetramethylethylendiamine, 
(TEMED)  
 
Roth, Karlsruhe, Germany  
 
Paraformaldehyde (PFA)  
 
Sigma-Aldrich, Taufkirchen, Germany  
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PBS  
 
PAA The Cell Culture Company, Pasching, 
Austria  
  
Penicilllin-Streptomycin  
 
PAA The Cell Culture Company, Pasching, 
Austria  
 
peqGold TriFastTM (Trizol) PeqLab, Erlangen, Germany  
 
Phalloidin  
 
Sigma-Aldrich, Taufkirchen, Germany  
 
Phosphatase-Inhibitor-Mix  
 
Sigma-Aldrich, Taufkirchen, Germany  
 
Potassium chloride  
 
Roth, Karlsruhe, Germany  
 
Potassium dihydrogen phosphate  
 
Roth, Karlsruhe, Germany  
 
Protease-Inhibitor-Mix M  
 
Serva Electrophoresis GmbH, Heidelberg, 
Germany  
 
Proteinase K  
 
Sigma-Aldrich, Taufkirchen, Germany  
 
Pt-catalyst 510 Evonik Hanse GmbH, Gesthach, Germany 
Rotiphorese® Gel 30 (30 % Acrylamid, 
0.8 % Bisacrylamid; 37.5:1)  
 
Sigma-Aldrich, Taufkirchen, Germany  
 
Saccharose  
 
Roth, Karlsruhe, Germany  
 
SDS (Sodium dodecylsulfat)  
 
Roth, Karlsruhe, Germany  
 
SIH-terminated polydimethyl siloxane Evonik Hanse GmbH, Gesthach, Germany 
Sodium chloride Roth, Karlsruhe, Germany 
Sodium dihydrogen phosphate  
 
Merck, Darmstadt, Germany  
 
Sodium hydroxide  
 
Roth, Karlsruhe, Germany  
 
Sodium phosphate  
 
Roth, Karlsruhe, Germany  
 
SYBR-Green I  
 
Qiagen, Hilden  
 
Tissue-Tek®  
 
Sakura, Zoeterwoude, Netherlands  
 
Transforming Growth Factor 2 
(TGF- β2)  
 
R&D Systems, Minneapolis, USA  
 
Tris HCl  
 
Roth, Karlsruhe, Germany  
 
Triton X 100  
 
Roth, Karlsruhe, Germany  
 
Tween 20  Roth, Karlsruhe, Germany  
 
Vectashield Mounting Medium for 
Fluorescence with DAPI  
 
Vector Laboratories, Burlingame, USA  
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vinyl-functional polydimethylsiloxane Evonik Hanse GmbH, Gesthach, Germany 
Water Rotisolv (Rnase-free)  
 
Roth, Karlsruhe, Germany  
 
Xylazine  
 
Serumwerk Bernburg, Bernburg, Germany  
 
Table 3-1: Reagents 
3.1.2. Enzymes and Reagent-Kits 
Enzymes and Reagent-Kits Source of supply 
qScript™cDNA Synthesis Kit  
 
Quanta Biosciencies, Gaithersburg, USA  
 
Mango Taq  
 
Bioline, Luckenwalde, Germany 
 
Proteinase K  
 
Roth, Karlsruhe, Germany 
 
Taq DNA Polymerase  
 
Self purification  
 
Universal SYBR Green Master (ROX) Roche, Mannheim, Germany 
TaqMan®Fast Advanced Master Mix (2x) ThermoFisher, Darmstadt, Germany 
Table 3-2: Enzymes and Reagent Kits 
 
 
3.1.3. Oligonucleotide primers and Taqman probes 
Primer Species Orientation Sequence 
βB1 mus 
musculus 
forward GGAAGTGCCAGCTCATCAGT 
βB1 mus 
musculus 
reverse GTGCGGGACAGAAACCTG 
SV40 mus 
musculus 
forward GTGAAGGAACCTTACTTCTGTGGTG 
SV40 mus 
musculus 
reverse GTCCTTGGGGTCTTCTACCTTTCTC 
LacZ mus 
musculus 
forward GCCGTCTGAATTTGACCTGA 
LacZ mus 
musculus 
reverse TCTGCTTCAATCAGCGTGCC  
CAG-Cre mus 
musculus 
forward ATGCTTCTGTCCGTTTGCCG  
CAG-Cre mus 
musculus 
reverse CCTGTTTTGCACGTTCACCG  
Coin/Coin mus 
musculus 
forward CACTTTCTACTCTGTTGAC 
Coin/Coin mus 
musculus 
reverse CCTTACATGTTTTACTAG 
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Exons2 mus 
musculus 
forward CCTGCTATGGGCCAGGACTG 
Exons2 mus 
musculus 
reverse CCAAAAGGTGAGGCCTCTGC 
Table 3-3: Oligonucleotide primers for genotyping 
 
Primer Species Orientation Position Sequence  
CTGF mus 
musculus 
forward 948-970 TGACCTGGAGGAAAACAT
TAAGA 
 
CTGF mus 
musculus 
reverse 1038-1059 AGCCCTGTATGTCTTCACA
CTG 
 
GFAP mus 
musculus 
forward 1156-1174 TCGAGATCGCCACCTACA
G 
 
GFAP mus 
musculus 
reverse 1201-1222 GTCTGTACAGGAATGGTG
ATGC 
 
CD44 mus 
musculus 
forward 2270 - 2289 ACTCAAGTGCGAACCAGG
AC 
 
CD44 mus 
musculus 
reverse 2338 - 2357 GCCAAGATGATGAGCCAT
TC 
 
RPL32 mus 
musculus 
forward 29-47 GCTGCCATCTGTTTTACG
G 
 
PRL32 mus 
musculus 
reverse 107-126 TGACTGGTGCCTGATGAA
CT 
 
Trpc1 mus 
musculus 
forward 1233-1258 TGAACTTAGTGCTGACTTA
AAGGAAC 
 
Trpc1 mus 
musculus 
reverse 1307-1287 CGGGCTAGCTCTTCATAAT
CA 
 
Trpv2 mus 
musculus 
forward 1578-1598 CACCATAGTTGCCTACCA
CCA 
 
Trpv2 mus 
musculus 
reverse 1621-1640 GTCGCTTTTGATGAGGGA
AT 
 
Trpm7 mus 
musculus 
forward 205-224 AGACGCTTTCCGATAGAT
GG 
 
Trpm7 mus 
musculus 
reverse 294-317 AAAGTGCTCTCTATCCAG
GATTTC 
 
Piezo1 mus 
musculus 
forward 1064-1083 ATGAGGAGCATGAGCTGG
AA 
 
Piezo1 mus 
musculus 
reverse 1130-1148 GTGGTCATGGGCATCTCA
C 
 
Piezo2 mus 
musculus 
forward 5211-5229 GGACACAATCGACGAGCA
C 
 
Piezo2 mus 
musculus 
reverse 5305-5323 GCAGGGTCGCTTCAGTGT
A 
 
Caveolin
1 
mus 
musculus 
forward 389-407 AACGACGACGTGGTCAAG
A 
 
Caveolin
1 
mus 
musculus 
reverse 474-493 CACAGTGAAGGTGGTGAA
GC 
 
Caveolin
2 
mus 
musculus 
forward 144-163 CCTCACCAGCTCAACTCT
CA 
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Caveolin
2 
mus 
musculus 
reverse 245-269 CACATATTTGCTGATTTCA
AAGAGA 
 
CD44 human forward 1942-1960 GACACATTCCACCCCAGT
G 
 
CD44 human reverse 2048-2067 TGGAATTTGGGGTGTCCT
TA 
 
RPL32 human forward 319 - 338 GAAGTTCCTGGTCCACAA
CG 
 
RPL32 human reverse 377 - 395 GCGATCTCGGCACAGTAA
G 
 
Table 3-4: Oligonucleotide primers for Real-time RT-PCR 
All primers were purchased from Invitrogen, Karlsruhe, Germany. 
 
Target Probe Amplicon Length Source of Supply 
 
RPL32 
 
Mm02528467_g1 
 
69 
ThermoFisher 
Scientific, 
Darmstadt, 
Germany 
 
GFAP 
 
Mm01253033_m1 
 
75 
ThermoFisher 
Scientific, 
Darmstadt, 
Germany 
 
CTGF 
 
Mm01192933_g1 
 
67 
ThermoFisher 
Scientific, 
Darmstadt, 
Germany 
Table 3-5: Taqman® probes 
 
3.1.4. Antibodies and molecular weight standards 
Protein Primary antibody Source of supply 
CTGF polyclonal goat anti-CTGF  Santa Cruz, Dallas, USA 
GFAP polyclonal chicken anti-
GFAP  
LifeSpan Biosciences, 
Seattle, USA 
Vimentin polyclonal goat anti-
Vimentin 
Sigma-Aldrich, 
Taufkirchen, Germany  
 
CD44 polyclonal mouse anti-
CD44 
R&D systems, 
Minneapolis, USA 
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CD44 polyclonal rabbit anti-
CD44 
antibodies-online GmbH, 
Aachen, Germany 
β-galactosidase polyclonal rabbit anti- β-
galactosidase 
icllab, Portland, Germany 
CD31 polyclonal goat anti-CD31 R&D systems, 
Minneapolis, USA 
β-catenin polyclonal rabbit anti- β-
catenin 
Cell Signaling Technology, 
Danvers, MA, USA 
Glutamine synthetase polyclonal goat anti-
Glutamine synthetase 
Santa Cruz, Dallas, USA 
CTGF polyclonal rabbit anti-
CTGF 
GeneTex, Irvine, USA 
α-tubulin polyclonal rabbit anti- α-
tubulin 
Rockland 
Immunochemicals, 
Limerick, USA 
Caveolin1 polyclonal rabbit anti-
Caveolin1 
BD Life Sciences, 
Heidelberg, Germany 
Caveolin1 polyclonal rabbit anti-
Caveolin1 
Cell Signaling Technology, 
Danvers, MA, USA 
myelin basic protein 
(MBP) 
polyclonal rabbit anti-MBP Dako, Agilent 
Technologies Company, 
Santa Clara, USA 
Calcium binding adaptor 
molecule 1 (IBA1) 
polyclonal rabbit anti-IBA1 Wako, Neuss, Germany 
Table 3-6: Primary Antibodies for Western blot, immunohistochemical and immunocytochemical 
staining 
 
 
Secondary antibody Source of supply 
Alexa Fluor® 488 goat anti-chicken IgG 
(H+L) 
Eurogene, Oregon, USA 
Alexa Fluor® 488 goat anti-rabbit IgG 
(H+L) 
Invitrogen, Carlsbad, USA 
Alexa Fluor® 488 goat anti-mouse IgG 
(H+L) 
Invitrogen, Carlsbad, USA 
Alexa Fluor® 488 donkey anti-goat IgG 
(H+L) 
Biotium, Inc., Fremont, CA, USA 
Alexa Fluor® 647 donkey anti-mouse 
IgG (H+L) 
Invitrogen, Carlsbad, USA 
Alexa Fluor® 647 donkey anti-rabbit IgG 
(H+L) 
Invitrogen, Carlsbad, USA 
Cy™3-conjugated AffiniPure goat anti-
rabbit IgG (H+L) 
Jackson Research Laboratories, West 
Grove, PA, USA 
Biotinylated anti-goat IgG (H+L) Vector Laboratories, Burlingame, CA, 
USA 
Biotinylated anti-rabbit IgG (H+L) Vector Laboratories, Burlingame, CA, 
USA 
rabbit anti-chicken IgG-h+l HRP  Bethyl Laboratories, Montgomery, USA 
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goat anti-rabbit IgG-h+l AP Bethyl Laboratories, Montgomery, USA 
goat anti-rabbit HRP Cell Signaling Technology, Danvers, MA, 
USA 
goat anti-rabbit AP Cell Signaling Technology, Danvers, MA, 
USA 
horse anti-mouse HRP Cell Signaling Technology, Danvers, MA, 
USA 
donkey anti-goat IgG-h+l HRP Bethyl Laboratories, Montgomery, USA 
Streptavidin Alexa Fluor® 488 Invitrogen, Carlsbad, USA 
Table 3-7: Secondary Antibodies for Western blot, immunohistochemical and 
immunocytochemical staining 
 
Description Source of supply 
Gene Ruler 100bp Plus DNA Ladder 
 
Fermentas, Schwerte, Deutschland 
 
EZ-Run Pre-Stained Rec Protein Ladder 
 
Fisher Scientific, Schwerte, Deutschland 
 
Table 3-8: molecular weight standards 
3.1.5. Chemical composition of gels, solvents and buffers 
Solvents and buffers Compounds 
0.1M Cacodylate Buffer 10.7g Cacodylate acid in 500 ml dH2O 
0.1 M Phosphate Buffer (Php), pH 7,4  
 
100 ml 0.2 M Na2HPO4 x 2H2O  
with 0.2 M NaH2PO4 x H2O, pH 7.4  
dilute with dH2O to 0.1M  
10 x Electrode Buffer 
 
250mM Tris/HCl  
400mM Glycine  
1% (w/v) SDS solved in dH2O; ad 1 l  
Coomassie-Destaining Solution  
 
500 ml Methanol  
10 ml Acetic acid  
filled up with H2O to 1 l   
Coomassie-Staining Solution 
 
40 ml Methanol  
2 ml Acetic acid 
0.2 g Coomassie-Brilliant Blue R-250  
dilute in dH2O, ad 100 ml  
Detection Buffer, pH 9  
 
15.76 g 0,1 M Tris/HCL (pH 6,8)  
5.84 g 0,1 M NaCl  
dilute in dH2O; ad 1 l  
EM fixative 2.5% paraformaldehyde 
2.5% glutaraldehyde 
in 0.1M cacodylatbuffer 
Epon stem A 62ml Glycidether 100 with 100ml DDSA 
Epon stem B 100ml Glycidether 100 with 89ml NMA 
LacZ fixative 
 
48,4 ml 0.1MPhp pH7.3  
100μl 1M MgCl2  
1ml 0.250M EGTA pH7.3  
0.4ml Glutaraldehyde 
LacZ-Staining Solution  72ml LacZ Washing Buffer  
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 3ml X-Gal (25mg/ml in DMSO)  
0.159g K4Fe(CN)6 3H2O  
0.123g K3Fe(CN)6  
LacZ-Washing Solution 1ml 1M MgCl2  
5ml 1% NaDC  
5ml 2% Tergitol  
489ml 0.1M Php pH 7.3 
Lyse Buffer 1.87 g KCL 
5ml 1M Tris-HCl pH 8.3 
255mg MgCl2-6H2O 
50mg galantine  
2.25 ml Tergitol 
2.25 ml Tween 20 
Mowiol with Dapi 2.4 g Mowiol 4-88  
6.0 g Glycerin  
6.0 ml H2O dest.  
12.0 ml 0.2 M Tris-HCl (pH 8.5)  
25.0 ml DABCO per 1.0 ml  
DAPI (1:10)  
PBS, 10x, pH 7,4  
 
80 g NaCl  
2 g KCl 
4.4 g Na2HPO4  
2.4 g KH2PO4  
dH2O ad 1 l, autoclave 
SDS-Solution, 10 % (w/v)  
 
10 g SDS  
in dH2O; ad 100 ml  
SDS-PAGE-Running Buffer, 10x  
 
250mM Tris/HCl  
400mM Glycin  
1% (w/v) SDS  
in dH2O; ad 1 l  
SDS-Sample Buffer, 4x  
 
0.25M Tris/HCl, pH 6.8  
30% Glycerin  
8% (w/v) SDS  
0.02% (w/v) Bromphenolblau  
0.3M DTT and 10% β-Mercaptoethanol  
TBE, 10x 108g Tris-base 
55g boric acid 
40ml 0.5M EDTA pH 8.0  
dilute in H2O, ad 1 l pH 7.0 
TBS, 10x, pH 7,4  
 
30 g Tris  
80 g NaCl  
2 g KCl 
dH2O ad 1 l, autoclave 
TBST, 1x  
 
100 ml 10x TBS  
0.05% (v/v) Tween 20  
dH2O ad 1 l  
Transfer Buffer, 10x  
 
5.8 g Tris  
2.9 g Glycine  
200 ml Methanol  
3.7 ml 10% (w/v) SDS  
dilute in dH2O, ad 1 l  
Tris/HCl, 1.0 M, pH 6.8  
 
121.14 g Tris  
dH2O; ad 1 l   
Tris/HCl, 1.5 M, pH 8.8  181.71 g Tris  
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 dH2O; ad 1 l  
Washing Buffer for protein isolation 
 
0.3 M Guanidin HCL  
in 95 % Ethanol  
Table 3-9: Chemical composition of gels, solvents and buffers 
3.1.6. Laboratory Equipment 
Description Source of supply 
Axiovert 40 CFL  
 
Zeiss, Göttingen, Germany  
CFX Connect Real-Time System BioRad, Munich, Germany 
Embedder  
 
EM TP Leica, Wetzlar, Germany  
 
FastPrep 24TM  
 
MP Biomedicals, Burlingame, USA  
 
HeatSealer RS 232 4titude, Berlin, Germany 
Hera Cell 150 incubator 
 
Heraeus, Hanau, Germany 
 
Hera Safe steril working bench 
 
Heraeus, Hanau, Germany 
 
Inolab pH-Meter  
 
Inolab pH-Meter  
 
Julabo SW20 Wasserbad  
 
JulaboLabortechnik GmbH, Seelbach  
 
Kern PJL 2100-2M Analysenwaage  
 
Kern & Sohn GmbH, Balingen-Fommern  
 
LAS 3000 Intelligent Dark Box  
 
Fujifilm, Düsseldorf  
 
Memmert water bath 
 
Memmert GmbH, Schwabach  
 
Mettler AE 163 special accurancy scales 
 
Mettler Toledo, Giessen  
 
Microm HM 500 OM Kryostat  
 
Microm International, Walldorf  
 
Mikroskop Axio Imager.Z1  
 
Zeiss, Göttingen  
 
MilliQ Plus PF water purification system Millipore Corporation, Billerica, USA  
 
Model 45-101-i ClassII Electrophoresis  
System  
 
 
Peqlab Biotechnologie GmbH, Erlangen  
 
NanoDrop-1000 Spectrophotometer  
 
Peqlab Biotechnologie GmbH, Erlangen  
 
Pipetman Pipets  
 
Gilson, Middleton, USA  
 
Research Pipets  
 
Eppendorf, Hamburg, Germany  
 
Roti®speed mixing tool Carl Roth GmbH, Karlsruhe, Germany 
Semi-Dry Electrophoretic Transfer Cell  
 
Peqlab Biotechnologie GmbH, Erlangen  
 
Sunrise-Basic ELISA Reader  Tecan Austria GmbH, Grodig, AUS  
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SuperCut 2050 Cambridge Instruments, Nußloch, 
Germany 
Systec V75 Autoclave  
 
Systec GmbH, Wettenburg  
 
Thermomixer comfort  
 
Eppendorf, Hamburg  
 
TonoLab Tonometer  
 
Icare Finnland, Helsinki, Finnland  
 
universal oven Memmert UF30Plus Memmert GmbH, Schwabach, Germany 
  
UV-light screen  
 
Bachhofer Laboratoriumsgeräte, 
Reutlingen, Germany  
 
Ultracut E-Ultramicrotom  
 
Reichert-Jung, Kirchseeon, Germany  
 
Ultra Thurax  
 
Biolabproducts, Bebensee, Germany  
 
Vortex Genie 2  
 
Scientific Industries Inc., New York, USA  
 
Centrifuges 5415D, 5415R, 5804R, 
5810R  
 
Eppendorf, Hamburg, Germany 
 
Table 3-10: Laboratory Equipment 
 
 
 
3.1.7. Consumables 
Description Source of supply 
µ-dish 35mm, high, uncoated ibidi, Martinsried, Germany 
3MM Blotting ("Whatman") –Paper 
 
Neolab, Heidelberg, Germany 
 
Biosphere Filter Tips  
 
Sarstedt, Nürnbrecht, Germany  
 
CellScraper  
 
Sarstedt, Nürnbrecht, Germany  
 
Culture Slides  
 
BD Falcon, Bedford, USA  
 
Cover slips, 24 x 60mm  
 
Menzel-Gläser, Braunschweig, Germany 
 
Dispomed Syringe, single use  
 
Dispomed Witt oHG, Geinhausen, 
Germany 
 
EasyFlasks Nunclon™ Δ T25, T75  
 
Nunc, Roskilde, Denmark 
 
Ecoflo Dissecting instruments 
 
Dispomed Witt oHG, Geinhausen, 
Germany  
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Falcon“ Reaction Tubes 15 ml, 50 ml  
 
Sarstedt, Nürnbrecht, Germany  
 
Glasware 
 
Schott, Roth, VWR, Germany 
 
Green Nitrile gloves Kimtech, Koblenz, Germany 
Hard-Shell® PCR plates 96-well, thin-
wall 
BioRad, Munich, Germany 
Liquid Blocker PAP-Pen SCI Science Services, München, 
Germany  
 
Lysing Matrix D  
 
MP Biomedicals, Burlingame, USA  
 
Multidishes Nunclon™ Δ 6- Nunc, Roskilde, Denmark 
 
Multi-Reaction Tubes 0,5 ml; 1,5 ml; 2,0 
ml  
 
Roth, Karlsruhe, Germany 
 
Omnifix syringe, sterile 
 
B. Braun, Wertheim, Germany  
 
Optically Clear Heat Seal  BioRad, Munich, Germany 
Parafilm  
 
Pechiney Plastic Packaging, Chicago, 
USA  
 
Pasteurpipets 
 
Brand, Wertheim, Germany 
 
PCRSoftTubes, 0.2ml Biozym, Hessisch Oldendorf, Germany 
Personna RRazor blades  
 
American Safety Razor Company, 
Verona, USA  
 
Pipet tips 
 
Sarstedt, Nürnbrecht, Germany  
 
Petri dishes 94x16 mm PS  Greiner bio-one, Kremsmünter, Austria 
Petrisoft 35, Collagen Coat 8kPa Cell Guidance Systems Ltd, Cambridge, 
UK 
Petrisoft 35, Collagen Coat 25kPa Cell Guidance Systems Ltd, Cambridge, 
UK 
Petrisoft 35, Collagen Coat, 50kPa Cell Guidance Systems Ltd, Cambridge, 
UK 
Pro Free Blue gloves Ulma, Neu-Ulm, Germany 
PVDF membrane (Roti®-PVDF), 0.45µm 
 
Roth, Karlsruhe, Germany 
Serological pipets 
 
Sarstedt, Nürnbrecht, Germany  
 
Sterican injection cannula 
 
B. Braun, Wertheim, Germany  
 
SuperFrost®Plus object slides 
 
Menzel-Gläser, Braunschweig, Germany  
 
Table 3-11: Consumables 
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3.2. Cell linies 
For in vitro studies murine optic nerve astrocytes and human trabecular meshwork (HTM) 
cells were used. Murine optic nerve astrocytes were isolated from the ON of CD1 wild 
type mice (see 3.7.3.) and HTM cells were available in the Institute of Human Anatomy 
and Embryology and the protocol was published previously (Stamer et al. 1995, Stamer 
et al. 2000, Tamm et al. 1996, 1996).  
3.3. Animal models 
3.3.1. Animals and animal husbandry 
βB1-CTGF1, CTGFLacZ+/-, CTGFCoin/Coin;CAGGCre-ER mice and CD1 wild type mice were 
used in the in vivo experiments of this study. βB1-CTGF1 mice were generated in our 
own working group and provided by Prof. Dr. R. Fuchshofer (Junglas et al. 2012). 
CTGFLacZ/+ were generated and kindly provided by M. Gannon (Department of Medicine, 
Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical 
Center, Nashville, Tennessee; Crawford et al., 2009). CTGFCoin/Coin were generated and 
kindly provided by E. Canalis (Department of Research, Saint Francis Hospital and 
Medical Center, Hartford, Connecticut; (Canalis et al. 2010). CD1 wild type and 
CAGGCre-ER mice were bred in the animal facility of Prof. Dr. E. Tamm, Institute of 
Human Anatomy and Embryology, University of Regensburg, started with a first breeding 
pair purchased from Charles River, Sulzfeld, Germany. Mice were housed under 
standardized conditions of 62% air humidity and 21°C room temperature. Feeding was 
ad libitum. Animals were kept at a 12-hour light/ dark cycle (6:00 – 18:00), accordingly 
to the ARVO Statement for the use of animals in ophthalmic and vision research. 
3.3.2. βB1- CTGF mice 
The βB1-CTGF1 mice carry a plasmid, expressing murine CTGF cDNA under the control 
of the chicken βB1 promotor, resulting in a high and specific expression of the transgene 
in the lens fibers of the mouse eye. Additionally, the plasmid contains the simian virus 
40 (SV-40) small T-intron and the SV-40 poly(A) sequence, to ensure a higher stability 
of the CTGF cDNA. For the in vivo experiments the βB1-CTGF1 mice were breed with 
CD1 wild type mice to receive the appropriate control group for each experiment. 
Genotyping of the mice was performed as described in 3.4.2.1. 
 
Figure 3-1: βB1 construct of βB1-CTGF1 mice. 
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3.3.3. CTGFLacZ/+ mice 
CTGFLacZ/+ mice were generated and kindly provided by M. Gannon (Department of 
Medicine, Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University 
Medical Center, Nashville, Tennessee; (Crawford et al. 2009). In this mouse line the 
CTGF gene is destroyed by replacing the coding sequence of CTGF within the exon 3 
to the end of the coding sequence in exon 5 with a transmembrane domain-LacZ 
cassette (Crawford et al., 2009). As WT animals were used as controls in the following 
experiments, heterozygous CTGFLacZ/+ mice were mated, resulting WT and CTGFLacZ+/- 
mice. Since the homozygous knockout of CTGF is embryonic lethal, no homozygous 
offspring were expected.  
3.3.4. CD1 wildtype mice 
The initial CD1 wild type mice was purchased form Charles River, Sulzfeld, Germany 
and afterwards bred in the animal facility of the Institute of Human Anatomy and 
Embryology (Prof. Dr. E. Tamm), University of Regensburg. 
3.3.5. CTGFCoin/Coin;CAGGCre-ER mice 
CTGFCoin/Coin mice were generated and kindly provided by E. Canalis (Department of 
Research, Saint Francis Hospital and Medical Center, Hartford, Connecticut; Canalis et 
al., 2010). By the conditional-by-inversion (COIN) approach a conditional null allele of 
CTGF was generated. The COIN intron was inserted into exon2, resulting in splitting of 
exon2 in two exons. This modification allows a regular expression of CTGF. The COIN 
intron is flanked by two loxP sequences, after Cre recombination the two loxP sites 
recombine and thereby invert the COIN intron, resulting in the inactivation of CTGF 
(Canalis et al., 2010). CTGFCoin/Coin mice were bred with CAGGCre-ER mice (Jackson 
Laboratory, Bar Harbor, Maine, USA). Finally, Mice with two Coin-Introns (CTGFCoin/Coin) 
were crossed with CTGFCoin/Coin;CAGGCre-ER mice, which are heterozygous for the Cre-
recombinase, to receive an cohort of  experimental mice (CTGFCoin/Coin;CAGGCre-ER) 
mice and control mice (CTGFCoin/Coin).  
 
3.4. Biomolecular Techniques 
3.4.1. Isolation of mouse tail DNA 
For genotype determination of different mouse strains, a 2 mm piece of the mouse tail 
was cut of under isoflurane anesthesia to obtain genomic DNA. The tissue was lysed 
under addition of 200 µl Lysebuffer and 5 µl proteinase K overnight at 55°C. The next 
day, proteinase K was inactivated at 95°C for 10 min and centrifugated for 10 min. DNA 
samples were stored at 4°C.  
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3.4.2. Genotyping 
Polymerase chain reaction (PCR) was used to determine genotypes of in this study used 
animals. For each mouse strain specific primer (Table 3-) and reaction mix (Table 3-12, 
13, 16, 18, 19, 20) were used. PCR products were analyzed by agarose gel 
electrophorese.  
 
3.4.2.1. Genotyping of βB1-CTGF1 mice 
For genotyping of βB1-CTGF1 mice two different PCRs (βB1 and SV40) were performed, 
which are both specific for transgenic animals. PCR reaction mix are shown in table 3-
12 and 3-13. Appropriate cycler programs are shown in table 3-14 and 3-15. 
 
βB1 PCR 
H2O 11.25µl 
Q buffer 1.5µl 
βb1 forward primer (10 µM) 0.3µl 
βb1 reverse primer (10 µM) 0.3µl 
dNTP`s (10mM) 0.3µl 
Taq DNA-polymerase 0.15µl 
DNA 1.2µl 
Table 3-12: Reaction mix for βB1 PCR 
SV40 PCR 
H2O 7.15µl 
Q buffer 1.5µl 
SV40 forward primer (10 µM) 0.3µl 
SV40 reverse primer (10 µM) 0.3µl 
dNTP`s (10mM) 0.3µl 
Taq DNA-polymerase 0.15µl 
glycerol 3µl 
MgCl2 (25mM) 0.3µl 
DNA 2µl 
Table 3-13: Reaction mix for SV40 PCR 
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βB1 PCR Cycler Program 
 temperature (°C) duration  
 
 
x32 
initiation 96 2min  
denaturation 94 30sec 
annealing 65 30sec 
elongation 72 20sec 
elongation 72 2min  
hold 4 ∞ 
Table 3-14: βB1 PCR Cycler Program 
SV40 PCR Cycler Program 
 temperature (°C)  duration   
 
 
x 35 
initiation 94 2min 
denaturation 94 30sec 
annealing 55 30sec 
elongation 72 45sec 
elongation 72 5min 
hold 4 ∞ 
Table 3-15: SV40 PCR Cycler Program 
3.4.2.1. Genotyping of CTGFLacZ/+ mice 
Genotyping of CTGFLacZ/+ mice was performed with two primers specific for the LacZ 
cassette. Reaction mix is shown in table 3-16. Appropriate cycler program is shown in 
table 3-17.   
CTGFLacZ/+ PCR 
H2O 16.55 µl 
5x PCR buffer 5 µl 
LacZ forward primer (10 µM) 0.5 µl 
LacZ reverse primer (10 µM) 0.5 µl 
dNTP’s (10 mM) 0.5 µl 
MgCl2 (50 mM) 0.75 µl 
Mango Taq DNA-polymerase  0.15 µl 
DNA 1 µl 
Table 3-16: Reaction mix for CTGFLacZ/+ PCR 
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CTGFLacZ/+ PCR Cycler Program 
 temperature (°C) duration (min)  
 
 
x 30 
 
initiation 95 6 
denaturation 95 1 
annealing 50 1 
elongation 72 1 
elongation 72 6 
hold 4 ∞ 
Table 3-17: CTGFLacZ/+ PCR Cycler Program 
 
3.4.2.3. Genotyping of CTGFCoin/Coin;CAGGCre-ER mice 
For genotyping of CTGFCoin/Coin;CAGGCre-ER mice three individual PCR, specific either 
of the Exon2 WT allele, the Coin-Intron or the Cre recombinase were performed. 
Reaction mix are shown in table 3-18, 3-19 and 3-20. Appropriate cycler programs are 
shown in table 3-21, 3-22 and 3-23.    
 
 
 
CAGGCre PCR 
H2O 9.45µl 
5x PCR buffer 3µl 
LacZ forward primer (100µM) 0.3µl 
LacZ reverse primer (100µM) 0.3µl 
dNTP’s (10mM) 0.3µl 
MgCl2 (50mM) 0.5µl 
Taq DNA-polymerase  0.15µl 
DNA 1µl 
Table 3-18: CAGGCre PCR Cycler Program 
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Coin/Coin PCR 
H2O 16.55 µl 
5x PCR buffer 5 µl 
LacZ forward primer (100µM) 0.5 µl 
LacZ reverse primer (100µM) 0.5 µl 
dNTP_`s (10mM) 0.5 µl 
MgCl2 (50mM) 0.75 µl 
Mango Taq DNA-polymerase  0.15 µl 
DNA 1 µl 
Table 3-19: Coin/Coin PCR Cycler Program 
 
Exon2 PCR 
H2O 16.55 µl 
5x PCR buffer 5 µl 
LacZ forward primer (100µM) 0.5 µl 
LacZ reverse primer (100µM) 0.5 µl 
dNTP’s (10mM) 0.5 µl 
MgCl2 (50mM) 0.75 µl 
Taq DNA-polymerase  0.15 µl 
DNA 1 µl 
Table 3-20: Exon2 PCR Cycler Program 
 
CAGGCre PCR Cycler Program 
 temperature (°C) duration   
 
 
x34 
initiation 95 3 min 
denaturation 95 30 sec 
annealing 61 30 sec 
elongation 72 35 sec 
elongation 72 5min 
hold 4 ∞ 
Table 3-21: CAGGCre PCR Cycler Program 
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Coin/Coin PCR Cycler Program 
 temperature (°C) duration   
 
 
x 40 
initiation 94 6 min 
denaturation 94 30 sec 
annealing 50.4 30 sec 
elongation 72 30 sec 
elongation 72 6 min 
hold 4 ∞ 
Table 3-22: Coin/Coin PCR Cycler Program 
 
Exon2 PCR Cycler Program 
 temperature (°C) duration   
 
 
x 35 
initiation 94 6 min 
denaturation 94 30 sec 
annealing 60 30 sec 
elongation 72 30 sec 
elongation 72 6 min 
hold 4 ∞ 
Table 3-23: Exon2 PCR Cycler Program 
 
3.4.3. Agarose gel-electrophorese 
After amplification, PCR products were analyzed by agarose gel-electrophorese. 
Therefore, 1 g agarose was dissolved in 100ml TBE buffer and 3 µl Ethidium bromide 
(EtBr) was added to a final concentration of 50 ng/ml. The characteristic of EtBr to 
intercalate into DNA was utilized to make the DNA fragments visible under UV light. 12µl 
of each sample was loaded on the gel and separated for 30 min at 120 V. To determine 
the size of the PCR products an additional standard DNA ladder was loaded on the gel. 
DNA fragments were visualized and analyzed under the UV light (302nm). 
3.5. Expression analysis 
3.5.1. RNA isolation 
RNA from mouse tissue as well as from human and murine cells was isolated after 
Chomczyski and Sacchi (Chomczynski & Sacchi 1987).For detachment of both cell types 
and digestion of mouse tissue and cells peqGold TriFast™ Trizol reagent was used. 
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PeqGold TriFast™ Trizol is a single-phase solution containing phenol and 
guanidinisothiocyanat. By addition of chloroform three different phases, the aqueous 
phase containing the RNA, the interphase including the DNA and the organic phase 
containing proteins, are generated. RNA isolation was performed as follows according 
to the manufactures instructions.  500 µl peqGold TriFast™ Trizol reagent was added to 
the mouse tissue and cell culture samples.  Anterior eye segments and retinae were 
digestated via the Ultra Thurax (Biolabproducts, Bebensee, Germany), optic nerves, 
optic nerve heads and corneal scleral rims with Shredder Tubes (Lysing Matrix D, MP 
Biomedicals, Burlingame, USA) via the FastPrep-24™ instrument (MP Biomedicals, 
Burlingame, USA) and cells were removed by using a cell scraper. Phase separation 
was made by adding 200 µl chloroform, shaking and centrifugation at 12000 rpm for 
20  min. Aqueous phase containing the RNA was transferred to a new tube and 250 µl 
isopropanol was added to precipitate RNA and incubated overnight at 4°C. After 
centrifugation (12000 rpm, 20 min) the supernatant was removed, and the pellet was 
washed twice with 75 % ethanol and centrifugation at 12000 rpm for 10 min. RNA pellet 
was finally dissolved in 10 µl RNase free water and stored at -80°C. 
 
3.5.2. RNA quantification 
With the NanoDrop photometer the RNA concentration and quality were measured. RNA 
concentration was determined with the absorption measurement at the wavelength 
260  nm. To detect protein and solvent contamination an additional measurement at the 
absorptions spectrum 220 nm to 350 nm was made. For pure RNA the A260/A280 
quotient should be between 1.9-2.1.   
3.5.3. cDNA synthesis  
At the procedure of the cDNA synthesis, the mRNA is transcribed via the enzyme 
Reverse Transcriptase. Therefore, the appropriate amount of RNA was mix with qScript 
Reaction Mix (5x) and qScript Reverse Transcriptase and the cycling program mentioned 
below (Table 3-23) was carried out (+RT). To test contamination of RNA negative 
controls, without Reverse Transcriptase) were performed for each sample (-RT). 
Reagent Amount 
RNA 0.1 – 0.5µg 
qScript Reaction Mix (5x) 2µl 
qScript Reverse Transcriptase 0.5µl 
RNase free H2O to 7.5µl 
Table 3-24: Reaction mix for cDNA synthesis 
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Temperature Duration 
22 °C 5 min 
42°C 30 min 
85 °C 5 min 
4°C hold 
Table 3-25: Cycler Program for cDNA synthesis 
3.5.4. Real-time RT-PCR 
The relative mRNA expression for the in vitro and in vivo experiments was determined 
via Real-time RT-PCR. The analysis was performed on the CFX Connect Real-Time 
System (BioRad, Munich, Germany), with the temperature profile as follows: 50 cycles 
of 20 s melting at 94°C, 10 s of annealing at 60°C and 20 s of extension at 60°C. All 
primers were purchased from Invitrogen and extended over exon-intron boundaries. 
RNA that was not reverse transcribed served as negative control (-RT) for Real-time RT-
PCR. For relative quantification of the experiments, RPL32 was used as a housekeeping 
gene. Quantification was performed using Bio-Rad iQ5 Standard Edition software 
version 2.0.148.60623 (BioRad). The mean value obtained from untreated cells or wild 
type mice was set at 1. The reaction mix was performed was follows. 
 
 
 
Reagent Amount for 1x reaction  
Universal SYBR Green 
Master (ROX) 
7.5µl  
Forward Primer 2.5µl Final concentration 300mM 
Reverse Primer 2.5µl Final concentration 300mM 
Nuclease-free water 2.2µl  
template (+RT, -RT, 
nuclease-free water) 
0.3µl  
Table 3-26: Reaction mix for Real-Time RT-PCR. 
3.5.5. TaqMan® Gene Expression Assay  
As in the ON and ONH of 1-month-old βB1-CTGF1 mice CTGF and GFAP are expressed 
in very low levels. Therefore TaqMan® Gene Expression Assay were performed for an 
improved amplification in comparison to the conventional Real-time RT-PCR. The 
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sequence specific Taqman® probes were obtained from ThermoFisher Scientific 
(Darmstadt, Germany), containing an Applied Biosystems™ FAM dye label on the 5’end 
and a minor groove binder (MGB) and non-fluorescent quencher (NFQ) on the 3’end. A 
suitable TagMan™Fast Advanced Master Mix, containing AmpliTaq®Fast DNA 
Polymerase, uracil-N glycosylase (UNG), dNTPs with dUTP, ROX™ dye (as a passive 
reference) and optimized buffer components was used for TaqMan® Gene Expression 
Assay. During denaturation step the signal form the fluorescent dye on the 5’end is 
quenched by the NFQ on the 3’end. In the next step, the specific TaqMan probe anneal 
to its specific target sequence. Taq DNA polymerase starts to synthesize the new strand. 
At the position of the TaqMan probe the 5’nuclease activity cleaves the probe and 
thereby separating the dye from the quencher. The produced fluorescent signal can be 
detected comparable to the conventional Real-time RT-PCR. 
 
Component Amount (µl) 
TaqMan®Fast Advanced Master Mix (2x) 10 
TaqMan® probe 1 
cDNA template 2 
Nuclease-free water 7 
Total volume per reaction 20 
Table 3-27: Reaction mix for TaqMan® Gene Expression Assay 
 
 
TaqMan® Gene Expression Assay Cycler Program 
 temperature (°C) duration (sec)  
Polymerase 
activation 
95 20  
denaturation 95 1  
x50 anneal/extend 60 20 
Table 3-28: TaqMan® Gene Expression Assay Cycler Program 
 
3.6. Biochemical techniques 
3.6.1. Protein isolation via peqGold TriFast™ Trizol method 
Besides RNA isolation, the peqGold TriFast™ Trizol method is utilized for protein 
isolation in the in vitro and in vivo experiments. Therefore, the total protein in the 
remaining organic phase contains the total protein, which was precipitated by addition of 
750µl isopropanol. After three washing steps with Washing Buffer for protein isolation 
(0.3 M Guanidine HCL in 95 % Ethanol) for 20 min following a centrifugation step for 
5  min at 700g and the final washing step with 95% ethanol (7600g, 5min), the protein 
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samples are dried. Finally, the protein pellet was dissolved in 1% SDS, containing 
protease- and phosphatase inhibitor and stored for further use at -80°C. 
 
3.6.2. Bicinchoninic Assay (BCA assay) 
The BCA assay is a photometric method for protein concentration measurement. The 
method relies on two reactions. The peptide bonds of the proteins reduce the Cu2+ to 
Cu+ and this Cu+ chelate to a purple-colored complex that absorbs light at a wavelength 
at 562 nm. This colored complex was measured on the Sunrise-Basic ELISA Reader 
(Tecan Austria GmbH, Groding, Austria). A standard row was additionally applied to the 
measurement, by this the concentration of the protein of human and murine cells as well 
as mouse tissue can be determined as the color change is proportional to the total protein 
amount.  
3.6.3. SDS polyacrylamide gel-electrophorese 
Proteins were separated for further Western Blot analysis by SDS polyacrylamide gel-
electrophorese (Laemmli 1970). Therefore, the suitable SDS polyacrylamide gel for the 
molecular weight of each protein was prepared, according to the following protocol 
(Table 3-29). 
 
Reagent Stacking 
gel 
Running gel 
  6% 10% 12% 15% 
dH2O 0.68µl 2.6µl 1.9µl 1.6µl 1.1µl 
Rotiphorese® 
mix 
0.17µl 1.0µl 1.7µl 2.0µl 2.5µl 
1.5 M 
Tris/HCl pH 
8.8 
 
- 
 
1.3µl 
 
1.3µl 
 
1.3µl 
 
1.3µl 
1.0 M 
Tris/HCl pH 
6.8 
 
0.13µl 
 
- 
 
- 
 
- 
 
- 
10% SDS 0.01µl 0.05µl 0.05µl 0.05µl 0.05µl 
10% APS 0.01µl 0.05µl 0.05µl 0.05µl 0.05µl 
TEMED 0.001µl 0.004µl 0.002µl 0.002µl 0.002µl 
Table 3-29: Components of SDS-gels. 
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The protein samples were blended with 5x Laemmli buffer and heated at 100°C for 
5  min, for protein denaturation. After the polymerization of the gels, 25 µl of each sample 
was loaded on the gel. For determination of molecular protein weight an additional 
molecular weight standard was added to one line. The electrophoresis was performed at 
20 mA for one gel for 1 to 1.5 h. 
3.6.4. Semidry-Blotting 
The proteins separated after the electrophoresis were then transferred on a PVDF 
membrane (pore size 0.45 µm) by semidry blotting. Therefor the membrane was 
activated in methanol for 1 min and the blots were assembled as follows: Cathode, 3 
Whatman paper, Running gel, PVDF membrane, 2 Whatman paper, Anode. Blotting was 
performed at 14 V, 190 mA per gel for 45 min. 
3.6.5. Detection of specific proteins 
Protein bands of the target protein in the Western blot analysis were detected by specific 
antibodies. The primary antibody is specific for the antigen of the desired protein. The 
originated antibody-antigen complex is then being targeted by the secondary antibody. 
By conjugate the secondary antibody with horseradish peroxidase (HRP) or alkaline 
phosphatase (AP) the binding complex can be visualized by adding a HRP- or AP-
substrate respectively. The protein synthesis analysis in this study were performed as 
follows. 
Protein Blocking solution Primary antibody Secondary 
antibody 
CTGF 5% BSA in TBST goat anti-CTGF 
1:500 in 0.5% BSA 
in TBST 
donkey anti-goat 
IgG HRP, 1:2000 in 
0.5% BSA in TBST 
GFAP 5% MM in TBST chicken anti-GFAP, 
1:10000 in 0.5% 
MP in TBST 
rabbit anti-chicken 
IgG HRP, 1:2000 in 
0.5% MP in TBST 
Vimentin 5% MM in TBST goat anti-Vimentin, 
1:500 in 0.5% MP 
in TBST 
donkey anti-goat 
IgG HRP, 1:2000 in 
0.5% MP in TBST 
CD44 5% BSA in TBST mouse anti-CD44, 
1:500 in 0.5% BSA 
in TBST 
horse anti-mouse 
IgG HRP, 1:2000 in 
0.5% BSA in TBST 
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α-tubulin 5% BSA in TBST rabbit anti- α-
tubulin, 1:2500 in 
0.5% BSA in TBST 
goat anti-rabbit IgG 
AP, 1:2000 in 0.5% 
BSA in TBST 
Caveolin1 5%BSA in TBST rabbit anit-
Caveolin1 1:4000 
in 0.5% BSA in 
TBST 
goat anti-rabbit IgG 
HRP, 1:5000 in 
0.5% BSA in TBST 
Table 3-30: Used blocking solutions, primary and secondary antibodies used for Western Blot 
analysis. 
3.6.6. Coomassie staining 
Via the Coomassie staining (Sambrook J. 1989) the whole amount on the membrane 
can be detected. Therefor the membrane was incubated in the Coomassie solution 
during shaking for 10 min. Afterwards the membrane was washed until the protein bands 
were visible. Finally, the dried membrane was recorded on the LAS 3000 Intelligent Dark 
Box.  
 
 
3.7. Cell culture 
3.7.1. Cell lines and culture conditions 
Cell line Medium Culture condition 
murine optic nerve 
astrocytes 
 
DMEM F12 + 10% (v/v) 
FCS, 1% astrocyte growth 
supplement, 100 U/ml 
Penicillin, 100 μg/ml 
Streptomycin  
 
37°C, 5% CO2 
human trabecular 
meshwork (HTM) cells 
DMEM F12 + 5% (v/v) 
FCS, 100 U/ml Penicillin, 
100 μg/ml Streptomycin  
 
37°C, 7% CO2 
Table 3-31: Used cell lines, appropriate medium and culture conditions 
3.7.2. General working conditions 
Cells were cultured in an incubator (Hera Safe, Heraeus, Hanau, Germany) with stable 
temperature and CO2 conditions. All treatments, passaging and other procedures of the 
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cells as well as production of buffers and solutions were performed under a sterile 
working bench (Hera Safe, Heraeus, Hanau, Germany). Glassware, buffers and 
solutions were autoclaved prior to use and plastic material was packed sterile.   
3.7.2.1. Passaging of cells 
Once cells reached 100% confluence, cells were removed from the bottom of the cell 
culture flask and transferred into a new flask. Therefore, the cell culture medium was 
removed, and cells were washed once with 1x PBS to get rid of remaining medium. By 
adding 1 ml 0.25% Trypsin cells were removed from the surface. After inactivation of the 
trypsin by adding FCS containing medium and centrifugation (5 min, 1000 rpm), the cell 
pellet was resuspended in cell culture medium and a defined number of cells were 
seeded in a new cell culture dish. For treatment cells were counted using Neubauer 
counting chamber and a defined number of cells was seeded in 6 wells.  
3.7.3. Isolation of murine optic nerve astrocytes 
CD1 mice were used for the isolation of ON astrocytes. After the mice were sacrificed, 
both eyes were enucleated, and the ON were cut off the globes. After removal of the 
dura, ON samples were digested in 200 µl 0.25% Trypsin (Gibco BRL, Karlsruhe, 
Germany) for 30 min at 37°C.  The tissue was then sheared by repeated pipetting and 
plated on laminin-coated 6-well plates. Cells were grown in DMEM F12 (Gibco BRL, 
Karlsruhe, Germany) enriched with 10% fetal bovine serum (FBS, Gibco BRL, Karlsruhe, 
Germany), 1% penicillin/streptomycin (Gibco BRL, Karlsruhe, Germany) and 
1%  astrocyte growth supplement (Sciencell, Carlsbad, CA, USA). Medium was not 
changed in the following seven days to allow the cells to attach to the tissue culture 
plates. After seven days, the medium was changed three times a week. A pure astrocyte 
culture was obtained by shaking the wells for 12 h to remove less adhesive cells. Cells 
were maintained in an incubator at 37°C and 5% CO2. After cells reached 100% 
confluence, they were seeded in 25 cm2 cell culture flasks (Nunc, VWR, Darmstadt, 
Germany). Astrocytes were characterized via GFAP-staining. Only cells from passage 2 
to 10 were used for experiments.  
3.7.4. In vitro experiments 
3.7.4.1. Treatment with CTGF and TGF-β2 
HTM and murine optic nerve astrocytes were treated either with 1ng/ml TGF-β2, 50ng/ml 
CTGF or left untreated as control. Therefore, the cells were seeded in 6wells and 
cultured until they reached confluency. Next the medium was replaced with medium 
containing 1% FCS (murine optic nerve astrocytes) or serum free medium (HTM cells) 
for 24 h. Prior to treatment the medium was replaced with fresh medium and the 
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appropriate amount of each growth factor was added. The cells were cultured again for 
24 h and harvest for RNA and protein analysis.  
3.7.4.2. Transfection of siRNA coated nanoparticles (NP) 
HTM cells in passage 5 to 7 were grown in 6-well cell culture dishes for several days. 
After reaching 80% confluency, cells were cultivated for 24 hours without serum and 
another 24 h with the addition of 1 ng/mL TGF-β2. NP (80 µg/mL) samples were 
prepared in Leibovitz media containing 0.35 % serum and 1 ng/mL TGF-β2 and left one 
hour at room temperature to form a protein corona. Cells were treated for four hours, 
washed with PBS once and left for 24 h in serum-supplemented medium. Thereafter, 
cells were cultured for additional 24 h without serum before RNA and protein extraction. 
3.7.4.3. Cultivation of murine ON astrocytes on increasing substratum stiffness 
To analyze the influence of increasing substratum stiffness murine optic nerve astrocytes 
were seeded on PDMS based cell culture (see 3.10.) dishes, for immunocytochemical 
staining (35 mm) or expression analysis (100 mm) and grown for week in serum 
containing medium. 24 h prior before harvesting the cells, the medium was exchanged 
with 1% FCS containing medium and cells were finally cropped for the corresponding 
analysis.  
3.8. In vivo experiments 
3.8.1. Preparation of anterior eye segments, retinae and corneal-scleral rims 
Before enucleation of the eyes, mice were anesthetized with CO2 and euthanized by 
atlanto-occipital dislocation. For the preparation of the anterior eye segments, the pos-
terior part of the eye was separated along the ora serrata and the whole anterior eye 
segment, including the cornea, trabecular meshwork, iris and ciliary muscle was transfer 
in a tube containing peqGold TriFast™ Trizol. The remaining retina in the posterior part 
was additionally taken out and, also transferred to a tube. For the preparation of the 
corneal scleral rims, the anterior eye segment was separated from the posterior part of 
the eye along the ora serrata and the lens was taken out. The anterior eye segment was 
cut in half and most of the cornea was removed. The hereby received tissue was trans-
ferred in containing peqGold TriFast™ Trizol containing tube for further expression anal-
ysis. 
3.8.2. Preparation of optic nerves and optic nerve heads 
Before enucleation of the eyes, mice were anesthetized with CO2 and euthanized by 
atlanto-occipital dislocation. First the anterior eye segment, the lens and retina were 
removed, and the optic nerve was cleaned from muscles and connective tissue. The 
sclera was cut away from the optic nerve head and potentially remaining parts of sclera 
and retina were removed. Second the optic nerve tissue was separated from the optic 
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nerve head. Both optic nerve and optic nerve head were stored in peqGold TriFast™ 
Trizol prior to RNA isolation.  
3.8.3. Preparation of retinal flat mounts 
Mice were anesthetized with CO2 and euthanized by atlanto-occipital dislocation and 
eyes were enucleated and fixed in 4% (w/v) paraformaldehyde (PFA) for 2 h. First the 
anterior eye segment and lens were removed, and the whole retina was taken out. To 
spread the retina flat on an object slide, it was incised on four opposite positions. The 
retinal flat mount was circuited with a fat pen (PapPen) and moisturized with 0.1 M Php.  
3.8.4. Transcardial perfusion 
Mice were anesthetized by injecting intraperitioneally a solution of ketamine (75 mg/ml) 
and Xylazine (5 mg/ml). As soon as the mice were completely anesthetized, the thoracic 
cavity was opened, and the heart was exposed. The injection needle was set into the left 
ventricle and the right atrial auricle was cut with a little incision and the mice were 
perfused first with 0.89 % NaCl and finally for fixation with 4% PFA (w/v). For retinal flat 
mounts mice were perfused with FITC-Dextran. Eyes were enucleated and incubated 
additionally in 4 % PFA (w/v) overnight.  
3.8.5. Perfusion of porcine and human eyes 
After the extraocular tissue was removed, the porcine and human eyes were submerged 
to the limbus in 0.89 % NaCl at 35°C. The perfusion system contained a perfusion 
chamber and a collection chamber. The infusion needle was inserted intracamerally 
through the transparent cornea into each eye and connected to the perfusion chamber. 
The needle was then carefully pushed through the pupil and the tip of the needle was 
placed in the posterior chamber. Next a second needle was placed intracamerally into 
the anterior chamber and connected to the collection reservoir. It is closed during the 
perfusion excepted during the exchanges. First a volume of 3 ml NPs was exchanged 
which took about 10 to 15 min, to ensure that the perfusion system as well as the anterior 
eye segment was filled with the perfusate. The eyes were either perfused with NP-
hyaluron (HA) or for control with NP-poly(ethylene imine) (PEI). In the next step, the 
collection chamber was closed, and the eyes were perfused at 10 mmHg constant 
pressure for 3 h. To rinse the perfused eyes, a second exchange with 3 ml 5 mM glucose 
was performed, which took again 10 to 15 min, followed by a second perfusion for 2 h 
with 5 mM glucose. For fixation, the eyes were additionally perfused with 4% (w/v) PFA 
for 30 min, again with a previous exchange step with 3 ml 4% (w/v) PFA. To get 
information about the distribution of NPs, the anterior chamber was dissected from the 
rest of the eyes and the iris was removed to free the outflow pathway. By fluorescent 
imaging the whole outflow ring was analyzed and regions with homogeneous distribution 
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of NPs were chosen for further investigations by marking them with needles. The probe 
was dissected and most of the sclera and cornea was removed. The small pieces were 
fixed with 4 % (w/v) PFA for 4 h and washed three times with 0.1 M Php.  
 
3.9. Histological techniques 
3.9.1. Cryo embedding and preparation of sections 
Eyes were incubated in 4 % (w/v) PFA overnight at 4°C. After three washing steps with 
0.1 M Php, the eyes were incubated in 10 %, 20 % and 30 % sucrose for 4 h respectively. 
Eyes were embbeded in Tissue-Tek® and stored at -20°C for further use. 12 µm 
tangential or sagittal sections were performed with the Microm HM500 OM Cryostat 
(Microm International, Walldorf, Germany). 
3.9.2. Paraffin embedding and preparation of sections 
Eyes were incubated in 4% (w/v) overnight and washed three times with 0.1  M 
phosphate buffer. Afterwards eyes were dehydrated in an ascending alcohol series 
and paraffin embedding was performed according to a standardized protocol (see 
table 3-32). 
Reagent Duration 
50% isopropanol 1h 
 
70% isopropanol 
1h 
overnight 
1h 
80% isopropanol 1h 
96% isopropanol 1h 
1h 
 
100% isopropanol 
1h 
1h 
2h 
100% Xylol 1h 
1.5h 
100% paraffin 4h 
8h 
Table 3-32: Protocol for ascending alcohol series and paraffin embedding  
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Afterwards eyes were embedded in liquid paraffin and by help with the cornea and 
the optic nerve the eyes were taken to a sagittal position. On the Supercut-Mikrotom 
6 µm sections were carried out and the they were dried overnight at 37°C and stored at 
RT for further use. 
3.9.3. Epon embedding and preparation of semi thin sections 
Eyes were fixed in EM-Fixative for 24h, following by three washing steps for 20 min with 
0.1 M cacodylate buffer. Afterwards eyes were additionally fixed with 
1%  osmimumtetraoxid and washed again with 0.1 M cacodylate buffer. Next eyes were 
dehydrated by an ascending alcohol series (70 %, 80 %, 90 %, 100 %). The Epon 
embedding was performed according to a standardized protocol: Ethanol/Acetone 1:1, 
Acetone 100 %, Epon/Acetone 1:2, Epon/Acetone 2:1, Epon 100 %. Eyes were 
hardened for 24 h at 60°C and 48 h at 90°C. For embedding with 2 % DMP-30 (Roth, 
Karlsruhe, Germany), Epon stem A and Epon stem B were mixed 1:1. Finally, 1 µm 
sections were performed and analyzed by light microscopy.  
3.9.4. Immunohistochemical staining of cryo sections 
Cryo sections were fixed to an objected slide and dried for 5 min. To remove 
remaining embedding medium slides were washed with 0.1 M phosphate buffer for 
5 min. Sections were orbited with a fat pen (PapPen) and incubate for 1 h at RT with 
the appropriate blocking solution. Afterwards the sections were incubated with the 
primary antibody at 4°C overnight. Next the sections were washed three times with 
0.1 M Php for 5 min and incubated with the secondary antibody for 1 h at RT. 
Appropriate staining protocol for each protein of this study is listed in the table below.  
Protein Blocking 
solution 
Primary antibody Secondary 
antibody 
CTGF 2% BSA, 0.2% 
CWFG, 0.1% 
Triton, 0.1M Php 
rabbit anti-CTGF 
1:100 in 0.2% BSA, 
0.02% CWFG, 
0.01% Triton, 0.1M 
Php 
goat anti-rabbit 
Cy™3 IgG 
1:2000 in 0.2% 
BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M Php 
GFAP 2% BSA, 0.2% 
CWFG, 0.1% 
Triton, 0.1M Php 
chicken anti-GFAP 
1:2000 in 0.2% BSA, 
0.02% CWFG, 
goat anti-chicken 
Alexa Fluor® 
488 IgG 1:1000 
in 0.2% BSA, 
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0.01% Triton, 0.1M 
Php 
0.02% CWFG, 
0.01% Triton, 
0.1M Php 
CD44 2% BSA, 0.2% 
CWFG, 0.1% 
Triton, 0.1M Php 
mouse anti-CD44 
1:100 in 0.2% BSA, 
0.02% CWFG, 
0.01% Triton, 0.1M 
Php 
donkey anti-
mouse Alexa 
Fluor® 488 IgG 
1:1000 in 0.2% 
BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M Php 
CD44 2% BSA, 0.2% 
CWFG, 0.1% 
Triton, 0.1M Php 
rabbit anti-CD44 
1:100 in 0.2% BSA, 
0.02% CWFG, 
0.01% Triton, 0.1M 
Php 
goat anti-rabbit 
Cy™3 IgG 1:2000 
in 0.2% BSA, 
0.02% CWFG, 
0.01% Triton, 
0.1M Php 
β-catenin 2% BSA, 0.2% 
CWFG, 0.1% 
Triton, 0.1M Php 
rabbit anti-β-catenin 
1:100 in 0.2% BSA, 
0.02% CWFG, 
0.01% Triton, 0.1M 
Php 
1. Biotinylated 
anti-rabbit IgG 
1:500 in 0.2% 
BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M Php 
2. Streptavidin 
Alexa Fluor® 488 
1:1000 in 0.2% 
BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M Php 
 
CD31 2% BSA, 0.1% 
Triton, 0.1M Php 
goat anti-CD31 
1:100 in 0.2% BSA, 
0.01% Triton, 0.1M 
Php 
1. Biotinylated 
anti-goat IgG 
1:500 in 0.2% 
BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M Php 
 
51 3. Material and methods 
2. Streptavidin 
Alexa Fluor® 488 
1:1000 in 0.2% 
BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M Php 
 
β-galactosidase 2% BSA, 0.2% 
CWFG, 0.1% 
Triton, 0.1M Php 
rabbit anti-β-
galactosidase 1:100 
in 0.2% BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M Php 
donkey anti-rabbit 
Alexa Fluor® 647 
IgG 1:200 in 0.2% 
BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M Php 
Glutamine 
synthetase 
2% BSA, 0.2% 
CWFG, 0.1% 
Triton, 0.1M Php 
goat anti-Glutamine 
synthetase 1:100 in 
0.2% BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M Php 
donkey anti-goat 
Alexa Fluor® 488 
IgG 1:1000 in 
0.2% BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M Php 
Caveolin1 2% BSA, 0.2% 
CWFG, 0.1% 
Triton, 0.1M Php 
rabbit anti-Caveolin1 
1:100 in 0.2% BSA, 
0.02% CWFG, 
0.01% Triton, 0.1M 
Php 
goat anti-rabbit 
Cy™3 IgG 1:2000 
in 0.2% BSA, 
0.02% CWFG, 
0.01% Triton, 
0.1M Php 
Myelin basic protein 
(MBP) 
2% BSA, 0.1% 
Triton, 0.1M Php 
rabbit anti-MBP 
1:200 in 0.2% BSA, 
0.01% Triton, 0.1M 
Php 
goat anti-rabbit 
Cy™3 IgG 1:2000 
in 0.2% BSA, 
0.01% Triton, 
0.1M Php 
Calcium binding 
adaptor molecule 
(IBA1) 
2% BSA, 0.2% 
CWFG, 0.1% 
Triton, 0.1M Php 
rabbit anti-IBA1 
1:100 in 0.2% BSA, 
0.01% Triton, 0.1M 
Php 
goat anti-rabbit 
Cy™3 IgG 1:2000 
in 0.2% BSA, 
0.02% CWFG, 
0.01% Triton, 
0.1M Php 
Table 3-33: Antibodies used for immunohistochemical staining 
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As a control for unspecific binding of the secondary antibody, negative controls were 
performed. Finally, 4,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, 
Burlingame, USA) was added to counterstain nuclear DNA. 
3.9.5. Immunohistochemical staining of paraffin sections 
Before immunohistochemical staining sections were deparaffinized (see table 3-34).  
Reagent Duration 
100% Xylol 2x 10min 
100% isopropanol 2x 10min 
96% isopropanol 2x 5min 
80% isopropanol 2x 5min 
70% isopropanol 1x 5min 
50% isopropanol 1x 5min 
dH2O  1x 5min 
Table 3-34: Protocol for deparaffinizing of paraffin sections 
In comparison to immunohistochemical staining on cryo sections, paraffin section must 
be pretreated before the actual staining. The pretreatment and the antibody staining were 
performed as follows. 
Protein Pretreatment Blocking 
solution 
Primary 
antibody 
Secondary 
antibody 
CD44 0.2M citric acid/ 
0.2M sodium 
citrate, 30min, 
boiling 
2% BSA, 
0.2% CWFG, 
0.1% Triton, 
0.1M Php 
mouse-anti 
CD44 1:100 in 
0.2% BSA, 
0.02% CWFG, 
0.01% Triton, 
0.1M Php 
donkey anti-
mouse Alexa 
Fluor® 647 
IgG 1:200 in 
0.2% BSA, 
0.02% CWFG, 
0.01% Triton, 
0.1M Php 
β-
galactosidase 
0.2M citric acid/ 
0.2M sodium 
citrate, 30min, 
boiling 
2% BSA, 
0.2% CWFG, 
0.1% Triton, 
0.1M Php 
rabbit-anti β-
galactosidase 
1:100 in 0.2% 
BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M 
Php 
donkey anti-
rabbit Alexa 
Fluor® 647 
IgG 1:200 in 
0.2% BSA, 
0.02% CWFG, 
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0.01% Triton, 
0.1M Php 
GFAP 0.2M citric acid/ 
0.2M sodium 
citrate, 30min, 
boiling 
2% BSA, 
0.2% CWFG, 
0.1% Triton, 
0.1M Php 
chicken-anti 
GFAP 1:2000 
in 0.2% BSA, 
0.02% CWFG, 
0.01% Triton, 
0.1M Php 
goat anti-
chicken Alexa 
Fluor® 488 
IgG 1:1000 in 
0.2% BSA, 
0.02% CWFG, 
0.01% Triton, 
0.1M Php 
CD31 1. 0.05 M TRIS-
HCL, 5 min 
2.  
3. 2 N HCL, 30 
min 
2% BSA, 
0.2% CWFG, 
0.1% Triton, 
0.1M Php 
goat anti-CD31 
1:100 in 0.2% 
BSA, 0.01% 
Triton, 0.1M 
Php 
1. Biotinylated 
anti-goat IgG 
1:500 in 0.2% 
BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M 
Php 
2. Streptavidin 
Alexa Fluor® 
488 1:1000 in 
0.2% BSA, 
0.02% CWFG, 
0.01% Triton, 
0.1M Php 
 
Table 3-35: Pretreatment and antibodies used for immunohistochemical staining 
As a control for unspecific binding of the secondary antibody, negative controls were 
performed. Finally, 4,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, 
Burlingame, USA) was added to counterstain nuclear DNA. 
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3.9.6. Immunohistochemical staining of retinal flat mounts 
Protein Pretreatment Blocking 
solution 
Primary 
antibody 
Secondary 
antibody 
β-
galactosidase 
50mM NH4Cl, 
1h, RT 
0.5% Triton-X 
100, 0.5h, RT 
2% BSA, 
0.2% CWFG, 
0.1% Triton, 
0.1M Php, 1h, 
RT 
rabbit-anti β-
galactosidase 
1:100 in 0.2% 
BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M 
Php, 2h, RT, 
following 
overnight at 
4°C 
goat anti-
rabbit Cy™3 
IgG 1:2000 in 
0.2% BSA, 
0.02% CWFG, 
0.01% Triton, 
0.1M Php, 1h, 
RT, following 
overnight at 
4°C 
Table 3-36: Pretreatment and antibody used for immunohistochemical staining of retinal flat 
mounts 
As a control for unspecific binding of the secondary antibody, negative controls were 
performed.  
3.9.7. Immunocytochemical staining  
HTM cells, seeded on coverslips and treated with either 1 ng/ml TGFβ2, 50 ng/ml CTGF 
or left untreated as controls and murine optic nerve astrocytes, cultured on cell culture 
dishes with increasing substratum stiffness were used for immunocytochemical staining 
in this study. Cells were washed twice with PBS, fixed with 4 % (w/v) PFA for 5 min and 
washed again three times with PBS. Specific antibodies were used as follows: 
Protein Blocking 
solution 
Primary antibody Secondary 
antibody 
CTGF 2% BSA, 0.2% 
CWFG, 0.1% 
Triton, 0.1M Php 
rabbit-anti CTGF 
1:100 in 0.2% BSA, 
0.02% CWFG, 
0.01% Triton, 0.1M 
Php 
goat anti-rabbit 
Alexa Fluor® 488 
IgG 1:1000 in 
0.2% BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M Php 
GFAP 2% BSA, 0.2% 
CWFG, 0.1% 
Triton, 0.1M Php 
chicken-anti GFAP 
1:2000 in 0.2% 
BSA, 0.02% 
goat anti-chicken 
Alexa Fluor® 488 
IgG 1:1000 in 
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CWFG, 0.01% 
Triton, 0.1M Php 
0.2% BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M Php 
CD44 2% BSA, 0.2% 
CWFG, 0.1% 
Triton, 0.1M Php 
mouse-anti CD44 
1:100 in 0.2% BSA, 
0.02% CWFG, 
0.01% Triton, 0.1M 
Php 
donkey anti-
mouse Alexa 
Fluor® 488 IgG 
1:1000 in 0.2% 
BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M Php 
Caveolin1 2% BSA, 0.2% 
CWFG, 0.1% 
Triton, 0.1M Php 
rabbit-anti 
Caveolin1 1:100 in 
0.2% BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M Php 
donkey anti-rabbit 
Alexa Fluor® 647 
IgG 1:200 in 0.2% 
BSA, 0.02% 
CWFG, 0.01% 
Triton, 0.1M Php 
Table 3-37: Antibodies used for immunocytochemical staining  
As a control for unspecific binding of the secondary antibody, negative controls were 
performed. Finally, 4,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, 
Burlingame, USA) was added to counterstain nuclear DNA. 
3.9.8. Phalloidin labeling 
To visualize the actin cytoskeleton of murine optic nerve astrocytes after different 
treatment, the cells were labeled with phalloidin-TRITC (Phallloidin-
Tetramethylrodamine B isothiocyanate; Sigma-Aldrich, Taufkirchen, Germany) 
1:1000 for 1 h at RT.  
3.9.9. β-galactosidase activity staining  
Before enucleation of the eyes, mice were anesthetized with CO2 and euthanized by 
atlanto-occipital dislocation. In this study mice with different age (P1, P5, P10, P15; P20, 
P49 and 1 year) were used for the following experiments. Embryos were obtained from 
time mating with noon of the day of vaginal plug discovery designated as 0.5 days of 
gastation (E 0.5). CTGF expression was analyzed at E11 and E16.5. Eyes and embryos 
were fixed with 2 % glutaraldehyde in 5mM EGTA (pH 7.3) and 2 mM MgCl2 dissolved 
in 0.1 M phosphate buffer for 30 min at RT. Followed by three washing steps with 
washing buffer (1 M MgCl2, 1 % NaDC, 2 % Tergitol in 0.1 M Php) and stained for 24 h 
at 37°C in the dark with X-Gal staining solution (2 mM MgCl2, 0.01 % sodium 
 
56 3. Material and methods 
deoxycholate, 0.02  %  Nonidet-P40, 5 mM potassium ferrocyanide, 5 mM potassium 
ferricyanide, 1  mg/ml X-Gal dissolved in 0.1 M Php) to visualize β-galactosidase activity. 
Afterwards tissues were washed three times for 10 min with washing buffer, following a 
second washing step for three times for 10 min with 0.1 M phosphate buffer. After the 
incubation for 1 h with 50% isopropanol and 1 h with 70% isopropanol, the tissues were 
embedded in paraffin. Finally, 6 µm sections were produced on the Supercut microtom 
(Reichert-Jung, Kirchseeon, Germany).  
3.9.10. β-galactosidase activity staining of retinal flat mounts 
Animal were sacrificed at P15 and both eyes were enucleated. Eyes were incubated in 
2% PFA for 1 h at RT, washed 3 times with LacZ washing buffer (1 M MgCl2, 1 % NaDC, 
2 % Tergitol in 0.1 M Php) for 10 min. Afterwards the whole retina was dissected and put 
on an object slide. The retina flat mounts were stained for 24 h at 37°C in the dark with 
X-Gal staining solution (2 mM MgCl2, 0.01% sodium deoxycholate, 0.02 % Nonidet-P40, 
5 mM potassium ferrocyanide, 5mM potassium ferricyanide, 1mg/ml X-Gal dissolved in 
0.1 M Php) to visualize β-galactosidase activity. Afterwards retinae were washed three 
times for 10 min with washing buffer, following a second washing step for three times for 
10 min with 0.1 M phosphate buffer. In a next step the tissues were mounted with Mowiol. 
The retinae were dried overnight before microscopy. 
3.10. Preparation of Polydimethylsiloxane Cell Substrata 
were purchased from Evonik Hanse GmbH, Gesthach, Germany. In the first step,  the 
components,  addition-curing basic polymer VS100 000 (vinyl-functional 
polydimethylsiloxane), the chain extender modifier 700 (SIH-terminated polydimethyl 
siloxane, difunctional structure), the reactive diluent MV2000 (mono-vinyl functional 
polydimethylsiloxane) and the inhibitor DVS (divinyl tetramethyl disiloxane) together with 
the plasticizer silicone oil (linear, non-reactive polydimethylsiloxane) AK10 (Wacker 
Chemie AG, Munich, Germany) were rotationally mixed for 6 min at 1000 rpm to form a 
basic elastomer (BE1) mixture. The mixing ratio of BE1 is shown in Table 3-38.  
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Mixtures Component Amount 
 
Basic elastomer mixture 
(BE1) 
VS100 000 14 g 
MV2000 2.5 g 
AK10 44 g 
Inhibitor DVS 250 µl 
Modifier 700 50 µl 
 
10 kPa 
BE1 12 g 
Cross linker AB116655 0.38 g 
Catalyst 510 40 µl 
 
 
30 kPa 
BE1 12 g 
Cross linker AB116655 0.38 g 
Cross linker 510 5 µl 
Catalyst 510 40 µl 
Inhibitor DVS 10 µl 
 
 
60 kPa 
BE1 12 g 
Cross linker AB116655 0.38 g 
Cross linker 510 20 µl 
Catalyst 510 70µl 
Inhibitor DVS 70µl 
Table 3-38: Elastomer mixtures of PDMS substrata, showing the parameters of the basic 
elastomer mixture and the additional amounts for the different substrata. 
In the next step, three different elastomers were prepared. All substrata (nominal 
indentation modulus    EIT = 10 kPa, 30 kPa, 60 kPa) based on the BE1 (12 g) were 
mixed with a cross linker AB116655 0.5-1% methylhydrosiloxane–dimethylsiloxane 
copolymer (ABCR GmbH, Karlsruhe, Germany), and a Pt-catalyst 510 (Evonik Hanse 
GmbH) in a defined mixture ratio. The “30 kPa” and “60 kPa” samples differ only in a 
small amount of additional cross linker 210 (Evonik Hanse GmbH) and a necessary 
additional catalyst and inhibitor ratio (Table 3-38). Depending on the batch, the parts 
corresponding to standard values must be slightly modified in order to precisely achieve 
target mechanical properties. In addition, air bubbles were removed by placing the 
elastomers in a vacuum chamber for 15 min. In conclusion, Petri dishes (µ-dish 35 mm 
high, uncoated, ibidi, Martinsried, Germany or greiner bio-one 94x16 mm PS) were 
coated (ibidi 0.5 g/greiner 4.5 g) with the finished, but uncured elastomer. In a further 
step, remaining air bubbles in the coating were removed using a vacuum chamber for 3 
min. The substrata were then cured in a universal oven (Memmert UF30Plus, Memmert 
GmbH, Schwabach, Germany) at 80°C for 1 hour and finally cured at 65°C 24 h (with 
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forced air circulation). The finished coated petri dishes were then washed twice with 70% 
isopropanol for 5 min and again with 99.5% ethanol for 5 min under slow shaking 
(Microplate mixer MX-M, China). The surfaces were then rinsed in ethanol 99.5% and 
dried in air. The cleaned coatings were then treated in an in-house designed ultra-
violet/ozone (UVO) emitter employing three 4 W (12 µW/cm2 at 1 m distance) low 
pressure mercury vapor lamps. The exposure times were 10 min with a 4 cm distance 
between the lamps and the sample’s surface in the same manner as documented (35). 
Directly after the UVO treatment, the surfaces were silanized with 3% aminopropyl-
triethoxysilane (APTES) in autoclaved deionized water (ddH2O) for 25 min at RT under 
slow shaking and washed five times in autoclaved water. In the next step, the petri dishes 
were treated with 0.3% glutardialdehyde (GDH) in filtered ddH2O for 40 min at RT under 
slow shaking and washed again five times in autoclaved ddH2O.  
3.11. Image Analysis 
The images were analyzed using ImageJ’s built-in measuring feature (Wayne Rasband, 
formerly National Institutes of Health, Bethesda, MD, USA). The surface area of the ONH 
section was calculated and the amount of area emitting fluorescent signal for GFAP or 
CTGF within the outlines of the ONH section was determined by a standardized macro 
routine consisting of ImageJ’s color threshold plugin and particle analyzer. The resulting 
values were used to calculate the percentage of area within the ONH section. These 
measurements were performed for each individual specimen after calibrating ImageJ 
with the scale bar.  
3.12. Light and Fluorescence Microscopy 
Histochemical, immunohistochemical and immunocytochemical stainings were analyzed 
using the Axio Imager Z1 microscope (Carl Zeiss, Göttingen, Germany). 
Immunocytochemical staining of stiffness experiments were analyzed on the Zeiss 
Observer Z1 (Carl Zeiss, Göttingen, Germany) and immunohistochemical staining of 
perfusion experiments were analyzed using the LSM 510 microscope (Carl Zeiss, 
Göttingen, Germany). 
3.13. Statistical Analysis 
Western blot and real-time RT-PCR was repeated at least three times with RNA and 
protein extract. Each real-time RT-PCR analysis was performed in triplicates. Data are 
presented as mean ± SD or SEM (quoted in each figure legend). Immunohistochemical 
and histological staining were performed at least three times on individual animals or cell 
lines. Student’s t-test was used for statistical analysis of the real-time RT-PCR and 
Western Blot. P value of ˂ 0.05 was considered to reflect statistical significance. 
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4. Results 
4.1. CTGF expression in the mouse eye 
Little is known about the localization and distribution of CTGF in the eye, especially 
during development. Since CTGF is a secreted protein, the CTGF expressing tissue and 
cell types cannot be identified by immunohistochemical staining. Therefore, the 
CTGFLacZ+/- mouse model, expressing β-galactosidase under the control of the CTGF 
promotor was used to determine the CTGF promotor activity in the relevant tissue and 
cell types. Histochemical and immunohistochemical studies in CTGFLacZ+/- mice were 
performed to identify the CTGF expressing tissue und cell types during development and 
in the adult mouse eye.  
Prior to the experiments each animal was genotyped (Figure 4-1). Since homozygote 
CTGF knockout mice are embryonic lethal (Ivkovic et al., 2003), the genotype of the 
offspring is either WT or heterozygous. The CTGFLacZ+/- PCR results is a single 500bp 
DNA band for CTGFLacZ+/- and no band for WT animals (Figure 4-1). 
 
 
 
Figure 4-1: CTGFLacZ+/- Genotyping. A representative CTGFLacZ+/- PCR showing the 500bp DNA band in heterozygous 
CTGFLacZ+/- mice. WT littermates exhibited no band in the CTGFLacZ+/- PCR.  
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4.1.1. Verification of heterozygous CTGF knockout 
To verify the heterozygous knockout of CTGF mRNA and protein analysis were 
performed on retinal tissue of CTGFLacZ/+ and WT mice, exemplary.  
 
Figure 4-2: Real-time RT-PCR and Western Blot analysis of CTGF in the retina of CTGFLacZ/+ and WT mice. (A) 
mRNA expression of CTGF in the retina of CTGFLacZ/+ mice (n=4; 0.50 ± 0.12 *p= 0.02) showed a significant heterozygous 
knockout in comparison to WT littermates (n=3; 1 ± 0.14). The mean value of WT mice was set at 1. RPL32 was used as 
housekeeping gene. (B) Densitometric analysis of CTGF protein synthesis in retinal tissue of CTGFLacZ/+ and WT mice. 
CTGF protein synthesis is significantly reduced in retina of CTGFLacZ/+ mice (n=6; 0.57± 0.35; *p=0.04) compared to WT 
littermates (n=6; 1 ± 0.23). A representative Western Blot is shown for CTGFLacZ/+ and WT mice. Mean value of WT mice 
was set at 1. α-tubulin was used as loading control. Data represented as mean ± SD.    
Real-time RT-PCR analysis showed a significantly reduced mRNA expression of CTGF 
in the retina of CTGFLacZ/+ mice (n=4; 0.50 ± 0.12 *p=0.02) in comparison to WT 
littermates (n=3; 1 ± 0.14) (Figure 4-2 A). Furthermore, the heterozygous knockout of 
CTGF could be confirmed by Western Blot analysis of retinal tissue (Figure 4-2 B). CTGF 
protein level of CTGFLacZ/+ (n=6; 0.57± 0.35; *p=0.04) retina tissue showed a significant 
reduction compared to WT control (n=6; 1 ± 0.23) (Figure 4-2 B).    
4.1.2. CTGF distribution during embryonic eye development 
To identify the CTGF promotor activity during the embryonic development of the mouse 
eye, two different timepoints were chosen for following experiments (Figure 4-3). The 
prenatal development of the mouse eye starts at 8 day of gestation (E8), therefore the 
timepoint E11 and E16.5 were analyzed for CTGF distribution in this study. At E11 the 
outer layer (future pigment layer of the retina) and the inner layer (future nervous layer 
of the retina) of the optic cup, as well as the lens vesicle are already developed (Figure 
4-3 A). By staining of the β-galactosidase activity at this timepoint, an expression of 
CTGF can be detected in the outer and inner layer of the optic cup, as well as in the lens 
vesicle (Figure 4-3 A). At the second analyzed timepoint (E16.5) several structures of 
the eye, as cornea, lens, sclera, ON, neural and pigment layer of the retina and a small 
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angle cavity, including the developing TM are well defined. At this future timepoint E16.5, 
CTGF expression can be observed in the anterior and posterior eye segment. In the 
anterior eye segment, CTGF expression can be detected in the epithelium of the cornea 
and in the anterior chamber angle, including the TM and the ciliary body. In the posterior 
eye segment, CTGF expression can be observed in the sclera, the choroidea, in the 
hyaloid artery and in the dura mater around the ON.  (Figure 4-3 B). As the lens is 
adhered to the corneal endothelium at this timepoint of development it cannot be 
distinguished if the LacZ staining is located to the endothelium of the cornea or the 
epithelium of the lens. (Figure 4-3 B).  
 
Figure 4-3: Staining of β-galactosidase activity during the embryonic development. (A) At E11, CTGF can be 
observed in the outer and inner layer of the optic cup and the lens vesicle. (B) At E16.5, CTGF expression can be detected 
in the endothelium and epithelium of the cornea, the lens epithelium, the sclera, the hyaloid artery and in the region of the 
developing TM. lv=lens vesicle; il = inner layer of the optic cup; ol = outer layer of the optic cup; irs = interretinal space; nr 
= nervous layer of the retina; pr = pigment layer of the retina; l = lens; c = cornea; ha = hyaloid artery; on = optic nerve; 
Scale bar: A = 50µm, B = 200µm. 
4.1.3. CTGF expression during postnatal development and in the adult eye 
In contrast to the human eye, several structures in the mouse eye are immature at birth 
and reach its maturation around postnatal day 21. For this reason, the mouse eye 
provides the ideal model to study developmental processes and expression pattern of 
proteins during eye development. Therefore, different timepoints were chosen to study 
the expression and distribution of CTGF in the postnatal developing mouse eye. CTGF 
expression was assessed on postnatal day 1, 5, 10, 15 and 20 (P1, P5, P10, P15, P20) 
(Figure 4-4 A-F). Additionally, adult mouse eyes were analyzed at the age of 7 weeks 
(Figure 4-4 G, H). The LacZ staining on WT littermates served as control and is shown 
for the timepoint P20 and the adult eye (Figure 4-4 F, H). 
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Figure 4-4: LacZ staining in sagittal sections of postnatal and adult CTGFLacZ+/- eyes. (A) CTGF expression at P1 
was shown in the corneal endothelium and epithelium, in the sclera and in the developing TM. (B) In P5 eyes CTGF is 
expressed in the corneal endothelium, epithelium and stroma, the sclera, in the developing TM and additionally in the ON. 
(C) At P10 a CTGF expression was observed in the corneal endothelium, epithelium and stroma, in the sclera, the retina, 
the TM and the ON. (D) At P15, LacZ staining visualized a comparable CTGF localization to P10, except the retina where 
the CTGF expression is increased. The CTGF expression at P20 (E) were finally restricted to the corneal endothelium, 
the sclera, the TM, the retina and the ONH. (F) LacZ staining in WT eyes showed no signal. re: retina; l: lens; c: cornea; 
*: ONH; Scale bar: 200µm.    
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4.1.3.1. CTGF expression in the anterior eye segment during postnatal 
development and in the adult eye 
In the anterior eye CTGF promotor activity is detected in the cornea, the TM and the 
ciliary body, with variations in the expression pattern depending on the developmental 
stage. The CTGF expression pattern in the cornea changes during development. At P1, 
a staining against β-galactosidase is detected in the corneal epithelium and stroma 
(Figure 4-4 A). As the lens is still adhered to the endothelium, it cannot clearly distinguish 
if the staining is located at the corneal endothelium or the epithelium of the lens capsule, 
but there is first evidence that the CTGF expression is localized to both structures (Figure 
4-4 A). By P5, the lens detaches from the corneal endothelium completely, whereby a 
LacZ staining in the corneal endothelium and epithelium of the lens can be detected. The 
CTGF expression in the corneal stroma and epithelium remains constant at this 
developmental stage (Figure 4-4 B). At P10 and P15 no changes in the CTGF expression 
in the different layers of the cornea are present (Figure 4-4 C, D). The LacZ staining in 
the lens epithelium is reduced, but still present at P10 and P15 (Figure 4-4 C, D). By 
P20, a shift in the corneal CTGF expression is observed. The LacZ staining is restricted 
to the corneal endothelium by this developmental point (Figure 4-4 E). The restricted 
CTGF promotor activity in the corneal endothelium is also observed in the adult eye 
(Figure 4-4 G). In the lens epithelium a low expression for CTGF is detected at P20 and 
in the adult eye, respectively (Figure 4-4 E, G).  
The LacZ staining of the anterior chamber angle indicated a high and persistent 
expression for CTGF in this region of the eye (Figure 4-5). The eye structures in the 
anterior chamber angle are derived from different origin. The formation of the iris and the 
ciliary body occurs at the peripheral edge of the optic cup. Therefore, the epithelial layers 
of iris and ciliary body have a neuroectoderm origin. In contrast, the stroma of both 
tissues is formed by a migration of mesenchyme cells along the epithelial layers. 
Additionally, the TM has a mesenchymal origin. At the embryonic timepoint E16.5, no 
differentiation into iris and ciliary had occurred, but lens and cornea are well defined. The 
anterior layer of future iris and ciliary body is heavily pigmented. At this timepoint, CTGF 
expression is present in the undifferentiated angle mesenchyme (Figure 4-6 B). One day 
after birth, the mesenchyme of developing iris and TM regions are distinguishable and 
the ciliary body processes have begun to form. CTGF promotor activity can be detected 
in mesenchyme of the developing iris, TM and in the pigmented epithelium of the ciliary 
body (Figure 4-5 C). By P5, the iris and the ciliary body are well formed. The CTGF 
expression is located to the inner surface of the pars plana of the ciliary body, the external 
epithelial layer of the iris and to the developing TM (Figure 4-5 D). The staining at P10 is 
similar to that detected at P5 (Figure 4-5 E). At P15, the CTGF promotor activity is 
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markedly increased with an intense staining in the TM, the inner surface of the pars 
plana, and both the pigmented and non-pigmented epithelium of the ciliary body (Figure 
4-5 F). Interestingly, at P20 CTGF is the restricted to the inner surface of the pars plana 
and the non-pigmented epithelium of the ciliary body. In the TM the CTGF expression 
remains constant (Figure 4-5 G). Finally, in the adult eye, the CTGF is located in the TM 
and the non-pigmented epithelium of the ciliary body (Figure 4-5 H).  
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Figure 4-5: Histological LacZ staining in the anterior chamber angle during development and in the adult eye. 
Panel shows enlarged excerpt of the anterior chamber angle of whole eye sections shown in Figure 4-4. Region of the 
enlarged excerpt is marked by the rectangle in A. (B) At E16.5, CTGF expression was detected in the undifferentiated 
angle mesenchyme. (C) At P1, CTGF promotor activity was shown in the mesenchyme of the developing iris and TM, and 
in the pigmented epithelium of the ciliary body. (D) At P5, CTGF expression was located in the pars plana of the ciliary 
body, the external layer of the iris and the developing TM. (E) At P10, CTGF expression is similar to P5. (F) At P15, CTGF 
expression was detected in the pars plana, the pigmented and the non-pigmented epithelium of the ciliary body. (G) At 
P20, CTGF expression was detected in the pars plana and the non-pigmented epithelium of the ciliary body as well as 
the TM. (H) In the adult eye, the CTGF expression was restricted to the TM and non-pigmented epithelium of the ciliary 
body. Scale bar: 50µm. 
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4.1.3.2. CTGF expression in the posterior eye during development and in the 
adult eye 
 
In the posterior part of the eye, CTGF promotor activity is detected in the retina, sclera, 
choroidea und ON with variations in the expression depending on the developmental 
timepoint (Figure 4-4 A-H). At P1, CTGF expression can be observed in the sclera and 
choroidea (Figure 4-6 A), in progress of the following developmental stages (P5, P10, 
P15 and P20) the expression is increased in both tissues (Figure 4-6 B-E). Additionally, 
CTGF promotor activity is detected in the RPE at these timepoints (Figure 4-6 B-E). In 
the adult eye, the expression in both choroidea and sclera is diminished and is 
completely absent in the RPE (Figure 4-6 F). Interestingly, in the retina CTGF expression 
is detected for the first time at P10 (Figure 4-4 C) and is persistent during the following 
developmental stages and in the mature eye (Figure 4-4 D, E, G). In detail, CTGF 
promotor activity visualized by LacZ staining is detected in the INL, ONL and GCL. In the 
ON, CTGF expression is first detected at P5 and increases during development and in 
the adult eye (Figure 4-4 A-G). Additionally, the dura mater around the ON revealed an 
intense CTGF promotor activity. The progress of the CTGF expression in the ON, ONH 
and dura mater is analyzed in detail in a following chapter. The LacZ staining in WT 
controls showed no signal either on P20 (Figure 4-4 F) nor in the adult eye (Figure 4-4 
H).  
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Figure 4-6: Histological LacZ staining in the choroidea and sclera during development and in the adult eye. Panel 
shows enlarged excerpts of the sections of the whole eyes in Figure 4-4. (A) At P1, CTGF promotor activity was detected 
in choroidea and sclera. (B) At P5, CTGF promotor activity was detected in the choroidea, sclera and in the RPE. (C) At 
P10, CTGF promotor activity was detected in the choroidea, sclera and RPE. (D) At P15, CTGF promotor activity was 
detected in the choroidea, sclera and RPE. (E) At P20, CTGF promotor activity was detected in the choroidea, sclera and 
RPE. (F) In the adult eye a CTGF promotor activity in the choroidea and sclera was detected. Scale bar: 50µm. 
Overall, an intense CTGF promotor activity is detected in the ONH during the 
development (Figure 4-7). At E16.5, the LacZ staining shows a CTGF promotor activity 
in the dura mater surrounding the ON and in the hyaloid artery (Figure 4-7 B). At P1, 
CTGF expression is increased in the dura mater (Figure 4-7 C). At P5, a strong alteration 
in the distribution of the CTGF expression can be observed as there is an intense 
expression in the glial lamina and the PRL region of the ONH. CTGF promotor activity in 
the dura mater remains constant at this developmental timepoint (Figure 4-7 D). This 
expression pattern of CTGF is persistent at all investigated developmental stages (Figure 
4-7 E-G). Only in the adult eye a reduced expression was observed in the dura mater 
(Figure 4-7 H). 
All in all, CTGF is highly expressed in the ONH during development and in the adult eye, 
mainly restricted to the region of the glial lamina and the PRL region.  
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Figure 4-7: Histological LacZ staining in the ON during development and in the adult eye. Panel shows enlarged 
excerpt of the region of the ONH of whole eye sections shown in Figure 4-4. Region of the enlarged excerpt is marked by 
the rectangle in A. (B) At E16.5, CTGF expression was detected in the dura mater around the ON and in the hyaloid 
artery. (C) At P1, CTGF expression was still located at the dura mater. (D) At P5, an intense CTGF promotor activity was 
detected in the glial lamina, the PRL region and the dura mater. (E, F) At P10 and P15, CTGF promotor activity was 
increased in the glial lamina, the PRL and the dura mater, and it shows a slight expression in the PSL. (G) At P20, CTGF 
expression was extenuated in the glial lamina but increased in the dura mater. (H) In the adult eye CTGF was expressed 
in the glial lamina and the PRL, and with a lower extent in the dura mater. PSL: postlaminar region; LC: Lamina cribrosa 
region; PRL: prelaminar region; ha: hyaloid artery. Scale bar: 50µm. 
Since it was difficult to localize the exact expression pattern of CTGF in the retina in the 
sagittal sections of the whole eye, retinal flat mounts were performed and analyzed by 
histological LacZ staining according to the detailed CTGF promotor activity. Based on 
the observed CTGF expression pattern P15 was chosen for the flat mount analysis. In 
retinal flat mounts, CTGF promotor activity is observed in the retinal vasculature and in 
cells spread over the entire retina (Figure 4-8 A). In Figure 4-8 B, the staining of the 
superficial plexus (asterisk) in the GCL and the cells spread over the entire retina (arrow) 
can be observed. Furthermore, the representation of the outer layer of the retina (Figure 
4-8 C) visualized a LacZ staining in the vasculature of the deep plexus (arrowhead) and 
also cells spread over the entire retina (arrow). 
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Figure 4-8: Histological LacZ staining of a retinal flat mount of P15 CTGFLacZ+/- mice. (A) In retinal flat mounts, the 
retinal vasculature and cells spread over the entire retina are detected. (B) Enlarged excerpt of the retinal flat mount 
showed the LacZ staining in the blood vessels of the superficial plexus (asterisk) and cells spread of the entire retina 
(arrow). (C) Enlarged excerpt of the retinal flat mount shoed the LacZ staining in the blood vessels of the deep plexus 
(arrowhead) and the cells spread of the entire retina (arrow). Scale bars: 500µm (A); 50µm (B, C).  
4.1.3.3. Immunohistochemical localization of CTGF expression in the anterior eye 
segment  
Since it is not possible to perform histological LacZ staining in combination with 
immunofluorescence staining, immunohistochemical staining with an antibody specific 
against β-galactosidase was performed to identify CTGF expressing cell types. 
Furthermore, the already identified CTGF expression pattern was confirmed by 
immunohistochemical staining against β-galactosidase. Following experiments were 
performed on sagittal and tangential sections of eyes at the developmental stage P15 
and the adult of the CTGFLacZ+/- mice. 
Immunohistochemical staining against β-galactosidase of sagittal section of the cornea 
verified the specific CTGF promotor activity depending on the developmental stage, 
which was already shown by histological LacZ staining in the previous experiments. At 
P15, CTGF expression is present in the corneal endothelium, epithelium and stroma 
(Figure 4-9 A). Whereas in the adult eye, CTGF promotor activity is restricted to the 
corneal endothelium (Figure 4-9 B).  
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Figure 4-9: CTGF promotor activity in the cornea. (A) Immunohistochemical staining against β-galactosidase (purple) 
in sagittal sections of the cornea of P15 CTGFLacZ+/- mice. CTGF promotor activity was detected in the corneal epithelium, 
stroma and endothelium. (B) Immunohistochemical staining in sagittal sections of the cornea of adult CTGFLacZ+/- mice. 
CTGF promotor activity was detected in the corneal endothelium. Nuclear DNA is labeled with DAPI (blue). ep: epithelium; 
st: stroma; en: endothelium. Scale bar: 50µm. 
Immunohistochemical staining against β-galactosidase in the anterior chamber angel 
could verify the previous findings in this region. CTGF shows an intense and persistent 
expression in the TM during development (P15) (Figure 4-10 A) and in the adult mouse 
eye (Figure 4-10 B). CTGF promotor activity in the ciliary body changes during the 
development and in the adult eye. At P15, CTGF is expressed in the ciliary stroma and 
the pigmented epithelium of the ciliary body (Figure 4-10 A). In the adult eye, CTGF 
promotor activity is detected mostly in the nonpigmented epithelium and with a low 
expression in the ciliary stroma (Figure 4-10 B). 
 
Figure 4-10: CTGF promotor activity in the anterior chamber angle. (A) Immunohistochemical staining against β-
galactosidase (purple) in the anterior chamber angle of P15 CTGFLacZ+/- mice showed an intense CTGF expression in the 
TM, the ciliary body and the cornea. (A) Immunohistochemical staining against β-galactosidase in the anterior chamber 
angle of adult CTGFLacZ+/- mice showed CTGF promotor activity in the TM, the non-pigmented epithelium of the ciliary 
body and the corneal endothelium. c: cornea; ir: iris; cb: ciliary body; re: retina; TM is depicted by an asterisk. Nuclear 
DNA is labeled with DAPI (blue). Scale bar: 50µm. 
To identify CTGF promotor activity in the endothelial lining of SC, sagittal sections of the 
anterior chamber angle of adult CTGFLacZ+/- mice were double stained with β-
galactosidase and CD31, a specific marker for endothelial cells (Figure 4-11 A, B). The 
endothelial lining of SC was nicely stained by CD31 (Figure 4-11 A, B). CTGF promotor 
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activity was detected directly adjacent to the SC, showing the expression in the TM and 
to a lower extent in endothelial cells of the SC (Figure 4-11 A’’, B’’; arrow).  
 
Figure 4-11: CTGF promotor activity in the endothelial lining of SC. (A) Immunohistochemical staining against β-
galactosidase (purple) and CD31 (green) in the anterior chamber angle of adult CTGFLacZ+/- mice. (B) Enlarged excerpt 
showed the colocalization of CTGF promotor activity (purple) with CD31 positive endothelial cells of the SC (green). Arrow 
depicts the colocalization. TM: trabecular meshwork; SC: Schlemm`s canal; Nuclear DNA is labeled with DAPI (blue). 
Scale bar: 20µm. 
4.1.3.4. CTGF expressing cell types in the developing and adult retina  
The analysis of CTGF promotor activity in the retina during development and in the adult 
eye by histochemical LacZ staining showed an equal expression pattern at both 
timepoints. CTGF expression was detected in the GCL, in cells in the innermost portion 
of the INL, in cell processes in the ONL, in the choroidea and in the sclera. 
Immunohistochemical staining against β-galactosidase in the retina during development 
and in adult eye confirmed the expression pattern of CTGF by histological LacZ staining. 
CTGF expression is detected in the GCL, the INL and in fibers extending through the 
entire retina, from the ILM to the OLM. Furthermore, signal for CTGF promotor activity is 
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detected in the choroidea and sclera. This expression pattern remains constant at both 
stages (Figure 4-12 A, B).  
 
 
Figure 4-12: Localization of CTGF promotor activity in the retina. (A) Immunohistochemical staining against β-
galactosidase (purple) in the retina of P15 CTGFLacZ+/- mice. CTGF promotor activity was detected in the GCL, in cells in 
the innermost portion of the INL, in processes extending the entire retina, the choroidea and the sclera. (B) 
Immunohistochemical staining against β-galactosidase (purple) in the retina of adult CTGFLacZ+/- mice. CTGF promotor 
activity was detected in the GCL, in cells in the innermost portion of the INL, in processes extending the entire retina, the 
choroidea and the sclera. Nuclear DNA is labeled with DAPI (blue). Scale bar: 50µm. 
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Retinal flat mounts at P15 were stained against β-galactosidase (Figure 4-13). The 
vertical view of the 3D reconstruction of z-stacks through the entire retina revealed an 
intense CTGF expression in the innermost layer of the retina, the GCL and in a deeper 
layer additionally (Figure 4-13 A). By single recording in the appropriate layer, the 
detailed CTGF expression in the blood vessels of the superficial plexus and the cells 
spreading over the entire retina (Figure 4-13 B) as well as the CTGF expressing cells in 
the deeper layer (Figure 4-13 C) were visualized in detail.  
 
Figure 4-13: Immunohistochemical staining against β-galactosidase (red) on retinal flat mounts of P15 CTGFLacZ+/- 
mice. (A) Vertical view of 3D representation of a retinal flat mount. An intense β-galactosidase staining was detected in 
the most inner layer of the retina and additionally in a deeper layer of the retina. (B) Enlarged excerpt of the staining in 
the inner layer of the retina. β-galactosidase staining indicated an endothelial expression and was localized in an additional 
cell type. (C) Enlarged excerpt of the β-galactosidase staining in the deeper layer of the retina, visualized a staining of 
rounded cell bodies of cells spread over the entire retina. Scale bar: 20µm. 
4.1.3.4.1. CTGF expression in the retinal and choroidal vasculature 
As CTGF shows an intense expression in the GCL and the choroidea, it leads to the 
suggestion that CTGF is expressed in endothelial cells of the superficial plexus and the 
choroidal vasculature Therefore, FITC-Dextran perfused retinal flat mounts and 
immunohistochemical staining against CD31 were double stained with β-galactosidase. 
FITC-Dextran perfused P15 retinal flat mounts visualized the superficial plexus and the 
double staining with β-galactosidase showed CTGF expression in endothelial cells of the 
superficial plexus (Figure 4-14 A). Enlarged sections visualized the close contact of β-
galactosidase positive cells to the blood vessels of the superficial plexus, indicating that 
endothelial cells are the source of the CTGF promotor activity in the GCL. (Figure 4-14 
B, C).  
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Figure 4-14: Immunohistochemical staining against β-galactosidase of FITC-Dextran perfused retinal flat mounts 
of CTGFLacZ+/- mice. (A) 3D representation of a FITC-Dextran (green) perfused retinal flat mount stained against β-
galactosidase (red) indicated an endothelial localization of CTGF expression. (B, C) Enlarged excerpts demonstrated the 
staining of β-galactosidase in endothelial cells. Scale bar: 20µm. 
 
 
Due to the thickness of retinal flat mounts, immunohistochemical staining is difficult as 
antibodies do not penetrate through the entire tissue Therefore, immunohistochemical 
staining were performed on retinal sagittal sections to identify CTGF expressing cell 
types. By immunohistochemical staining against CD31, the endothelial cells in the 
vasculature of retinal superficial plexus (Figure 4-15 A’, B’) and the choroidea (Figure 4-
16 A’, B’) was visualized. In combination with β-galactosidase staining a localization of 
CTGF in endothelial cells of the retinal (Figure 4- 15 A’’, B’’; arrow) and choroidal 
vasculature (Figure 4-16 A’’, B’’; arrow) was detected. 
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Figure 4-15: CTGF promotor activity in the adult retinal vasculature. Immunohistochemical staining against β-
galactosidase (purple) and CD31 (green) of retinal sections of adult CTGFLacZ+/- mice. (A) CD31 (green) specifically stained 
the endothelial cells in the blood vessels of the superficial plexus in the GCL. Co-staining against β-galactosidase (purple) 
visualized a co-localization with endothelial cells. (B) Enlarged excerpt demonstrated the localization of β-galactosidase 
(purple) with endothelial cells, stained with CD31 (green). Arrow depicts co-localization. Nuclear DNA is labeled with DAPI 
(blue). Scale bar: 20µm.   
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Figure 4-16: CTGF promotor activity in the choroidal vasculature. (A) Immunohistochemical staining of β-
galactosidase (purple) and CD31 (green) in sagittal sections of adult CTGFLacZ+/- mice. Endothelial cells of the choroidal 
vasculature are nicely visualized by CD31 staining. β-galactosidase staining shows a CTGF expression in the retina, 
choroidea and sclera. (B) Enlarged excerpt of choroidal vasculature showing the localization of the CTGF promotor activity 
in the endothelial cells of blood vessels in the choroidea. Nuclear DNA is labeled with DAPI (blue). Scale bar: 20µm. 
 
4.1.3.4.2. CTGF expression in retinal glial cells 
Furthermore, β-galactosidase staining in the NFL and GCL leads to the suggestion that 
the observed CTGF expression derives from retinal astrocytes. Therefore, 
immunohistochemical staining against β-galactosidase in combination with GFAP, a 
specific marker for astrocytes were performed on sagittal retinal sections of P15 and 
adult CTGFLacZ+/- mice. GFAP immunoreactivity identified the retinal astrocytes restricted 
to the vitreal surface of the retina, merely located in the NFL (Figure 4-17 A’- D’). By 
double staining with β-galactosidase no CTGF expression was detected in retinal 
astrocytes either on P15 nor in the adult retina (Figure 4-17 A’’-D’’).  
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Figure 4-17: CTGF is not expressed in retinal astrocytes. (A) Immunohistochemical staining against β-galactosidase 
(purple) and GFAP (green) on retinal section of P15 CTGFLacZ+/- mice. (B) Enlarged excerpt showed no co-localization of 
β-galactosidase (purple) and GFAP (green). (C) Immunohistochemical staining against β-galactosidase (purple) and 
GFAP (green) on retinal section of adult CTGFLacZ+/- mice. (D) Enlarged excerpt showed no co-localization of β-
galactosidase (purple) and GFAP (green). Nuclear DNA is labeled with DAPI (blue). Scale bar: A, C: 50µm; B, D: 20µm. 
As it was shown that retinal astrocytes are not the source of the CTGF promotor activity 
in the GCL and as the expression of CTGF detected in fibers extending the entire retina, 
it leads to the suggestion that Müller cells are the CTGF expressing cell type. Therefore, 
double staining against glutamine synthetase (GS), a specific marker for Müller cells and 
β-galactosidase were performed (Figure 4-18 A-E). GS staining specifically visualized 
the Müller cell processes penetrating the whole retina, from the ILM to the OLM (Figure 
4-18 A’-E’). This expression pattern of GS in Müller cells matches the immunoreactivity 
observed for β-galactosidase (Figure 4-18 A-E). This co-localization of GS and CTGF 
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promotor activity demonstrates that Müller cells are a source of CTGF promotor activity 
in the retina during development and in the adult eye (Figure 4-18 A’’- E’’).  
 
Figure 4-18: CTGF promotor activity in Müller cells of the retina. (A) Immunohistochemical staining of β-galactosidase 
(red) and GS (green) in retinal sagittal sections of P15 CTGFLacZ+/- mice. (B) Enlarged excerpt of the GCL and IPL indicated 
by the rectangle in A, showing CTGF expression in Müller cells, forming the ILM. (C) Enlarged excerpt of the ONL indicated 
by the rectangle in A, showing CTGF expression in Müller cells processes and in the OLM, formed by Müller cells. (D) 
Immunohistochemical staining of β-galactosidase (purple) and GS (green) in retinal sagittal sections of adult CTGFLacZ+/- 
mice. (E) Enlarged excerpt, indicated by the rectangle in D, showing CTGF expression in Müller cell processes, in the ILM 
and the OML. Nuclear DNA is labeled with DAPI (blue). Scale bar: 50µm (A); 20µm (B-E).  
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As CTGF promotor activity was detected in the GCL the possibility that microglia cells 
are an additional source of the CTGF expression was tested by immunohistochemical 
staining against the ionized calcium binding adaptor molecule 1 (IBA1), a specific marker 
for microglia and macrophages. It was not possible to perform double 
immunohistochemical staining against IBA1 and β-galactosidase as the host species of 
both antibodies was rabbit. Furthermore, the issue that these antibodies were the best 
working one, the analysis of microglia as a potential source of the CTGF promotor activity 
was performed on two consecutive sections of the same retina. IBA1 staining visualized 
the well-defined localization of microglia in the IPL and OPL as well as the GCL and the 
ON (Figure 4-19 B, D). To compare both staining enlarged excerpts of the same region 
of the retina of both sections were analyzed (Figure 4-19 C, D). No β-galactosidase 
staining is observed in the IPL or OPL layer, which indicates that microglia located at 
these retinal layers are not the CTGF expressing cells type (Figure 4-19 C, D). Since no 
CTGF promotor activity was observed in the IPL and OPL, it leads to the assumption 
that microglia are not a CTGF expressing cell type within the retina and the ON. 
 
Figure 4-19: Immunohistochemical staining of retinal sections of adult CTGFLacZ+/- mice against β-galactosidase 
and IBA1. (A) β-galactosidase staining (purple) of sagittal sections of the retina and the ON. (B) IBA1 staining (red) of 
sagittal sections of the retina and the ON. (C) Enlarged excerpt of β-galactosidase staining (purple) showed CTGF 
expression in the GCL and INL. (D) Enlarged excerpt of the IBA1 staining (red) visualized microglia located at the GCL, 
IPL and OPL. Nuclear DNA is labeled with DAPI (blue). Scale bar: 50µm. 
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4.2.3.4.3. CTGF expression in retinal interneurons 
Additionally, to CTGF positive Müller cells, β-galactosidase staining was detected in cells 
in the GCL and the innermost layer of the INL (Figure 4-20 A-D). By combination of their 
position within the retina, cell morphology and cell quantity, these cells have pegged as 
amacrine cells. Amacrine cells, a heterogeneous group of retinal interneurons, are 
located at the vitreal side of the INL and as displaced amacrine cells in the GCL. They 
can be distinguished from bipolar and horizontal cells, by their cell morphology and 
location within the retina. Horizontal cells are located at the outmost portion of the INL 
and bipolar cells are found in the INL, but not in the GCL.  Additionally, by 
immunohistochemical staining against Syntaxin-1A, a marker for amacrine cells, it was 
confirmed that amacrine cells express CTGF in the adult eye (Figure 4-21 A, B).  
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Figure 4-20: CTGF promotor activity in the INL and GCL. (A) Immunohistochemical staining against β-galactosidase 
(red) on retinal sections of P15 CTGFLacZ+/- mice. (B) Enlarged excerpts demonstrated the expression of CTGF in cells in 
the INL and GCL, indicating for amacrine cells as the source of the CTGF promotor activity. (C) Immunohistochemical 
staining against β-galactosidase (purple) on retinal sections of adult CTGFLacZ+/- mice. (D) Enlarged excerpts demonstrated 
the expression of CTGF in cells in the INL and GCL, indicating for amacrine cells as the source of the CTGF promotor 
activity. Nuclear DNA is labeled with DAPI (blue). Scale bar: 20µm. 
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Figure 4-21: CTGF promotor activity in amacrine cells in the adult retina. (A) Immunohistochemical staining against 
β-galactosidase (purple) and Syntaxin-1A (green) of retinal sections of adult CTGFLacZ+/- mice. Syntaxin-1A staining detects 
specifically amacrine cells in the outermost portion of the INL. (B) Enlarged excerpt shows a Syntaxin-1A stained amacrine 
cell in the INL and demonstrates the CTGF promotor activity in amacrine cells by the co-localization with β-galactosidase 
(purple). Sytnaxin-1A and β-galactosidase co-localization is depicted by an arrow. Nuclear DNA is labeled with DAPI 
(blue). Scale bar: 10µm 
All in all, it can be summarized that CTGF expressing cell types in the retina do not differ 
at P15 and in the adult eye. It was shown that Müller cells, amacrine cells and endothelial 
cells are the source for CTGF promotor activity in the mouse retina during development 
and in the adult eye.  
 
4.1.3.5. CTGF expressing cell types in the developing and adult ON 
In the ON, especially in the ONH an intense CTGF promotor activity was observed by 
histological LacZ staining during the development and in the mature eye. The major cell 
type in the ON are astrocytes, therefore immunohistochemical staining against GFAP in 
combination with an antibody against β-galactosidase was performed on sagittal and 
tangential sections of the ON.  β-galactosidase expression is observed throughout the 
entire ON with a more intense staining in the PRL region and the glial lamina (Figure 4-
22 A, C). Within the RPL region and the glial lamina, the enhanced CTGF promotor 
activity is mostly localized adjacent to the astrocyte nuclei (Figure 4-22 B, D) The CTGF 
expression pattern is equal in the developmental and adult ON. The expression intensity 
of P15 and adult sections cannot be compared as they the staining was not performed 
simultaneously.  
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Figure 4-22: CTGF promotor activity in the ON. (A) Immunohistochemical staining against β-galactosidase (purple) 
and GFAP (green) on sagittal ON sections of P15 CTGFLacZ+/- mice. The β-galactosidase staining revealed CTGF 
expression in the entire ON with an enhanced expression in the glial lamina. (B) Enlarged excerpt demonstrated the co-
localization of the CTGF promotor activity with ON astrocytes.  (C) Immunohistochemical staining against β-galactosidase 
(purple) and GFAP (green) on sagittal ON sections of adult CTGFLacZ+/- mice. β-galactosidase staining revealed CTGF 
expression in the entire ON, with an enhanced expression in the glial lamina and the PRL region. (D) Enlarged excerpts 
demonstrated the colocalization of the CTGF promotor activity with ON astrocytes. Nuclear DNA is labeled with DAPI 
(blue).  Scale bar: 50µm (A, B); 20 µm (B, D). 
As the composition of cell types varies depending on the localization in the ON sections 
we analyzed variations in CTGF promotor activity in these different regions. Therefore, 
successive tangential sections of the same ON at different positions were produced for 
both P15 and adult CTGFLacZ+/- mice. In the schematic illustration, the ONH and the major 
elements are shown (Figure 4-23). The positions of the tangential sections performed in 
the following experiments are depicted in the schematic illustration with different letters 
A to C (Figure 4-23).  
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Figure 4-23: Schematic illustration of the ONH and the major elements located there. The red lines demonstrate the 
origin of the tangential sections performed in the following experiments. V: blood Vessel; Ax: axons; RPE: retinal 
pigmented epithelium; PRL: prelaminar region; PRL: postlaminar region (Adapted and modified from Sun et al., 2009; 
Howell et al., 2007). 
 
The section depicted with A is located in the myelinated ON, containing mostly 
oligodendrocytes, myelinated axons and astrocytes with lower extent. The double 
staining in this region showed a slight CTGF expression colocalized with GFAP-positive 
astrocytes, specifically marked by GFAP (Figure 4-24 A and Figure 4-25 A). The highest 
expression is observed in the dura mater around the ON (Figure 4-24 A and Figure 4-25 
A). In the anterior region of the ON, tangential sections in two different positions of the 
glial lamina were produced. The sections depicted with B was established at the posterior 
side of the glial lamina, indicated by the formation of astrocyte processes to glial tubes 
and the entering of the blood vessel (Figure 4-24 B and Figure 4-25 B). The sections 
depicted with C was produced in the more anterior position of the glial lamina indicated 
by the position of the blood vessel with in the ON sections (Figure 4-24 C and Figure 4-
25 C). Immunohistochemical staining against β-galactosidase shows the highest CTGF 
promotor activity in the glial lamina, showed by the tangential sections B and C. The 
CTGF expression is colocalized with the intermediate filaments of the astrocytes. In 
comparison to the posterior part of the ON, an enhanced CTGF promotor activity is 
detected adjacent to the cell nuclei of astrocytes (Figure 4-24 B’’, C’’ and Figure 4-25 B’’, 
C’’). The CTGF expression pattern in the ON and the glial lamina is equal at both stages 
(Figure 4-24, 25).  
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Figure 4-24: CTGF promotor activity in optic nerve astrocytes in P15 CTGFLacZ+/- mice. A-C show successive 
tangential sections from the same ON. The origin of the tangential sections was shown in the schematic illustration in 
Figure 4-21. Immunohistochemical staining against β-galactosidase (purple) and the astrocyte marker GFAP (green). (A) 
β-galactosidase staining in tangential sections of the posterior, myelinated ON revealed CTGF expression in astrocytes 
and the dura mater. (B, C) Immunohistochemical staining against β-galactosidase in tangential sections of the glial lamina 
revealed an intense CTGF expression in astrocytes, with the highest expression adjacent to the astrocyte cell nuclei. The 
further CTGF expression not localized in astrocytes indicated an additional cell type as the source for the expression. (D-
F) Enlarged excerpts of the different tangential sections indicated by the rectangle demonstrates the CTGF expression 
(purple) in astrocytes (green). Nuclear DNA is labeled with DAPI (blue). Scale bar: 20µm (A-C); 5µm (D-F). 
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Figure 4-25: CTGF promotor activity in optic nerve astrocytes in adult CTGFLacZ+/- mice. A-C show successive 
tangential sections from the same ON. The origin of the tangential sections is shown in the schematic illustration in Figure 
4-21. Immunohistochemical staining against β-galactosidase (purple) and the astrocyte marker GFAP (green). (A) β-
galactosidase staining in tangential sections of the posterior, myelinated ON revealed a CTGF expression in astrocytes 
and the dura mater. (B, C) Immunohistochemical staining against β-galactosidase in tangential sections of the glial lamina 
revealed an intense CTGF expression in astrocytes, with the highest expression adjacent to the astrocyte cell nuclei. The 
further CTGF expression not localized in astrocytes indicates an additional cell type as the source for the expression. (D-
F) Enlarged excerpts of the different tangential sections indicated by the rectangle demonstrates the CTGF expression 
(purple) in astrocytes (green). Nuclear DNA is labeled with DAPI (blue).  Scale bar: 20µm (A-C); 5µm (D-F). 
 
Since the observed CTGF expression was not exclusively localized in astrocytes, an 
additional cell type must be the source of CTGF promotor activity. Therefore, a β-
galactosidase immunostaining was performed in combination with a staining against 
CD31 on sagittal sections of the adult ON (Figure 4-26). The double staining revealed 
an expression of CTGF in endothelial cells of blood vessels in the ON. CTGF promotor 
activity was mostly adjacent to the cell nuclei of endothelial cells (Figure 4-26 B’’; arrow). 
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Figure 4-26: CTGF promotor activity in endothelial cells in ON blood vessels. (A) Immunohistochemical staining 
against β-galactosidase (purple) and CD31 (green) in ON sections of adult CTGFLacZ+/- mice. CTGF promotor activity is 
detected in endothelial cells stained with CD31 (green) of ON blood vessels, (B) Enlarged excerpt of a blood vessel in the 
ON. Arrow depicts CTGF promotor activity (purple) in endothelial cells (green). Nuclear DNA is labeled with DAPI (blue). 
Scale bar: 20µm 
All in all, astrocytes and endothelial cells were identified as the source of CTGF 
expression in the developmental and adult ON with the highest expression in the glial 
lamina. Additionally, CTGF expression was detected in the dura mater around the ON. 
This expression is more intense during the development confirming the findings of 
histological LacZ staining.  
Overall, it can be concluded that CTGF is expressed in various tissues in the mouse eye 
throughout the entire development and in the fully developed eye. A persistent 
expression is detected in the corneal endothelium, the TM, the SC endothelium, the 
ciliary body, the choroidea, the sclera, the retina, the dura mater and the ONH. Variations 
in the expression pattern of CTGF during development in contrast to the mature eye 
were investigated in the corneal stroma and epithelium and the ciliary body. Within the 
ONH, the dura mater and the retina a change in the expression is seen in different 
developmental stages. In the retina, Müller cells, amacrine cells and endothelial cells 
were identified as the source of the CTGF promotor activity. Furthermore, the endothelial 
cells of the choroidea and SC were identified as a source of CTGF expression. ONH 
astrocytes as well as endothelial cells were identified as the major CTGF expressing cell 
type.  
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4.2. Effect of mechanical stress and increasing substratum stiffness on 
astrocyte reactivity 
 
Transgenic mice with lens-specific CTGF overexpression develop POAG characterized 
by higher IOP and progressive loss of axons in the ONH (Junglas et a., 2012). This 
glaucoma model was used to identify POAG-related changes in the glial lamina.  
Prior to all following experiments animals were genotyped at the age of 3 weeks (Figure 
4-27). Two different PCR were performed, both βB1 and SV40 specific for the transgenic 
animals. The βB1 PCR results in a 300bp product (Figure 4-27 A) and SV40 PCR results 
in a 360bp product (Figure 4-27 B) for transgenic animals. WT littermates show no 
product for both PCR.  
 
Figure 4-27: Representative βB1 (A) and SV40 (B) PCR. TG animals exhibited a DNA band in both PCR, whereas WT 
showed no band.   
4.2.1. GFAP and CTGF alterations in the ONH of 2-month-old βB1-CTGF1 mice 
To investigate POAG-related changes in the astrocytes that constitute the glial lamina of 
the transgenic animals, we investigated the presence of GFAP, a marker for reactive 
astrocytes, in tangential sections of the glial lamina of 1-month and 2-month-old βB1-
CTGF mice. GFAP immunostaining in the glial lamina of the 1-month old transgenic and 
WT mice showed no alteration in the protein level or the morphology of the astrocytes 
(Figure 2-28). This finding could be confirmed by the quantification of the GFAP stained 
area in the glial lamina (Figure 4-30 B; WT: n=8, 69.76 ± 3.85; TG: n=4, 74.47 ± 12.39).In 
2-month-old transgenic animals, the immunoreactivity for GFAP was increased and the 
processes of the astrocytes in the glial lamina were thickened in comparison to WT 
controls (Data were obtained and analyzed by Gregor R. Weber, MD thesis) Figure 4-29 
C, D). As a result, the spaces between the astrocyte processes of control mice were 
more open than in the transgenic animals. The quantification of the GFAP stained area 
in the glial lamina at the ONH showed a significant increase in the TG animals compared 
to WT littermates (Figure 4-30 D; WT: n=10, 37.43 ± 13.12; TG: n=13, 51.99 ± 17.50; 
*p= 0.039). To address the question, whether the amounts of CTGF are also changed in 
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the glial lamina of TG animals we analyzed the immunoreactivity against CTGF. A faint 
staining throughout the entire ON tissue with no obvious preference for glial or neuronal 
tissue is observed in TG and WT littermates. Immunoreactivity against CTGF showed no 
changes in the glial lamina of 1-month-old TG and WT mice (Figure 4-28). Furthermore, 
quantification of CTGF stained area in the sections of the glial lamina could not identify 
any variation (Figure 4-30 A; WT: n=5, 89.60 ± 2.20; TG: n=5, 87.74 ± 3.91). 2-month-
old WT animals showed the same distribution for CTGF as it was observed for the 1-
month-old animals. Interestingly, the intensity of the immunoreactivity for CTGF was 
dramatically increased in the 2- month-old animals compared to WT animals (Gregor R. 
Weber, MD thesis, Figure 4-29 E, F). Measurements of CTGF stained areas in the ONH 
show a significant increase in the TG mice in comparison to the WT littermates (Figure 
4-30 C; WT: n=3, 38.60 ± 1.51; TG: n=5, 62.21 ± 17.34; *p= 0.028). 
 
 
Figure 4-28: Immunostaining against GFAP and CTGF in the glial lamina of 1-month-old βB1-CTGF1 mice. (A,B) 
GFAP reactivity showed no alteration either in the protein synthesis nor in the astrocytes morphology in the TG mice in 
comparison to WT littermates. (C,D) CTGF reactivity showed no change in the TG animals compared to the WT 
littermates. Nuclear DNA is labeled with DAPI (blue). Scale bar: 50µm 
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Figure 4-29: The immunoreactivity of GFAP and CTGF was altered in tangential section of 2-month-old transgenic 
animals. GFAP was increased and the processes of the astrocytes in the glial lamina were thickened in comparison to 
controls. Further in the glial lamina region of the WT animals the spaces between the astrocyte processes were more 
open than in TG animals. Immunohistochemical staining against CTGF showed a faint staining in WT animals, in TG 
animals an increased signal for CTGF was observed. Nuclear DNA is labeled with DAPI (blue). Scale bar = 50µm (Gregor 
R. Weber; MD thesis). 
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Figure 4-30: Quantification of immunohistochemistry staining of CTGF and GFAP in the glial lamina of 1-month-
old WT and βB1-CTGF1 mice. The quantification showed no alternations for CTGF (A) (WT: n=5, 89.60 ± 2.20; TG: n=5, 
87.74 ± 3.91) and GFAP (B) (WT: n=8, 69.76 ± 3.85; TG: n=4, 74.47 ± 12.39).  
 
Figure 4-31: Quantification of immunohistochemistry staining of CTGF and GFAP in the glial lamina of 2-month-
old WT and βB1-CTGF1 mice. The quantification showed an increase for CTGF (A) (WT: n=3, 38.60 ± 1.51; TG: n=5, 
62.21 ± 17.34; *p= 0.028) and GFAP (B) (WT: n=10, 37.43 ± 13.12; TG: n=13, 51.99 ± 17.50; *p= 0.039) in TG animals 
compared to WT littermates. (Gregor R. Weber; thesis Dr.med.). 
 
Real-time RT-PCR analyses were performed to determine expression levels of CTGF 
and GFAP in the ON and ONH of 1-month -old and 2-month-old transgenic βB1-CTGF 
and WT mice (Figure 4-32). Analysis for CTGF mRNA show no changes in the 
expression either in the ON (Figure 4-32 A; WT: n=7, 1 ± 0.10; TG: n=4, 1.21± 0.14) or 
in the ONH (Figure 4-32 A; WT: n=6, 1 ± 0.18; TG: n=3, 1.06 ± 0.14). Similar results 
were detected in the Real-time RT-PCR analysis for GFAP, in which no change for the 
mRNA expression in the ON (Figure 4-32 B; WT: n=7, 1 ± 0.06; TG: n=5, 1.19  ±  0.24) 
and the ONH (Figure 4-32 B; WT: n=6, 1 ± 0.14; TG: n=5, 1.14 ± 0.15) could be revealed.  
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Interestingly, real time RT-PCR experiments showed a huge increase of CTGF in the 
ONH of TG animals compared to WT littermates (Figure 4-32 C; WT: n=6, 1 ± 0.12; TG: 
n=5, 10.04 ± 1.66; **p= 0.006). Intriguingly, the mRNA analyses of the ON showed no 
change the CTGF expression (Figure 4-32 C; WT: n=15, 1 ± 0.69; TG: n=17, 
1.07  ±  0.49). Furthermore, the examination of the GFAP mRNA level in the ON and the 
ONH revealed an increase in the ONH in the TG animals (Figure 4-32 D; WT: n=6, 
1  ±  0.13 TG: n=5, 5.08 ± 1.62; *p= 0.04), but not in the ON (Figure 4-32 D, WT: n=15, 
1  ±  0.68; TG: n=16, 0.85 ± 0.45) compared to WT control. 
 
 
Figure 4-32: Real-time RT-PCR analysis for CTGF and GFAP in 1-month-old and 2-month-old βB1-CTGF1 and 
wildtype mice. (A) mRNA expression analysis showed no alternation in the ON (WT: n=7, 1 ± 0.10; TG: n=4, 1.21± 0.14) 
and ONH (WT: n=6, 1 ± 0.18; TG: n=3, 1.06 ± 0.14) for CTGF in the TG animals in comparison to WT littermates. (B) 
GFAP mRNA expression was not changed in the ON (WT: n=7, 1 ± 0.06; TG: n=5, 1.19 ± 0.24) and the ONH (WT: n=6, 
1 ± 0.14; TG: n=5, 1.14 ± 0.15) of TG mice compared to WT. The mean value of WT mice was set at 1. RPL32 was used 
as a housekeeping gene. (C) mRNA analysis of CTGF showed no change in ON (WT: n=15, 1 ± 0.69; TG: n=17, 1.07 ± 
0.49), but a high significant increase in the ONH (WT: n=6, 1 ± 0.12; TG: n=5, 10.04 ± 1.66; **p= 0.006) of βB1-CTGF1 
mice, compared to WT littermates. (D) GFAP mRNA expression was not changed in the ON (WT: n=15, 1 ± 0.68; TG: 
n=16, 0.85 ± 0.45), but was significant enhanced in the ONH (WT: n=6, 1 ± 0.13 TG: n=5, 5.08 ± 1.62; *p= 0.04) of βB1-
CTGF1, in comparison to WT controls. Mean value of WT mice was set at 1. PRL32 was used as a housekeeping gene. 
Data represented as mean ± SEM. 
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4.2.3. Establishment of murine optic nerve astrocytes  
To understand what kind of effects CTGF, TGFβ2 and increasing substratum can 
provoke in ON astrocytes, we wanted to analyze the murine optic nerve astrocyte in vitro. 
7 days after preparation first cells were growing out from the neuronal tissue of the ON. 
The neuronal tissue of the retrolaminar ON contains three different glial cell types beside 
axons, oligodendrocytes, astrocytes and microglial cells After another week, cells grow 
to confluence and the dominant cell type were astrocytes to a lesser extend 
oligodendrocytes and microglial cells were observed in the culture dishes, showing that 
with a specific supplement, astrocytes had an advantage in proliferation. After shaking 
the culture dishes overnight, the oligodendrocytes and microglial cells detached from the 
surface and were eliminated by repeated wash steps with PBS.  
To prove the purity of the astrocyte culture, the cells were stained with GFAP, a specific 
astrocyte marker, with IBA-1, a marker for microglia, and with MBP, a marker against 
oligodendrocytes. Neither MBP nor IBA-1 showed any positive staining in the purified 
cell culture (data not shown). Only GFAP showed a positive staining in all cells, so that 
we had established a pure murine optic nerve astrocyte culture (Figure 4-33).  
 
 
Figure 4-33: Immunocytochemical staining against GFAP in the astrocytes culture. GFAP reactivity showed a pure 
astrocyte cell culture. Nuclear DNA is labeled with DAPI (blue). Scale bar= 50µm. 
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4.2.3. Increasing substratum stiffness cause reactive changes in murine optic 
nerve astrocytes 
 
To investigate the effect of increasing substratum stiffness on mouse ON astrocytes, 
cells were cultured on PDMS substratum with different E-moduli (10 kPa, 30 kPa, 
60  kPa). To study the effect on the structure of the actin cytoskeleton, the actin stress 
fibers were labeled with phalloidin. We could observe an enhanced staining with 
increasing stiffness (Figure 4-34). Additionally, increased substratum stiffness caused 
an intensification in longitudinally-oriented actin stress fibers. Astrocytes grown on a 
substratum with a stiffness of 60 kPa contained numerous longitudinally arranged actin 
stress fibers (Figure 4-34), which were longer and thicker compared to those grown on 
substratum with 10 kPa or 30 kPa (Figure 4-34).  
 
 
Figure 4-34: Phalloidin-labeling of murine optic nerve astrocytes cultured on increasing substratum stiffness. 
The visualization of the actin cytoskeleton via phalloidin labeling  revealed an increase in signal with increasing substratum 
stiffness. Astrocytes grown on a substrate with a stiffness of 60 kPa contained numerous longitudinally arranged actin 
stress fibers which were longer and thicker, compared to those grown on substrate with 10 kPa or 30 kPa. Nuclear DNA 
is labeled with DAPI (blue). Scale bar: 50µm. 
 
To test the effect of substratum stiffness on astrocyte reactivity, Western blot analyses 
for GFAP and vimentin were performed. Cells grown on substratum with a 60 kPa 
stiffness, showed a 3.66-fold ± 5.10-fold (*p < 0.05) and astrocytes grown on 30 kPa 
showed a 1.67-fold ± 0.51 increase (Figure 4-35 B; *p ≤0.02) increased GFAP synthesis 
compared to those from cells grown on 10 kPa (Figure 4-35 B).). Vimentin was increased 
by 2.44-fold ± 1.7 for cells grown on 30kPa and by 2.58-fold ± 0.2 (Figure 4-35 C; 
*p  ≤0.02) for cells grown on 60 kPa compared to astrocytes plated on 10 kPa (Figure 
4- 35 C). The results were confirmed by immunostaining with antibodies against GFAP 
which showed an increase in GFAP immunoreactivity in cells grown on stiffer substratum 
(Figure 4-35 A).  
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Figure 4-35: Increasing substratum stiffness lead to an increased reactivity in murine optic nerve astrocytes. (A) 
Immunocyctochemical staining of GFAP showed an increase in immunoreactivity in astrocytes cultured on stiffer 
substratum compared to softer control. Nuclear DNA is labeled with DAPI (blue). Scale bar: 50µm (B) Western Blot 
analysis of GFAP revealed a significant increase in GFAP protein synthesis in murine optic nerve astrocytes grown on 30 
or 60 kPa in comparison to the softer control (10kPa). (C) Western Blot analysis of Vimentin showed a significant increase 
in Vimentin protein level when the cells were cultured on 60 kPa compared to the 10 kPa control. α-tubulin was used as 
a loading control. The mean value of the 10kPa control was set at 1. Data represented as mean ± SD.    
 
Next, we turned our attention to the effect of increased substratum stiffness on CTGF 
synthesis. Western blotting experiments of protein from astrocytes grown on a 
substratum with an E-modulus of 60 kPa showed an increase in the amounts of CTGF 
(Figure 4-36 B) (30 kPa 3.05 ± 2.05; * p < 0.05; 60 kPa 3.47 ±2.28; * p < 0.05), compared 
with protein from astrocytes cultured on substrata with an E-modulus with either 10 kPa 
or 30 kPa (Figure 4-36 B). The upregulation of CTGF in relation to increasing substratum 
stiffness was confirmed by immunocytochemistry (Figure 4-36 A).  
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Figure 4-36: Increasing substratum stiffness causes increased CTGF level in murine optic nerve astrocytes. (A) 
Immunocytochemical staining of CTGF in murine optic nerve astrocytes cultured on increasing substratum stiffness 
showed an increased CTGF immunoreactivity in astrocytes grown on stiffer substratum, compared to those cells plated 
on softer substratum. Nuclear DNA is labeled with DAPI (blue). (B) Western Blot analysis of CTGF showed an increase 
protein synthesis in murine optic nerve astrocytes cultured on 30 kPa or 60 kPa in comparison to the 10 kPa control. α-
tubulin was used as a loading control. The mean value of the 10 kPa control was set at 1. Scale bar:50µm. Data 
represented as mean ± SD.    
Taken together, mRNA and protein level of CTGF and GFAP are increased in the ONH, 
but not in the ON of 2-month-old βB1-CTGF mice. Furthermore, increasing substratum 
stiffness lead to an increased reactivity and CTGF level in murine ON astrocytes in vitro.  
 
4.2.4. Potential mechanisms of astrocyte reactivity 
Since it could be observed that increasing substratum stiffness lead to astrocyte 
reactivity in vitro and astrocytes are reactivated in a murine glaucoma model in vivo, 
potential mechanism of astrocytes reactivity were investigated.  
4.2.4.1. Trp-channels expression related to increasing substratum stiffness 
The participation of channels of the Transient receptor potential (TRP) channel 
superfamily in mechanosensation and -transduction was already shown in different 
tissues and cell types (Dietrich et al. 2005, Earley et al. 2004, Lin & Corey 2005, Muraki 
et al. 2003, Numata et al. 2007a, 2007b, Welsh et al. 2002). Therefore, the expression 
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of different TRP channels were assessed in murine ON astrocytes and variation related 
to increasing substratum stiffness was investigated. TRP channel mRNA expression was 
studied in murine ON astrocytes growing on culture dishes with increasing substratum 
stiffness (10 kPa, 30 kPa, 60 kPa) (Figure 4-37). Trpc1 mRNA expression was significant 
decreased when astrocytes were gown on 60 kPa (Figure 4- 37; 0.60 ± 0.14; n=5; 
*p=0.003), compared to 10 kPa control (Figure 4-37; 1 ± 0.0; n=5). 30kPa substratum 
stiffness had no significant effect on Trpc1 expression (Figure 4-37; 0.75 ± 0.30; n=5). 
Real-time RT-PCR analysis for Trpm7 revealed a high significant decrease in murine ON 
astrocytes cultured on 30 kPa (Figure 4-37; 0.67 ± 0.21; n=5; **p=0.008) and on 60 kPa 
(Figure 4-37; 0.61 ± 0.33; n=5; *p=0.03), in comparison to control (Figure 4-37; 10kPa; 
1 ± 0.0; n=4). The most prominent effect was shown for Trpv2, as astrocytes grown on 
30 kPa culture dish showed a high significant decrease (Figure 4-37; 0.61 ± 0.22; n=4; 
**p=0.01) and seeded on 60 kPa (0.56 ± 0.13; n=4; ***p=0.0004) a highly significant 
reduction in Trpv2 mRNA expression, in comparison to 10kPa control (1 ± 0.0; n=4).  
 
 
Figure 4-37: Real-time RT-PCR analysis of TRP channel expression in murine optic nerve astrocytes depending 
on increasing substratum stiffness. mRNA expression of Trpc1 was significantly reduced in murine ON astrocytes 
growing on 60 kPa, compared to 10 kPa control (10kPa: 1 ± 0.0, n=5; 30kPa: 0.75 ± 0.30, n=5; 60kPa: 0.60 ± 0.14; n=5; 
*p=0.003). Increasing substratum stiffness led to significant downregulation of Trpm7 in murine ON astrocytes (10kPa: 1 
± 0.0, n=4; 30kPa: 0.67 ± 0.21, n=5, **p=0.008; 60kPa: 0.61 ± 0.33, n=5, *p=0.03). Murine ON astrocytes grown on 30 or 
60kPa revealed a reduced mRNA expression for Trpv2 (10kPa: 1 ± 0.0, n=4; 30kPa: 0.61 ± 0.22, n=4, **p=0.01; 60kPa: 
0.56 ± 0.13; n=4; ***p=0.0004). RPL32 was used as housekeeping gene. Mean value of 10kPa control was set at 1. Data 
represented as mean ± SD.          
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4.2.4.2. Effect of increasing substratum stiffness on Piezo channel expression 
The novel ion channel family, including Piezo1 and Piezo2, showed a strong evidence 
to play a crucial role in response to mechanical stress (Coste et al. 2010). Therefore, it 
was of interest to investigate expression of these channels in response to increasing 
substratum stiffness. Piezo channel mRNA expression was assessed in murine ON 
astrocytes growing on increasing substratum stiffness. Real-time RT-PCR revealed a 
significant reduction of Piezo2 expression in murine ON astrocytes cultured on 60 kPa 
(0.37 ± 0.34; n=3; *p=0.03) compared to10 kPa control (1 ± 0.0; n=3). (30 kPa 0.79 ± 
0.52; n=3; Figure 4-38). mRNA expression analysis for Piezo1 did not detect any 
expression changes related to increasing substratum stiffness (10 kPa: 1± 0.0, n=3; 30 
kPa: 1.14 ± 0.18, n=3; 60 kPa: 1.16 ± 0.55; n=3; Figure 4-38). 
 
 
Figure 4-38: Real-time RT-PCR analysis of Piezo channel expression in murine optic nerve astrocytes depending 
on increasing substratum stiffness. Increasing substratum stiffness led to a significant downregulation of Piezo2 mRNA 
expression in murine ON astrocytes (10 kPa: 1 ± 0.0, n=3; 30 kPa: 0.79 ± 0.52, n=3; 60 kPa: 0.37 ± 0.34, n=3, *p=0.03). 
No differences in Piezo1 expression was observed related to increasing substratum stiffness (10 kPa:1± 0.0, n=3; 30 kPa: 
1.14 ± 0.18, n=3; 60 kPa: 1.16 ± 0.55, n=3). RPL32 was used as a housekeeping gene. Mean value of 10kPa control was 
set at 1. Data represented as mean ± SD.       
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4.2.4.3. Implication of Caveolins in astrocytes and the ONH in the pathogenesis of 
POAG 
Since caveolae and Caveolin1, one main constitute of caveolar structure, work as 
mechanosensors and their maintenance is altered by external mechanical cues, it was 
of great interest to prove the appearance of Caveolin1 in murine optic nerve astrocytes 
and the implication in the pathological changes occurring the glaucomatous ON (Boyd 
et al. 2003, Kurzchalia et al. 1992, Park et al. 2000, Rizzo et al. 2003, Rothberg et al. 
1992, Sedding et al. 2005, Sinha et al. 2011). 
4.2.4.3.1. Caveolin1 expression murine ON astrocytes 
For further analysis of the impact of Caveolin1 in astrocyte reactivation, the appearance 
of Caveolin1 in murine astrocytes was analyzed. Therefore, immunochemical staining 
against Caveolin1 in murine ON astrocytes were performed in vitro and in vivo. Caveolin1 
was detected in murine ON astrocytes in vitro (Figure 4-39) und in astrocytes in the 
murine ON head in vivo (Figure 4-40, 41). 
 
Figure 4-39: Immunocytochemical staining against Caveolin1 in murine ON astrocytes in vitro. Caveolin1 (purple) 
was expressed in murine ON astrocytes in vitro. Phalloidin labeling (green) visualized the astrocyte cytoskeleton. Nuclear 
DNA is labeled with DAPI (blue). Scale bar: 20µm. 
By immunohistochemical staining, Caveolin1 is detected throughout the entire ON, and 
additionally in the vasculature in and adjacent to the ON. The fact that the Caveolin1 
level were extremely higher in blood vessels, in contrast to ON tissue, lead to the 
difficulties to record the staining in the ON. In the enlarged excerpt the co-localization of 
Caveolin1 in ON astrocytes is shown (Figure 4-40).  
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Figure 4-40: Immunohistochemical staining against Caveolin1 and GFAP in the sagittal ON of 2-month-old WT 
mice. (A) Immunohistochemical staining against Caveolin1 (red) and GFAP (green) were performed on sagittal section 
of the glial lamina of 2-month-old WT mice. (B) Enlarged excerpt showed a localization of Caveolin1 in ON astrocytes. 
Additionally, a staining of Caveolin1 in ON blood vessel was detected. Nuclear DNA is labeled with DAPI (blue). Scale 
bar: 20µm. 
 
For a better representation of Caveolin1 localization in ON astrocytes, tangential sections 
of the glial lamina were double stained against Caveolin1 and GFAP. In these staining 
the localization of Caveolin1 could be clearly detected in GFAP positive astrocytes 
(Figure 4-41). 
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Figure 4-41: Immunohistochemical staining against Caveolin1 and GFAP in the glial lamina of 2-month-old WT 
mice (A) Immunohistochemical staining against Caveolin1 (red) and GFAP (green) were performed on tangential section 
of the glial lamina of 2-month-old WT mice. (B) Enlarged excerpt of the glial lamina showing that Caveolin1 was co-located 
with the astrocyte marker GFAP, indicating that Caveolin1 was expressed in murine ONH astrocytes in vivo. Nuclear DNA 
is labeled with DAPI (blue). Scale bar: 20µm. 
4.2.4.3.2. Effect of increasing substratum stiffness on Caveolin1 and 2 expression 
As the appearance of Caveolin1 in murine optic nerve astrocytes was shown, the effect 
of increasing substratum stiffness on the expression of Caveolin1 and 2 was 
investigated. The mRNA expression of Caveolin1 as well as Caveolin2 was assessed in 
murine ON astrocytes cultured on 8-10 kPa, 25-30 kPa and 50-60 kPa cell culture dishes. 
Real-time RT-PCR analysis showed a high significant decrease for Caveolin1 mRNA 
expression in murine ON astrocytes cultured on 25-30 kPa (0.61 ± 0.31; n=8; **p=0.002). 
In contrast, when murine ON astrocytes were grown on 50- 60 kPa the Caveolin1 mRNA 
is significantly increased (1.93 ± 1.08; n=8; *p=0.02), compared to the 10 kPa control (1± 
0.0; n=9) (Figure 4-42). For the Caveolin2 mRNA a significant increase in murine ON 
astrocytes cultured on 50-60 kPa (3.51 ± 2.78; n=8; *p=0.02), in comparison to murine 
ON astrocytes cultured on 8-10 kPa (8- 10 kPa: 1 ± 0.0; n=9; 25-30 kPa: 1.98 ± 1.73; 
n=8) (Figure 4-42). 
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Figure 4-42: Real-time RT-PCR analysis of Caveolin1 and 2 mRNA expression related to increasing substratum 
stiffness. Caveolin1 mRNA was high significant reduced in murine ON astrocytes grown on 25-30 kPa (0.61 ± 0.31; n=8; 
**p=0.002) and significant increased on 50-60 kPa (1.93 ± 1.08; n=8; *p=0.02), compared to the 8-10 kPa control (1± 0.0; 
n=9). Caveolin2 mRNA was significantly increased in murine ON astrocytes grown on 50-60 kPa (3.51 ± 2.78; n=8; 
*p=0.02), compared to the 8-10 kPa control (8-10kPa: 1 ± 0.0; n=9; 25-30 kPa: 1.98 ± 1.73; n=8). The mean value of 8-
10 kPa was set at 1. RPL32 was used as a housekeeping gene. Data represented as mean ± SD.     
 
4.2.4.3.3. Effect of TGF-β2 and CTGF on Caveolin1 in vitro 
Murine optic nerve astrocytes were treated either with 1 ng/ml TGF-β2 or 50 ng/ml CTGF, 
or left untreated as controls for 24 h, and Caveolin1 was assessed in Western Blot and 
Real-time RT-PCR analysis (Figure 4-43). Real-time RT-PCR analysis showed a 
significant increase in Caveolin1 mRNA expression after treatment either with 1 ng/ml 
TGFβ2 (1.94 ± 0.84; n=6; *p=0.02) or 50ng/ml CTGF (1.61 ± 0.60; n=6; *p=0.03), in 
comparison to untreated control (1±0.0; n=6) (Figure 4-43 A). Additionally, Western Blots 
showed enhanced levels of Caveolin1 protein after the treatment with TGF-β2 and 
CTGF. Relative densitometry to α-tubulin confirmed the significant increase after the 
treatment with TGF-β2 (1.63 ± 0.54; n=3; *p=0.03) or 50ng/ml CTGF (1.80 ±0.58; n=3; 
*p=0.02) compared to control (1± 0.0; n=5) (Figure 4-43 B).  
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Figure 4-43: Analysis of Caveolin1 after treatment with TGFβ2 and CTGF in murine ON astrocytes. (A) Real-time 
RT-PCR analysis showed a significant increase of Caveolin1 mRNA expression after the treatment with 1 ng/ml TGF-β2 
and 50 ng/ml CTGF for 24h (control: 1±0.0, n=6; TGF-β2:1.94 ± 0.84, n=6, *p=0.02; CTGF: 1.61 ± 0.60, n=6, *p=0.03). 
RPL32 was used as a housekeeping gene. Mean value of untreated control was set a 1. (B) Western Blot analysis of 
Caveolin1 protein synthesis showed a significant increase in protein level after the 24h treatment with TGF-β2 (1.63 ± 
0.54; n=3; *p=0.03) and CTGF (1.80 ±0.58, n=3, *p=0.02; control: 1± 0.0; n=5). Caveolin1 protein levels were normalized 
to α-tubulin. Mean value of untreated control was set at 1. Data represented as mean ± SD.    
 
4.2.4.3.4. Caveolin1 in the ONH of the murine glaucoma model 
POAG-related changes of Caveolin1 were assessed in 2-month-old βB1-CTGF1 mice. 
Real-time RT-PCR analysis could detect a high significant increase in Caveolin1 mRNA 
expression in the ONH of TG mice (6.64 ± 1.63; n=5; **p=0.007) compared to WT 
controls (1 ±0.15; n=6) (Figure 4-44 A). Additionally, it was shown that Caveolin1 
expression is not altered in the ON of TG mice (1.02 ± 0.30; n=16) by contrast with WT 
littermates (1 ± 0.29; n=13) (Figure 4-44 A). Furthermore, a significant increase in 
Caveolin1 protein synthesis was shown by Western Blot analysis for TG mice 
(2.53  ±0.58; n=9; *p=0.05) in comparison to WT control (1± 0.09; n=9) (Figure 4-44 B). 
 
Figure 4-44: Caveolin1 levels in the ON and ONH of 2-month-old βB1-CTGF1 mice. (A) Real-time RT-PCR analysis 
showed a high significant increase in Caveolin1 mRNA in the ONH of TG animals (6.64 ± 1.63; n=5; **p=0.007) compared 
to WT littermates (1 ±0.15; n=6). No difference for Caveolin1 mRNA expression was observed in the ON of βB1-CTGF1 
mice compared to WT controls (TG: 1.02 ± 0.30, n=16; WT: 1 ± 0.29; n=13). RPL32 was used a housekeeping gene. 
Mean values of WT controls was set at 1. (B) Western Blot analysis showed a significant increase in Caveolin1 protein 
synthesis in the ON of TG animals compared to WT (TG: 2.53 ±0.58, n=9; *p=0.05; WT: 1± 0.09; n=9). Caveolin1 protein 
levels were normalized to α-tubulin. Mean value of WT mice were set at 1. Data represented as mean ± SEM.    
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All in all, the presents of proteins involved in mechanosensation, like Trpc1, Trpv2, 
Trpm7, Piezo1 and Piezo2, and Caveolin1 and 2 was shown in murine optic nerve 
astrocytes. In relation to increasing substratum stiffness, the expression of these proteins 
is changed, arguing for an implication in mechanosensation in murine optic nerve 
astrocytes. Furthermore, an increase for Caveolin1 after CTGF and TGFβ2 treatment in 
murine optic nerve astrocytes in vitro and in the ONH of 2-month-old βB1-CTGF1 mice 
in vivo was observed.  
 
 
4.3. Intracameral delivery of layer-by-layer coated siRNA nanoparticles 
As it was shown in this study, that CTGF is persistently expressed in the TM and the SC 
and its lens-specific overexpression in mice results in an elevated IOP and the 
progressive and significant loss of ON axons (Junglas et al., 2012), it can be suggested 
that CTGF is implicated in the dysregulation of AH outflow pathway. Therefore, the aim 
of this study was to design a tool to reduce CTGF in the cells and tissue of the outflow 
pathway to establish a new therapeutic strategy to reduce IOP in POAG.  
Hence, nanoparticles (NP) were designed, which follow the drainage pathway of AH and 
reach target tissue and cells of the outflow pathway. Preparation and characterization of 
NP’s were obtained by Michaela Guter and Miriam Breunig (Department of 
Pharmaceutical Technology, University of Regensburg). The core of the NP’s consisted 
of biodegradable, FDA approved poly(D,L-lactide-co-glycolide) (PLGA) with a MW of 38-
54 kDa. PLGA NP’s were prepared by nanoprecipitation and then stabilized with 
polycationic polymer PEI with a MW of 25 kDa. PEI-NPs were then coated with 
negatively charged hyaluron (HA) of 13 kDa resulting in HA-NPs. As HA-NPs are coated 
with HA they can bind to the CD44 receptor, which is expressed in both healthy TM and 
SC cells (Acott et al., 2008). Therefore, a nonspecific, adhesive interaction, which can 
be observed for PEI can be prevented. PEI-NP’s were used as control, as they 
nonspecifically interact with cells and tissue.  
To prove the ability of CD44 as a potential target for NP delivery, expression and protein 
synthesis of CD44 were investigates in HTM and SC cells as well as in the outflow tissue 
of human glaucoma patients and in the glaucoma mouse model.  
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4.3.1. CD44 expression in HTM cells in vitro 
To investigate the protein synthesis of CD44 in vitro, HTM cells were treated either with 
1 ng/ml TGF-β2, 50 ng/ml CTGF or left untreated as control for 24h. Western Blot 
analysis and immunocytochemical staining against CD44 in HTM cells were performed 
(Figure 4-45). Treatment with TGF-β2 led to a significant increase in CD44 protein level 
(n=5, 2.23 ± 0.49; P=0.045) compared to the untreated control (n=6, 1.14 ± 0.14) (Figure 
4-45 A). Additionally, the CTGF treatment led to a significantly enhanced CD44 protein 
synthesis (n=5, 3.82 ± 0.71; P=0.003; Figure 4-45 A). Immunocytochemical staining 
against CD44 in HTM cells treated either with 1 ng/ml TGF-β2, 50 ng/ml CTGF or left 
untreated as control could confirm the Western Blot results as it showed an increase in 
CD44 protein synthesis after both treatments (Figure 4-45 B). 
 
 
Figure 4-45: CTGF and TGF-β2 induce CD44 in HTM cells in vitro. (A) Western blot analysis for CD44 in proteins of 
HTM cells 24 hours after treatment with 1ng TGF-β2 or 50ng CTGF. The mean value obtained from untreated cells was 
set at 1. α-tubulin was used as loading control (n=5-6; *P= 0.045; ** P= 0.003). Data represented as mean ± SEM.   (B) 
Immunohistochemical staining for CD44 (green) in HTM cells treated with either 1 ng TGF-β2 or 50 ng CTGF. Nuclear 
DNA is labeled with DAPI (blue) Scale bar: 50µm.  
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4.3.2. CD44 expression in βB1-CTGF1 mice in vivo 
Transgenic mice with lens-specific CTGF overexpression (βB1-CTGF1) develop POAG 
characterized by higher IOP and progressive loss of axons in the ONH (Junglas et al., 
2012). The increased IOP is associated with pathological changes within the outflow 
pathway. To analyze whether those changes are linked with alterations in CD44 expres-
sion and localization anterior eye segments of 2-month old βb1-CTGF1 and WT mice 
were investigated. The mRNA expression of CD44 was significantly increased in corneal-
scleral rims of βB1-CTGF1 animals compared to their WT littermates (WT: 1 ± 0.06; βB1-
CTGF1: 3.13 ± 0.83; p=0.04; Figure 4-46 A). The corneoscleral-rim contains the TM, SC, 
but also portion of the sclera, therefore we performed immunohistochemical staining to 
precisely analyze the localization of CD44 in the anterior eye segment. CD44 signal was 
localized in the iris, ciliary body, trabecular meshwork and the SC of 2-month-old WT 
mice, whereas no signal was observed in the sclera despite in the endothelial cells of 
the aqueous plexus (Figure 4- 46 B). In the βB1-CTGF1 mice, a similar distribution of 
CD44 was observed in the anterior chamber angle, however the signal was markedly 
increased in the tissues of the outflow pathway. The immunohistochemical analysis 
showed that CTGF induced increase of CD44 mRNA expression arises from the outflow 
tissues as no changes were observed in the sclera (Figure 4-46 B). 
 
 
 
Figure 4-46: Expression and Distribution of CD44 in βB1-CTGF1 and WT mice. (A) Quantitative real-time RT-PCR 
analysis for mRNA of CD44 in βb1-CTGT1 and WT mice. The mean value obtained from WT mice was set at 1. RPL32 
was used as a reference gene (n=4; *P= 0.04). Data represented as mean ± SEM.  (B) Immunohistochemical staining for 
CD44 (red) in 2-month old TG and WT mice. Nuclear DNA is labeled with DAPI (blue) Scale bar: 50µm. 
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4.3.3. Localization and expression of CD44 in the chamber angle of POAG 
patients 
To evaluate CD44 expression in glaucoma versus healthy patients and to have a first 
impression about the sufficient targeting and binding of HA-decorated nanoparticles, 
CD44 levels were assessed in glaucomatous and healthy human donor eyes and in 
normal and glaucomatous SC cells. Expression of CD44 was studied in SC cells isolated 
from normal and glaucomatous human donors (Figure 4-47). Real-time RT-PCR 
analyzes showed a significant increase of CD44 mRNA expression in glaucomatous SC 
cells compared to healthy controls (normal: 1 ± 0.52, n=4; glaucomatous: 6.26 ± 3.11, 
n=5; *p=0.05). 
 
 
Figure 4-47: Quantitative real-time RT-PCR analysis for mRNA of CD44 in healthy and glaucomatous SC cells. 
CD44 mRNA expression was significantly increased in glaucomatous SC cells compared to healthy controls (healthy: 1 ± 
0.52, n=4; glaucomatous: 6.26 ± 3.11, n=5; *p=0.05). Mean value of healthy controls was set at 1. RPL32 was used as a 
reference gene. Data represented as mean ± SEM.      
 
Immunohistochemical staining was performed on cryo sections of healthy and 
glaucomatous human donor eyes and protein level was analyzed in the iridocorneal 
angle. CD44 could be detected in the iris, the TM and the SC in both healthy and 
glaucomatous eyes. Indeed, CD44 is increased in these identified tissues in the 
glaucomatous human donor eyes compared to healthy control. We could detect an 
increased protein synthesis in the SC endothelium, the TM and the iris (Figure 4-48).  
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Figure 4-48: Localization and expression of CD44 in the chamber angle of POAG patients. (A, B) 
Immunohistochemical staining for CD44 in the chamber angle of healthy (A) and glaucomatous (B) human donor eyes. 
CD44 was seen adjacent to the SC, in the entire TM and in the iris. In glaucomatous donor eyes immunoreactivity was 
more intense in the identified tissue. (C, D) Enlarged images. Nuclear DNA is labeled with DAPI (blue). Scale bar: 100µm. 
 
4.3.4. Perfusion of porcine eyes with nanoparticles 
As it could be shown that CD44 synthesis is changed in outflow tissue of our mouse 
glaucoma model and in glaucomatous patients, it can be suggested that the application 
of nanoparticles targeting CD44 would be a promising approach. Therefore, 
nanoparticles coated with HA, the natural ligand, and nanoparticles coated with PEI as 
a control, were perfused in the anterior chamber of porcine eyes. Following perfusion, 
the anterior segments were dissected and the whole outflow ring was investigated. The 
NP-HA perfused eyes showed a consisted distribution and intensity in the entire outflow 
tissue, in comparison the NP-PEI perfused eyes revealed an irregular localization and a 
reduced abundance (Figure 4-49 A). Quantitative measurement of integrated density of 
NP-HA and NP-PEI perfused porcine eyes showed a significant increase in the 
fluorescent intensity for NP-HA perfused eyes compared to NP-PEI perfused controls 
(NP-PEI: n=8, 15.50 ± 1.72; NP-HA: n=9, 45.98 ± 14.21; *p =0.05) (Figure 4-49 B). 
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Figure 4-49: Perfusion of porcine eyes with NP-PEI and NP-HA. (A) Fluorescent imaging of porcine outflow rings after 
perfusion with NP-PEI (red) and NP-HA (red). Scale bar: 2000µm (B) Quantitative measurement of integrated density of 
NP-PEI or NP-HA perfused porcine eyes. (NP-PEI: n=8; NP-HA: n=9; *P=0.049). Data represented as mean ± SEM.    
 
For detailed analysis of NP distribution and localization, the whole outflow ring was 
dissected, and sagittal sections of the outflow pathway tissue and immunohistochemical 
staining against CD44 and CD31 were performed. As expected, a CD44 signal was 
detected throughout the entire TM and the VP (venous plexus) (Figure 4-50), as it was 
already shown in mouse (4.3.2.) and human TM and SC (4.3.3.). HA decorated NPs 
were distributed in the entire TM and even reach the lumen of the VP. In contrast, PEI-
NPs were accumulated at the outer region of the TM and did not enter the inner layers 
of TM or even the lumen of VP (Figure 4-50).  
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Figure 4-50: Immunohistochemical staining of NP-PEI and NP-HA perfused porcine eyes against CD44 (green). 
NP-PEI (red) distribution was restricted to the outer layer of the TM. NP-HA (red) entered the inner layer of the TM and 
the VP. CD44 (green) immunoreactivity was shown throughout the entire TM and the VP. Scale bar: 50µm 
To determine the location of HA-NPs in the lumen of the VP, immunohistochemical 
staining against CD31 was performed to visualize the endothelial cells of VP. By CD31 
the endothelial lining of VP could be nicely visualized, and the HA- coated NPs could be 
shown to reach the lumen of VP (Figure 4-51 B), as it was shown by the CD44 staining 
(Figure 4-54). In none of the performed experiments PEI-NPs were transported into the 
deeper layers of TM or reach the endothelial lining of the VP (Figure 4-51 A). In a higher 
magnification by showing a top and later view of the same sagittal sections, the HA-NPs 
could be detected to be taken up by the endothelial cells and enter the VP (Figure 4-51 
D). Again, PEI-NPs were located at the outer layer of the TM and do not enter the deeper 
layers or even the VP (Figure 4-51 C).  
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Figure 4-51: Immunohistochemical staining against CD31 of sagittal sections of NPs perfused porcine eyes. 
(A)  NP-PEI (red) distribution was restricted to the outer layer of the TM. (B) NP-HA (red) entered the inner layer of the 
TM and are located in the endothelial lining of the VP. (C,D) Top and ventral view of the same sagittal sections. Scale 
bar: 50µm. 
 
4.3.5. Perfusion of human eyes with nanoparticles 
One eye pair of a human donor was used to investigate the distribution of NP’s after 
perfusion. One human donor eye was perfused with PEI-coated NPs and the other one 
with HA-coated NPs, following by performance of sagittal sections and staining against 
CD44 (Figure 4-52) to evaluate NP distribution. As expected, a CD44 expression could 
be detected throughout the entire TM and in the SC (Figure 4-52), as it was already 
shown in healthy and glaucomatous donor eyes (4.3.3.). NP distribution reveal a 
comparable pattern as it was shown for porcine perfused eyes. PEI-coated NPs are 
located at the entrance and in the inner layer of the TM (Figure 4-52). In contrast, HA 
coated NP’s are distributed in all layers of the TM (Figure 4-52), with reaching the 
outermost layer, the JCT, as well.  
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Figure 4-52: Immunohistochemical staining against CD44 (green) of sagittal sections of NP’s perfused human 
eyes. (A) Sagittal section of NP-PEI (red) perfused human TM. (B) Sagittal section of NP-HA (red) perfused human TM. 
(C) Enlarged excerpt of NP-PEI perfused human TM showed the localization of the NP in the inner layer of the TM. (D) 
Enlarged excerpt of the NP-HA perfused human TM showed the distribution of HA coated NPs in all layers of the TM. 
(E,F) 3D representation of the same sections shown in C and D, shows the colocalization of NP-HA with the CD44 
receptor. Scale bar: 20µm. 
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4.3.6. CTGF silencing by nanoparticles 
For further investigations, the ability of siRNA coated NPs to reduce CTGF in HTM cells 
was analyzed. Therefore, HTM cells were transfected with siRNA coated nanoparticles. 
For further control, HTM cells were only transfected with siRNA (Figure 4- 53). 
Transfection of HTM cell with PEI-coated siRNA NPs showed no downregulation of 
CTGF (0.97 ± 0.14; n=4) in comparison to scrblsiRNA PEI-NPs (1 ± 0.00; n=4). Indeed, 
HTM cells transfected with HA-coated siRNA NPs revealed a highly significant 
downregulation of CTGF protein (0.51 ± 0.05; n=4; ***P=0.0001), compared to 
scrblsiRNA HA-NP control (1 ± 0.00; n=4). The internal control transfection with siRNA 
without NPs also lead to a highly significant downregulation of CTGF in HTM cells 
(0.24  ± 0.05; n=4; ***p=0.0009), in comparison to the control (1 ± 0.00; n=4) (Figure 
4- 53).  
 
 
Figure 4-53: Western Blot analysis of CTGF silencing by nanoparticles in HTM cells. (A) Densitometric analysis of 
CTGF protein synthesis after transfection with siRNA coated NPs. (B) Representative Western blot for CTGF after 
transfection with siRNA coated NP`s. α-tubulin was used for normalization. The mean value of scrblsiRNA was set at 1. 
Data represented as mean ± SEM.  
 
All in all, it can be stated that the target receptor CD44 for the new designed approach 
is expressed in both HTM and SC cells, and is upregulated in the glaucomatous outflow 
pathway of human donors. Furthermore, the here designed NPs are able to follow the 
natural outflow pathway of AH and reach the target TM cells and bind to the CD44 
receptor, in both human and porcine perfused eyes. Finally, the initial experiments show 
the ability of siRNA coated HA-NPs to reduce CTGF expression in HTM cells. 
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4.4. Effect of conditional CTGF knockdown on mouse eye development 
To use CTGF as a specific target for IOP reduction in the progression of POAG, the 
effect of a CTGF knockdown or knockout, respectively has to be proven. As it was shown 
in the previous analysis of this study, that CTGF is highly expressed in different ocular 
tissue, like TM, ONH and retina related to the pathogenesis of POAG. Therefore, the 
involvement of CTGF in the development of the eye has to be analyzed.  
Since the homozygous knockout of CTGF is embryonic lethal and the heterozygous 
knockout does not result in an ocular phenotype, a conditional knockout of CTGF was 
generated, which allow a conditional deletion of CTGF via the Cre-loxP system to study 
the effect of CTGF deficiency on eye development. Mice with two Coin-Introns 
(CTGFCoin/Coin) were crossed with CTGFCoin/Coin;CAGGCre-ER mice, which are 
heterozygous for the Cre-recombinase. Experimental mice (CTGFCoin/Coin;CAGGCre-ER) 
mice and control mice (CTGFCoin/Coin) were treated with Tamoxifen eyedrops with a 
concentration of 5mg/ml three times a day from P1 to P5. For all following experiments 
mice were genotyped for the Cre recombinase (Figure 4-54 C) and the Coin-Intron 
(Figure 4-54 A) and the WT allele (Figure 4-54 B), respectively. The product of the Coin-
PCR results in a 350bp PCR product for all tested animals. The Exon2 PCR, amplifying 
the WT allele results in a PCR product of 275bp only for the positive control, as mice 
homozygous for the Coin-Intron are crossed. The amplification of the CAGGCre 
recombinase results in a PCR product of 275bp.  Mice containing the Cre recombinase 
were used as experimental mice (CTGFCoin/Coin;CAGGCre-ER mice) and littermates with 
two non-inverted Coin-Introns are referred to as control mice. 
 
Figure 4-54: Representative CAGG-Cre, CTGFCoin/Coin and CTGFExon2 PCR. (A) CTGFCoin/Coin PCR product 350bp. (B) 
CTGFExon2 PCR product 270bp. (C) CAGGCre PCR product 270bp. 
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4.4.1. Verification of conditional CTGF knockdown 
To prove efficient induction for Cre recombinase and knockdown of CTGF, Real-time 
RT-PCR analysis and immunohistochemical staining of retina and ON of tamoxifen 
treated CTGFCoin/Coin; CAGGCre-ER and CTGFCoin/Coin were performed. 
 
Real-time RT-PCR analysis of retinal tissue of P17 mice revealed a high significant 
knockdown of CTGF in CTGFCoin/Coin;CAGGCre-ER mice (0.36 ± 0.05; n=8; **P=0.005) 
compared to control mice (1±0.13; n=7) (Figure 4-55).  
 
 
 
 
 
Figure 4-55: Real-time RT-PCR analysis of retinal CTGF knockdown. mRNA expression was highly significant 
reduced in the retina of CTGFCoin/Coin;CAGGCre-ER (0.36 ± 0.05; n=8; **P=0.005) mice in comparison to CTGFCoin/Coin  
littermates (1±0.13; n=7). RPL32 was used as a housekeeping gene. Mean value of CTGFCoin/Coin control mice was set 
at  1. Data represented as mean ± SD. 
Additionally, the knockdown of CTGF on mRNA expression level could be confirmed on 
protein level. Therefore, immunohistochemical staining with a specific antibody against 
CTGF on retinal and ON sections of CTGFCoin/Coin;CAGGCre-ER and CTGFCoin/Coin mice 
at P17 were performed (Figure 4-56). In comparison to the CTGF promotor expression 
pattern, which shows a specific expression in retinal Müller cells, amacrine cells and 
endothelial cells, the secreted CTGF protein is located in the entire retina, showing 
protein synthesis in the GCL, IPL, INL, OPL, ONL and the photoreceptor outer segments 
in CTGFCoin/Coin control mice (Figure 4-56 A). This signal is mostly reduced in the retina 
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of experimental mice (CTGFCoin/Coin;CAGGCre-ER), indicating an efficient tamoxifen 
depending induction of the Cre recombinase, resulting in successful conditional 
knockdown of CTGF (Figure 4-56 B). This result is comparable with the staining 
observed in the ON, where CTGF protein is located in the entire ON, with no obvious 
preference for glial or neuronal tissue in CTGFCoin/Coin control mice Figure 4-56 C) and a 
markedly decrease in the CTGFCoin/Coin;CAGGCre-ER mice (Figure 4-56 D).  
 
 
Figure 4-56: Immunohistochemical staining of CTGF on retina and ON sections of CTGFCoin/Coin;CAGGCre-ER 
mice. CTGF levels were mostly reduced in the entire retina in CTGFCoin/Coin;CAGGCre-ER mice (B) compared to 
CTGFCoin/Coin control mice (B).
 
Additionally, the successful CTGF knockdown was shown in the ON. CTGFCoin/Coin control 
mice showed a CTGF synthesis in the whole ON (C), and a reduced CTGF signal was detected in the ON of 
CTGFCoin/Coin;CAGGCre-ER mice (D). nuclear DNA is labeled with DAPI (blue). Scale bar: 50µm.  
 
4.4.2. Morphological analysis of CTGF knockdown 
Semi thin sections of CTGFCoin/Coin and CTGFCoin/Coin;CAGGCre-ER mice were performed 
to investigate the effect of CTGF knockdown on eye morphology (Figure 4-57). Analysis 
of these sections revealed that the postnatal knockdown of CTGF does not result in 
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obvious morphological alterations in CTGFCoin/Coin;CAGGCre-ER mice on P17 in 
comparison to littermate controls (Figure 4-57). Especially the eye tissue expressing high 
levels of CTGF during the development, like the TM, cornea, sclera and ON showed no 
changes in development in experimental mice (CTGFCoin/Coin;CAGGCre-ER) (Figure 4-
58). In the ON of CTGFCoin/Coin and CTGFCoin/Coin;CAGGCre-ER mice no structural 
differences were monitored. There are no obvious signs that the conditional knockout of 
CTGF did lead to structural alterations in the development of the ON (Figure 4-58 A, B). 
Interestingly, there is evidence that the conditional knockout of CTGF did lead to a 
persistence or rather to a decreased regression of the hyaloid artery. The persistent 
hyaloid artery was not observed in every CTGFCoin/Coin;CAGGCre-ER eye, suggesting 
that the decreased regression of the hyaloid artery is related to the level of the CTGF 
knockdown (Figure 4-58 A, B). Observing the anterior chamber angle in more detail, it 
was seen, that the anterior chamber angel is open in both animals and the ciliary body 
and the TM showed no obvious signs of differences in structure and organization, 
indicating that the AH outflow pathway is not influenced by the conditional knockout of 
CTGF (Figure 4-58 C, D). In addition, also the cornea exhibited no obvious differences 
in CTGFCoin/Coin;CAGGCre-ER mice. In both animals the corneal endothelium, epithelium, 
stroma and Descement´s membrane, respectively are normally developed. The 
thickness of all layers did not differ in conditional CTGF knockdown mice in comparison 
to CTGFCoin/Coin controls (Figure 4-58 E, F).  
All in all, in can be concluded that the conditional CTGF knockout did not lead to obvious 
structural difference in the development of different eye structures.  
 
 
Figure 4-57: Semi-thin sections of CTGFCoin/Coin and CTGFCoin/Coin;CAGGCre-ER mice. No morphological differences 
were observed. Scale bar: 200µm. 
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Figure 4-58: Semi-thin sections of ONH, anterior chamber angle and cornea of CTGFCoin/Coin and 
CTGFCoin/Coin;CAGGCre-ER mice. Enlarged excerpts of semi-thin sections shown in Figure 4-57. (A) The ONH of 
CTGFCoin/Coin and CTGFCoin/Coin;CAGGCre-ER mice showed no morphological differences. (B) The anterior chamber angle 
of CTGFCoin/Coin and CTGFCoin/Coin;CAGGCre-ER mice showed no morphological differences. (C) The cornea of 
CTGFCoin/Coin and CTGFCoin/Coin;CAGGCre-ER mice showed no morphological differences. Scale bar: 50µm (A-D); 20µm 
(E,F). 
Since there is no possibility to prove the successful conditional knockdown in each 
individual animal, which was conducted to morphological analysis, because it is not 
possible to combine this experimental approach with immunohistochemical staining 
against CTGF, an additive approach was investigated. Therefore, it was examined a 
potential reduction of CTGF after the tamoxifen treatment in additional organs, for 
example the lung (Figure 4-59). Initial Real-time RT-PCR analysis for CTGF in lung 
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mRNA of CTGFCoin/Coin and   CTGFCoin/Coin;CAGGCre-ER mice showed a trend for a CTGF 
knockout to 50% in CTGFCoin/Coin;CAGGCre-ER animals (n=2; 0.5±0,14), compared to 
littermate controls (n=3;1±0.33) (Figure 4-59).  
 
 
Figure 4-59: Real-time RT-PCR analysis of CTGF knockdown in the lung. mRNA expression was reduced in the lung 
of CTGFCoin/Coin;CAGGCre-ER mice in comparison to CTGFCoin/Coin littermates. RPL32 was used as a housekeeping gene. 
Mean value of CTGFCoin/Coin control mice was set at 1. Data represented as mean ± SD. 
 
 
4.4.3. Effect of conditional CTGF knockout on astrocyte network in the retina 
As studies for CTGF distribution demonstrated a high CTGF expression in the retina 
during development, GFAP staining on retinal flat mounts of CTGFCoin/Coin;CAGGCre-ER 
and CTGFCoin/Coin mice were examined to analyze the development of the retinal 
astrocytic network. Interestingly, CTGFCoin/Coin;CAGGCre-ER mice showed a 
dramatically altered astrocyte network in the retina. The connection between astrocytes 
and the vasculature is altered, as the blood vessels are not ensheathed with fine 
processes, as in CTGFCoin/Coin control mice which showed a normally developed 
astrocytic network, covering the entire retina, with astrocyte processes contacted and 
intertwined each other and end-feet enveloping the retinal vasculature (Figure 4-60 
A,  B). Instead, the astrocytes built enlarged cell somata sitting on the retinal vasculature 
(Figure 4-60 C, D arrow). Furthermore, alteration in the morphology of astrocyte 
processes can be observed, as their processes showed an increase in thickness (Figure 
4-60).  All in all, it can be stated that the conditional knockdown of CTGF led to thickened 
retinal astrocyte processes and furthermore led to the appearance that retinal blood 
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vessels are not ensheated with fine astrocyte processes instead, they are enlaced by 
the astrocyte cell bodies.  
 
Figure 4-60: Immunohistochemical staining against GFAP of retinal flat mounts of P17 CTGFCoin/Coin;CAGGCre-ER 
mice. (A,B) GFAP positive astrocyte network in CTGFCoin/Coin control mice. (C,D) GFAP positive astrocyte network in 
CTGFCoin/Coin;CAGGCre-ER mice. Arrows depict morphologically changed retinal astrocytes. Scale bar: 50µm. 
4.4.4. Effect of conditional CTGF knockdown on astrocyte structure in the ON 
Since CTGF is highly expressed in astrocytes in the ON, especially in the region of the 
glial lamina during postnatal eye development, it was of great interest to analyze the 
effect of CTGF deficiency on the astrocyte development and glial lamina establishment. 
GFAP staining on sagittal section of CTGFCoin/Coin;CAGGCre-ER (n=3) and CTGFCoin/Coin 
mice (n=4) were executed (Figure 4-61). The glial lamina in control mice could 
constituted as a region of transversely dense packed GFAP positive astrocytes (Figure 
4-61 A). This special arrangement of astrocytes is missing in CTGF conditional 
knockdown mice. No transversely arranged astrocytes were observed, instead the 
astrocytes are already longitudinal orientated parallel to the long axis of the ON, which 
normally first occurs in the myelinated region of the ON posterior to the glial lamina 
(Figure 4-61 B).   
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Figure 4-61: Immunohistochemical staining against GFAP (green) on sagittal ON section of CTGFCoin/Coin and 
CTGFCoin/Coin;CAGGCre-ER mice. (A) GFAP staining in CTGFCoin/Coin control mice. Bracket indicates the normal presence 
of the glial lamina. (B) GFAP staining in CTGF knockdown mice showed no existence of the glial lamina. nuclear DNA is 
labeled with DAPI (blue). Scale bar: 50µm. 
Based on the observation that CTGF deficiency lead to changes in formation of the glial 
lamina during development, immunohistochemical staining against myelin basic protein 
(MBP) were performed to analyze if the altered constitution of astrocyte arrangement 
leads to additional changes in the composition of the ON (Figure 4-62). The myelination 
of the ON starts typically 120-170µm behind the sclera (Sun et al., 2009). The MBP 
staining showed that the CTGF knockdown does not lead to variations between the 
unmyelinated and myelinated region of the optic nerve Figure 4- 62 A, B). The beginning 
of the myelination was measured in CTGFCoin/Coin;CAGGCre-ER (n=3) and CTGFCoin/Coin 
(n=1) mice. The distance in ON of the control eye is 154 µm and ON of 
CTGFCoin/Coin;CAGGCre-ER eyes showed a distance of 141 µm ± 28 µm (Figure 4-62 A, 
B).  
 
Figure 4-62: MBP staining of sagittal ON sections of CTGFCoin/Coin and CTGFCoin/Coin;CAGGCre-ER mice. (A) MBP 
staining (red) in the CTGFCoin/Coin ON. (B) MBP staining in the ON of CTGFCoin/Coin;CAGGCre-ER mice. (C) Representation 
of structures involved in the measurement. Dotted line represents the level of the sclera. Dashed line represents the 
measured distance. Unmyelinated region is depicted by brackets. Scale bar: 50µm. 
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All in all, initial data show that the conditional knockdown of CTGF effects the morphology 
of retinal astrocytes, resulting in thickened processes, increased cell bodies and an 
altered interaction with retinal blood vessels. Furthermore, the formation of the glial 
lamina constituted of ON astrocytes is altered as a result of the conditional CTGF 
knockout.  
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5. Discussion 
5.1. Summary 
The aim of the study was to investigate the involvement of CTGF in eye development 
and the pathology of POAG. The expression of CTGF during eye development and in 
the adult eye was investigated in the different ocular tissue, furthermore the CTGF 
expressing cell types were identified. The involvement of CTGF in the ONH pathology of 
POAG was examined by the correlation of CTGF expression changes and astrocytes 
reactivity in the ON and ONH after applying mechanical stress in vivo and by increasing 
substratum stiffness in vitro. Furthermore, siRNA coated layer-by-layer NPs were 
designed as a new tool to reduce CTGF in the AH outflow pathway tissue. 
During eye development CTGF is expressed in various eye structures. In early 
embryonic development an expression in the outer and inner layer of the optic cup as 
well as the lens vesicle was detected. In the following embryonic and postnatal 
developmental stages, a CTGF expression was detected in tissues of the anterior eye 
segment like corneal endothelium, epithelium and stroma, in the TM and the ciliary body. 
In the posterior eye segment, an expression could be observed in the retina, choroidea, 
sclera, ONH and dura mater. During the development of the eye, an altered CTGF 
expression pattern could be observed in the cornea, the ciliary body, the retina, the ONH 
and the dura mater, whereas the expression in the TM remained constantly high. The 
characterization of the CTGF expressing cell types revealed that the trabecular 
meshwork cells, Müller cells, amacrine cells, ON astrocytes and endothelial cells of the 
SC and of the retinal and choroidal vasculature were the source of the CTGF signal. An 
important role for CTGF in the correct formation of astrocytic morphology in the retina 
and the ONH could be shown in CTGF conditional knockdown mice. 
Besides the involvement of CTGF in developmental processes, a correlation between 
CTGF expression and pathological changes in the murine glaucoma model were 
analyzed. An increased astrocyte reactivity was associated with an enhanced CTGF 
synthesis in the ONH, related to the chronically elevated IOP, whereas none of those 
changes were observed in the adjacent parts of the ON. Interestingly, cultured murine 
ON astrocytes could sense changes in stiffness of the surrounding ECM, causing the 
same changes as in the in vivo glaucoma model. The analysis of mechanosensitive ion 
channels showed a broad spectrum of expression changes dependent on the substratum 
stiffness, but the most promising changes were seen in Caveolin expression. An 
enhanced Caveolin synthesis in ON astrocytes was detected on increasing substratum 
stiffness and after treatment with CTGF and TGF-β2 in vitro and in the ONH of the murine 
glaucoma model.  
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Based on the observation that CTGF can cause POAG-like changes, we started a 
cooperation with Miriam Breunig (Department of Pharmaceutical Technology, University 
of Regensburg) to develop a new tool to reduce CTGF in the AH outflow pathway tissues 
and cells. Layer-by-layer coated NPs were designed and successfully delivered by 
anterior chamber perfusion to the outflow pathway tissues and cells of porcine and 
human eyes. CD44 was identified as an ideal target for HA coated NP’s, as CD44 is 
permanently present in cultured HTM cells, in the anterior chamber angle of the murine 
glaucoma model and in cells and outflow pathway tissues of human donors. The 
implication of CD44 in POAG could be shown by the enhanced expression in 
glaucomatous SC cells and the anterior chamber angle of human glaucomatous donor 
eyes. Finally, siRNA coated NPs could successfully reduce CTGF synthesis in HTM cells 
in vitro.  
 
5.2. CTGF expression in ocular tissues and cell types during development 
and in the adult eye 
To date, little is known about the function of CTGF during development and in healthy 
tissue, as most of the studies focus on the role under pathological conditions. CTGF is 
upregulated in many disorders associated with a pathological ECM increase, like 
scleroderma, renal and pulmonary fibrosis, inflammatory bowel disease, atherosclerosis 
and POAG (Cicha et al. 2005, Di Mola et al. 2004, Ito et al. 1998, Junglas et al. 2012, 
Sato et al. 2000, Yamamoto et al. 2005b).In processes occurring during development 
such as migration and differentiation, the ECM plays an essential role and provides cues 
for cellular metabolism (Adams & Watt 1993, Lin & Bissell 1993, Perris 1997). CTGF can 
function as a modulator of migration, adhesion, ECM production, cell cycle, proliferation 
and differentiation in various cell types (Babic et al. 1999, Bradham et al. 1991, Brigstock 
2003, Frazier et al. 1996, Igarashi et al. 1993, Kireeva et al. 1997, Perbal 2001, Perbal 
2004, Winter et al. 2008). Therefore, an implication of CTGF in the different processes 
occurring during eye development seems likely. In this study we report CTGF expression 
in various ocular structures during development and in the adult eye.  
5.2.1. Involvement of CTGF in the development of the anterior eye segment 
The morphogenesis of the anterior eye segments involves an exact interaction of various 
transcription factors and signaling proteins (Cvekl & Tamm 2004). In the anterior eye 
segment, a CTGF expression was detected in the in the ciliary body, the TM and the SC, 
and depending on the developmental stage in the corneal epithelium, stroma and 
endothelium.   
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During development, CTGF is expressed in all three layers of the cornea prior to eye lid 
opening, afterwards it is restricted with a low expression to the corneal endothelium. The 
fact that the expression pattern is changed after eyelid opening, which indicates the 
maturation of the cornea leads to the hypothesis that CTGF plays a role in the 
development and formation of the corneal structure. The corneal stroma constitutes of 
various types of collagen, like collagen type I, III, V and VI. (Birk et al. 1986, Keene et al. 
1987, Marshall et al. 1991a, 1991b, Zimmermann et al. 1986). In addition, to collagen a 
second group of extracellular proteins, the proteoglycans, including Decorin, Lumican, 
Kerstocan and Mimecan are a major component of the corneal stroma. They are thought 
to play an essential role in maintaining position of the fibrils and controlling fibril growth 
(Borcherding et al. 1975, Rada et al. 1993, Scott & Orford 1981, Scott & Thomlinson 
1998). Interestingly, Decorin deficient mice show no corneal phenotype. In contrast 
Keratocan and Lumican deficient mice reveal an impaired corneal composition 
(Chakravarti et al. 1998, Chakravarti et al. 2000, Danielson et al. 1997). CTGF can 
enable interactions with a variety of heparan sulfate containing proteoglycans via its 
heparin-binding domain (Chen & Lau 2010, Gao & Brigstock 2005, Leask & Abraham 
2006, Vial et al. 2011). The ability of CTGF to induce collagen synthesis in corneal 
fibroblasts points towards the assumption that CTGF is involved in ECM formation in the 
cornea (Blalock et al. 2003). For the optimal transparency of the cornea it is very 
important that the collagen fibers are correctly orientated because a variation in collagen 
structure will result in opacity of the cornea. Therefore, it can be supposed that CTGF is 
crucial for the initial formation of the collagen fibers, a process that is completed at the 
timepoint of the eyelid opening, which results in a cutoff of CTGF expression to prevent 
a keloid matrix production. The heterogenous CTGF promotor activity in the mature 
cornea was already shown in CTGFp-eGFP mice (Gibson et al. 2014). The key role of 
the corneal endothelium is to keep the balance of corneal stroma hydration by generation 
of fluid outflow by ion transporters. This finding indicates a role of CTGF in the normal 
tissue homeostasis. 
A few transcription factors and signaling molecules have been identified to play an 
essential role in the morphogenesis of the anterior chamber angle. In humans, a 
heterozygous mutation in the Pax6 gene leads to aniridia, which is associated with iris 
hypoplasia, corneal opacification, cataract and foveal dysplasia (Glaser et al. 1992, 
Jordan et al. 1992, Ton et al. 1991). In case of aniridia, 50-70% of patients develop 
glaucoma due to an abnormal differentiation of the TM and/or absence of SC (Nelson et 
al. 1984). Baulmann et al., (2002) could show a similar phenotype in heterozygous Pax6 
mice, exhibiting an undifferentiated TM and the absence of SC (Baulmann et al. 2002). 
Similar observations were made in TGF-β2 knockout mice, where the anterior chamber 
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is not present and in BMP-4 heterozygous knockout mice, which develop a small or 
absent SC and a hypoplastic or absent TM (Chang et al. 2001, Sanford et al. 1997). The 
similarities between these observations point to the fact that Pax6 signaling can be 
controlled by members of the TGF-β superfamily. In this study, we could show that CTGF 
is expressed in the TM during the entire developmental process and persists in the 
mature TM. CTGF can arrange interactions with both BMP-4 and TGF-β2, leading to an 
inhibition of the BMP signaling pathway and enhancement of TGF-β signaling, 
suggesting a role for CTGF to keep the homeostatic balance between these different 
signaling molecules (Abreu et al. 2002). Furthermore, CTGF has a protective effect on 
HTM cell viability after different stressors (Kuespert et al. 2015), indicating a crucial role 
of CTGF in TM morphogenesis. An important factor in the regulation of anterior chamber 
development is the synthesis and remodeling of unique ECM (Cvekl & Tamm 2004). In 
the TM, various ECM components like different types of collagen, elastic fiber 
components, proteoglycans and FN are found. The exact impact of ECM on TM 
development, including expression, differentiation and interaction with signaling 
molecules is still unclear, but the ability of CTGF to interact and induce various ECM 
components in HTM cells suggests a possible role of CTGF in formation and 
maintenance of the ECM in the TM (Junglas et al. 2009). The observation that BMP7 is 
essential for the development of the ciliary body (Zhao et al. 2002a) and the fact that 
mice with an extreme overexpression of CTGF do not develop a ciliary body 
(unpublished data), leads furthermore to the suggestion that CTGF is necessary to keep 
the homeostatic balance of different growth factors. 
The initial analysis of the effect of CTGF deficiency on eye development revealed no 
obvious morphological changes in the development of anterior eye structures. Due to 
the problem that   parallel analysis of the CTGF knockdown and the morphological 
investigations can not be performed, we successfully tested the knockdown in other 
organs, like the lung. Additionally, compensatory pathways, including other members of 
the CCN protein family may restore the function of CTGF, resulting in a normal 
development of the anterior eye segment. It is also important to mention that this mouse 
model is based on an inducible conditional knockout, which results in a knockdown of 
CTGF. However, we can not generate a complete knockout of CTGF. Therefore, it is 
possible that the remaining amount of CTGF is sufficient for normal anterior eye 
development. For further examination we will confirm the knockdown within this 
experimental approach and we will analyze the phenotype, using additional techniques, 
like electron microscopy. This will allow for a more detailed analysis, especially of the 
morphological structure of the TM.  Thereby we will identify the role of CTGF in anterior 
eye segment morphogenesis and differentiation. 
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5.2.2. Involvement of CTGF in the development of posterior eye structures 
In the posterior eye segment CTGF is expressed in the retina, choroidea, sclera and the 
ONH. In the sclera CTGF is expressed throughout the entire development and is 
maintained in the adult eye. The sclera has a dual origin, it differentiates from neural 
crest cells and a small temporal portion from the mesoderm (Johnston et al. 1979). This 
is similar to the differentiation of cartilage and bones. The sclera is constituted of fibrillar 
collagens, proteoglycans, small amounts of various glycoproteins and matrix secreting 
fibroblasts. The expression of CTGF was already detected in cartilage, bones and teeth 
(Friedrichsen et al. 2003, Ivkovic et al. 2003, Safadi et al. 2003, Shimo et al. 2002). CTGF 
plays an essential role in skeletogenesis, as CTGF knockout mice manifest multiple 
skeletal dysmorphisms, due to impaired growth plate chondrogenesis, angiogenesis and 
bone formation (Ivkovic et al. 2003). The similarities in origin of sclera and cartilage and 
the important role of CTGF in skeletogenesis suggest a role of CTGF in control of the 
development and maintenance of the sclera. Furthermore, interaction partners of CTGF, 
like TGF-β2 and BMP-2 enhance ECM production and expression of cartilage-
associated genes in cultured scleral cells (Hu et al. 2008, Wu et al. 2015).  
5.2.2.1. Involvement of CTGF in development of the retina 
In the retina, CTGF is expressed in Müller cells, endothelial cells of the retinal 
vasculature and amacrine cells during development in a specific time dependent 
expression pattern. This expression pattern is maintained in the mature retina. The 
distinct expression at the defined place and time suggests a role of CTGF in the retinal 
development. BMP signaling pathways and Notch signaling pathways are known to play 
a crucial role in retinal development. Müller cell differentiation is promoted by both 
pathways and can control various processes during retinal development (Bao & Cepko 
1997, Bernardos et al. 2005, Furukawa et al. 2000, Mateos et al. 2007). Blocking of BMP 
signaling results in impaired retinal organization and an extenuated Müller cell 
differentiation (Huillard et al. 2005). CTGF has the ability to bind members of the BMP 
family, leading to inhibition of the signaling (Abreu et al. 2002) and is related to Notch-1 
inhibition (Smerdel-Ramoya et al. 2008) and can be the target of Notch signaling (Canalis 
et al. 2014). As neuronal differentiation is almost complete at the time point when the 
expression of CTGF starts at P10 (Rapaport et al. 2004), it can be suggested that CTGF 
is necessary for maintenance of Müller cell and amacrine cell function and differentiation 
state. Amacrine cells are inhibitory interneurons, and can be classified by their 
neurotransmitter, GABA or glycine (MacNeil et al. 1999, MacNeil & Masland 1998). The 
identified CTGF expressing amacrine cells are located in the INL as well as the GCL. 
This distribution pattern is typical for GABAergic amacrine cells (Haverkamp & Wässle 
2000). This observation suggests that GABAergic amacrine cells express CTGF and 
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CTGF plays a role in their normal cell function, but the exact role of CTGF has to be 
identified. Müller cells are important players in the inflammatory response and they are 
implicated in various retinal disorders. However, they provide a variety of functions to 
support neurons and keep the retinal homeostasis in balance, like neurotransmitter 
recycling and supply of neurotransmitter precursors, regulation of  retinal blood flow, 
extracellular space volume, ion and water homeostasis and maintenance of inner blood-
retina barrier in the healthy retina (Bringmann et al. 2004, Bringmann et al. 2009, Choi & 
Kim 2008, Metea & Newman 2006, Tout et al. 1993). 
Laminins, a major component of the retinal basements membranes (BM), are important 
for different retinal processes, like vascular development, retinal synapse formation, 
formation of ILM and Bruch’s membrane and guidance of RGC axons (Byström et al. 
2006, Li et al. 2012, Libby et al. 1997, Morissette & Carbonetto 1995, Stenzel et al. 
2011).They are mainly produced by Müller cells in the mature retina (Libby et al. 2000). 
Additionally, FN is located in the ILM (Vecino et al. 2015). Since CTGF could be shown 
to induce FN and laminin in different cell types (Fuchshofer et al. 2005, Nagai et al. 2009, 
Neumann et al. 2008, Zode et al. 2011), it can be speculated that one function of CTGF 
expressed by Müller cells is to induce ECM components in the retina by an autocrine 
and/or paracrine mechanism.  
The expression of CTGF in endothelial cells was already shown in different species 
(Bradham et al. 1991, Lin et al. 1998, Wunderlich et al. 2000). In the mouse retina 
angiogenesis occurs within the postnatal period of development. Multiple cellular 
processes like proliferation, migration and cell adhesion are involved in angiogenesis. 
CTGF can promote and enhance endothelial cell proliferation, migration and cell 
adhesion (Kireeva et al. 1997, Lin et al. 1998, Shimo et al. 2002). One critical player of 
retinal angiogenesis is VEGF (Campochiaro et al. 2016). CTGF can build a complex with 
VEGF, leading to an inhibition of VEGF induced angiogenesis (He et al. 2003, Inoki et 
al. 2002, Jang et al. 2004, Kuiper et al. 2007, Suzuma et al. 2000). Furthermore, blocking 
CTGF during retinal angiogenesis results in a reduced growth of the superficial plexus 
(Pi et al. 2011). Due to these observations it can be suggested that CTGF plays an 
essential role in retinal angiogenesis. The invasion of endothelial cells from the ON into 
the retina, forming the superficial plexus, is guided by astrocytes migrating from the optic 
nerve. In turn, endothelial cells provide molecular factors, like leukemia inhibitory factor 
(LIF), promoting astrocyte differentiation and maturation (Bonni et al. 1997, Galli et al. 
2000, Koblar et al. 1998, Mi & Barres 1999, Nakagaito et al. 1995, Richards et al. 1996, 
Yoshida et al. 1993). In this study we could show that a conditional CTGF knockdown 
leads to an altered astrocyte network in the retina. Astrocytes in CTGF deficient retinae 
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have enlarged cell somata, thickened processes and blood vessels are not ensheathed 
by fine astrocyte processes. Cells from the astrocytic lineage migrate as a mixture of 
astrocyte precursor cells and immature perinatal astrocytes from the ONH into the retina. 
The implication of CTGF in astrocyte differentiation was already shown, as CTGF can 
increase the number of GFAP-positive cells after treatment of neural progenitor cells 
(Mendes et al. 2015).  
 
5.2.2.2. Involvement of CTGF in the development of the ONH 
In the ON, the first expression of CTGF was detected at P5, following an increased 
expression in the glial lamina throughout development. This distinct expression pattern 
is maintained in the adult ON. We could identify optic nerve astrocytes as the major 
source of CTGF expression in mouse ON during development and in the mature eye. 
Abnormal differentiation of astrocytes leads to pathologies like coloboma and optic nerve 
dysplasia (Friedlander 2007). Additionally, ON astrocytes are essential for retinal 
angiogenesis (Gariano 2003). In the ON, type 1 astrocytes derive from neuroepithelial 
astrocyte progenitor cells in the embryonic optic stalk. In contrast, type 2 astrocytes and 
oligodendrocytes derive from ventricular zone neuroepithelial cells in the postnatal optic 
stalk (Ffrench-Constant et al. 1988, Mi et al. 2001, Mi & Barres 1999, Small et al. 1987). 
As CTGF is not expressed in the ON during embryogenesis, a role of CTGF in type 1 
astrocyte differentiation can be excluded. As the implication of CTGF in astrocyte 
differentiation was already shown (Mendes et al. 2015), it can be suggested that CTGF 
contributes to the differentiation of type 2 astrocytes. The glial lamina of the murine ONH 
constitutes of transversely dense packed GFAP positive astrocytes. The characteristic 
property of the astrocytes within the glial lamina is established between P7 and P14 
(Ding et al. 2002). This special constitution, in comparison to the random orientation in 
the posterior ON is thought to be due to a combination of mechanical and functional 
factors (Tehrani et al. 2014). The physiological IOP applies a mechanical force on the 
cells in the ONH, in comparison to the posterior part of the ON where the force is 
dramatically reduced. In cell culture it was shown that cells re-orientate their actin 
bundles in the direction of the force (Heidemann et al. 1999, Kaunas et al. 2005, 
Neidlinger-Wilke et al. 2001), CTGF is upregulated in response to mechanical stress and 
in cultured murine ON astrocytes CTGF can induce cytoskeletal proteins like α-actinin 
(Dillinger et al., in prep). In this study we could observe that in CTGF deficient mice this 
characteristic arrangement of astrocytes in the glial lamina is missing. Interestingly, the 
myelination of the optic nerve does not differ in CTGF deficient mice, although it is known 
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that the glial lamina functions as a barrier for oligodendrocyte migration during 
development.  
5.3. Astrocyte reactivity in the ONH of a murine glaucoma model 
In POAG, the changes in ECM observed in the LC correlate with increased reactivity of 
astrocytes in the ONH (Hernandez & Pena 1997, Kerr et al. 2011). These changes, 
including abnormal elastin deposition, increased levels and remodeling of collagen type 
IV and thickening of connective tissue sheathes around capillaries in the prelaminar 
region might occur due to a disruption of the homeostatic balance of growth factors and 
signaling molecules in the ONH (Fuchshofer 2011, Hernandez 1992, Hernandez et al. 
1994, Pena et al. 1998, Pena et al. 2001, Tektas et al. 2010). One of these growth factors 
is TGFβ2, which is elevated in the AH and the ONH of glaucoma patients (Inatani et al. 
2001, Min et al. 2006, Ochiai & Ochiai 2002, Ozcan et al. 2004, Pena et al. 1999, Picht 
et al. 2001, Tripathi et al. 1994, Trivedi et al. 2011, Yamamoto et al. 2005a, Zode et al. 
2011). The increase of TGF-β2 is co-localized to reactive astrocytes in the ONH and 
TGF-β2 can induce the synthesis of ECM components in human ONH astrocytes. These 
findings lead to the assumption that reactive astrocytes are the major source of the 
enhanced TGF-β2 levels (Fuchshofer et al. 2005, Neumann et al. 2008, Pena et al. 2001, 
Zode et al. 2011). The fibrotic effect of TGF-β2 is dependent on its downstream mediator 
CTGF, as the silencing of CTGF inhibited the ECM increase following TGF-β2 treatment 
(Fuchshofer et al. 2005). Both growth factors can induce ECM expression in murine ON 
astrocytes (Dillinger et al., in prep). Furthermore, they can enhance migration rates and 
GFAP synthesis in murine ON astrocytes (Dillinger et al., in prep). These findings show 
the capacity of CTGF to induce a reactive phenotype in murine ON astrocytes. In this 
study we found an increase of CTGF in the ONH of our murine glaucoma model at the 
age of 2 months. At this age, the mice suffer from a significantly elevated IOP and 
progressive loss of axons (Junglas et al. 2012). In contrast, the analysis of the ON did 
not reveal any changes in the expression of CTGF. Furthermore, 1-month-old animals 
showed no differences in CTGF expression compared to their WT littermates. These 
findings lead to the assumption that long-lasting elevated IOP and the altered 
biomechanical properties of the peripapillary sclera can induce CTGF expression and 
synthesis. The possibility that the CTGF increase might be due to diffusion of 
transgenically overexpressed CTGF from the lens causing an autoregulatory mechanism 
can be excluded due to the observation that 1-month-old TG animals did not show an 
increase in CTGF levels in the ONH. The increased CTGF expression was associated 
with a reactive phenotype of ONH astrocytes, indicated by an increase in GFAP 
expression, thickening of astrocytes processes and reduced open spaces within the glial 
lamina. These changes in the astrocytic phenotype was not observed in the 1-month-old 
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animals. As the 1-month old animals already show an increased IOP and a loss of axons 
(Junglas et al. 2012), it can be argued that the gliosis reaction is not the cause for the 
axon loss in this mouse model. BMP signaling plays a crucial role in RGC axon 
development and outgrowth. BMPrIb deficient mice show an impaired axonal pathfinding 
and different BMPs have the ability to increase the number of outgrowing neurons in 
culture (Kerrison et al. 2005, Liu et al. 2004). As CTGF can inhibit BMP signaling by 
binding different members of the BMP family (Abreu et al. 2002), it is possible that the 
initial number of RGC axons is decreased in the TG animals compared to WT littermates. 
In a recent study it was shown that inhibition of the STAT3 pathway and thereby 
prevention of astrocyte gliosis reaction in an ocular hypertension model results in an 
increase in RGC death and visual function loss (Sun et al. 2017). It can be carefully 
stated that the astrocyte reactivity is beneficial for RGC axons, but involvement of STAT3 
in other pathway independent from astrocyte reactivity has to be kept in mind and will be 
part of future investigations (Sun et al. 2017). 
5.3.1. Mechanosensing of murine ON astrocytes 
IOP causes changes in biomechanical properties of the peripapillary sclera, indicated by 
the fact that an experimentally elevated IOP leads to an increased scleral stiffness, which 
is similar to the observations in glaucomatous human eyes (Downs et al. 2005, Nguyen 
et al. 2013). Astrocytes building the glial lamina in the murine ONH, are in direct contact 
with the peripapillary sclera via their processes (Sun et al. 2009). Therefore, it can be 
assumed that ONH astrocytes are capable to directly transfer scleral wall tension to the 
passing ON axons (Quigley & Cone 2013). The findings of this study clearly indicate that 
ON astrocytes can sense changes in stiffness of their surrounding ECM and react to 
increasing stiffness with enhanced synthesis of GFAP, vimentin and CTGF synthesis.  
Several molecules can act as regulatory candidates of mechanosensation and -
transduction. Caveolin1 can act as a mechanosensor, despite its function as a main 
component of caveolae (Kurzchalia et al. 1992, Rothberg et al. 1992). Caveolae are 
small pits, 60-80 nm in diameter, representing a specialized type of microdomain in the 
plasma membrane (Palade 1953). Biological functions of caveolae include endocytosis, 
cholesterol and lipid metabolism, mechanosensation and cellular signaling (Parton & 
Simons 2007, van Deurs et al. 2003). Caveolin1 is synthesized in the endoplasmic 
reticulum (ER), forms an integral membrane protein, travels to the Golgi complex and is 
finally transported by exocytotic caveolar carries to the plasma membrane (Monier et al. 
1995, Parton & Simons 2007, Pol et al. 2005, Tagawa et al. 2005). As the main 
component of caveolae, Caveolin is necessary for their induction and formation (Drab et 
al. 2001, Fra et al. 1995, Razani et al. 2001). Several studies could demonstrate the 
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implication of Caveolin1 in mechanosensing in various cell types. For instance, exposure 
of endothelial cells to chronic shear stress invokes the ERK pathway in a caveolae-
dependent manner (Boyd et al. 2003, Park et al. 2000, Rizzo et al. 2003). In smooth-
muscle cells, cyclic stretch can mediate the activation of Akt signaling, dependent on 
Caveolin1. Additionally, Caveolin1 is essential for cell cycle progression under cyclic 
stretch (Sedding et al. 2005). Caveolae provide a mechanism to extenuate an increase 
in membrane tension applied by acute mechanical stress by caveolae flattening (Sinha 
et al. 2011). Shear and cyclic stress increase the release of Nitric oxide (NO), a potent 
vasodilator and enhance endothelial nitric oxide synthase (eNOS) mRNA and protein 
(Harrison et al. 1996). eNOS hyperactivity is observed in Cav1 deficient mice and 
caveolae are shown to be essential for shear stress induced eNOS activation in vascular 
endothelium (Drab et al. 2001, Yu et al. 2006, Zhao et al. 2002b). However, the direct 
function of caveolae and Caveolin1 in mechanosensation and the underlying 
mechanisms implicated in cell response to mechanical stress occurring in astrocytes 
remain unknown. In addition to the function in mechanosensing, Caveolin1 has already 
been shown to be involved in the pathogenesis of POAG. A polymorphism in the 
Caveolin1/Caveolin2 gene was associated by genome wide association studies with 
both POAG and IOP (Chen et al. 2014, Huang et al. 2014, Hysi et al. 2014, Kim et al. 
2015, Loomis et al. 2014, Ozel et al. 2014, Thorleifsson et al. 2010, van Koolwijk et al. 
2012, Wiggs et al. 2011). Recently, a study investigated that Caveolin1 deficiency results 
in IOP elevation, reduced AH drainage and increased sensitivity of Caveolin1-deficient 
outflow pathway cells to rupture from acute IOP elevation (Elliott et al. 2016). This finding 
is in line with two other studies showing that in caveolae-deficient mice the outflow facility 
is reduced (Kizhatil et al. 2016, Lei et al. 2016). In contrast, a transient knockout of 
Caveolin1 in TM cells leads to an increase in outflow rates in anterior eye segments (Aga 
et al. 2014). In this study, it could be shown that both Caveolin1 and Caveolin2 
expression are enhanced related to increasing substratum stiffness. This finding is in line 
with studies in other cell types showing the induction and implication of Caveolin1 in 
response to mechanical stress. Furthermore, we could show that Caveolin1 is increased 
in the ONH in our murine glaucoma model in vivo and after treatment with TGF-β2 and 
CTGF in murine ON astrocytes in vitro. Caveolin1 expression is enhanced in the ONH, 
but not in the ON of 2-month-old animals. Therefore, it can be assumed that changes of 
Caveolin1 expression in the ONH of the murine glaucoma model is a key effect to 
generate caveolae flattening to extenuate the increase in membrane tension. A second 
group of proteins known to be implicated in mechanosensation are the transient receptor 
potential (TRP) channels. TRP channels are non-selective cation channels permeable 
for Ca2+, subdivided into 28 TRP channel subtypes (Nilius & Owsianik 2011). A couple 
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of these molecules have been implicated in mechanosensation (Arnadóttir & Chalfie 
2010, Birder et al. 2002, Christensen & Corey 2007, Davis & Hill 1999). Different 
subtypes of TRP channels are expressed in the retina and ONH, especially in astrocytes. 
A direct role of TRP channels in different aspects of the pathogenesis of glaucoma was 
assigned (Choi et al. 2015, Gilliam & Wensel 2011, Ho et al. 2014, Križaj et al. 2014, 
Leonelli et al. 2009, Morgans et al. 2009, Ryskamp et al. 2011, Ryskamp et al. 2014, 
Sappington et al. 2009, Sappington & Calkins 2008, Shen et al. 2009, Verkhratsky et al. 
2014, Ward et al. 2014, Weitlauf et al. 2014). Various subtypes of TRP channels were 
detected in the murine ONH, but only a few of them in mouse ON astrocytes. Choi et al., 
(2015) could identify an expression of Trpc1, Trpc2, Trpv2, Trpm7, Trpp1 and Trpp2. 
(Choi et al. 2015). Interestingly Trpc1, Trpv2, Trpm7 and Trpp2 are the most abundant 
isoforms within each group in the ONH. These findings are in line with our results. We 
could detect an expression of Trpc1, Trpv2 and Trpm7 in murine ON astrocytes in vitro. 
The expression of all detected channels was reduced by increasing substratum stiffness.  
Another class of mechanosensitive cation channels are represented by the Piezo 
channels. Both members, Piezo1 and Piezo2, are expressed in ONH astrocytes and are 
a substantial constituent of distinct stretch-activated channels (Choi et al. 2015, Coste et 
al. 2010). Interestingly, Piezo2 is regulated in the glaucoma-prone DBA/2J mouse strain, 
showing an increased expression in the progression of glaucoma, in contrast a mild 
elevation in IOP has no influence on Piezo2 expression (Choi et al. 2015). In our study, 
we could show that Piezo2 expression is downregulated in response to increasing 
stiffness. The involvement of Piezo channels in cell morphology, adhesion and migration, 
is an interesting point of linking this function to morphological changes in ON astrocytes 
in the pathogenesis of glaucoma (McHugh et al. 2010, McHugh et al. 2012, Ranade et 
al. 2014, Sun et al. 2013, Volkers et al. 2015, Yang et al. 2014). However, the direct role 
of these mechanosensitive channel in astrocyte reactivity has to be elucidated in future 
investigations using specific channel blocking agents in vitro and knockout mouse 
models in vivo. 
 
5.4. Intracameral delivery of layer-by-layer coated siRNA nanoparticles 
      Multiple, randomized clinical studies demonstrated that lowering IOP reduces the 
progression of POAG, which clearly reveals that IOP is a major risk factor for POAG 
(1998, 2000). Therefore, reducing IOP is the central point of action to prevent the 
progression of POAG. Current glaucoma treatments include, application of eye drops, 
laser procedures and surgery. The main medications involve prostaglandin analogs and 
beta blocker. The target of all glaucoma treatment strategies is reducing the amount of 
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AH produced by the ciliary body or increasing AH drainage. All these strategies have in 
common that they do not affect the primary cause of elevated IOP. Additionally, current 
glaucoma medications exhibit various disadvantages, like short duration of action, thus 
requiring frequent administration, systemic side effects, inadequate application by 
patients and usually low compliance by patients, resulting in an ineffective treatment. 
Application of naked siRNA frequently used as gene therapy offer drawbacks, like rapid 
degradation and inefficiency in crossing cellular membranes (Kanasty et al. 2013, Thakur 
et al. 2012). Hence, we pursued the strategy to use NP as carrier for siRNA delivery to 
the outflow pathway tissue of the eye to enhance stability and intracellular availability. 
Various types of NP were already used for drug delivery (Janagam et al. 2017). 
CD44 is the principle receptor of hyaluron and is involved in its uptake and degradation 
(Culty et al. 1992, Entwistle et al. 1996, Sherman et al. 1996). CD44 appearance was 
already demonstrated in tissues of the anterior chamber, like ciliary body stroma, anterior 
iris, ciliary body muscle, iris root and TM (Knepper et al. 1998). In this study we could 
confirm these findings. We could show a CD44 expression in HTM cells and in the 
anterior chamber angle of mice and human donor eyes. CD44 as a POAG related target 
was identified, as we could observe an increased expression in glaucomatous SC cells 
and enhanced synthesis in the TM and SC endothelium in human donor eyes of POAG 
patients. In this study HA-coated NPs were successfully designed and delivered via 
anterior chamber perfusion in the outflow pathway tissue of human and porcine eyes. 
We could report that these HA-coated NPs enter the entire TM and finally reach the 
endothelial lining of SC, in comparison to PEI-coated NPs, which build big agglomerates, 
resulting in immobilization in the tissue and therefore do not enter the tissue of outflow 
pathway. Interestingly, we could report a cellular uptake of HA-coated NPs via CD44 
receptors. These findings indicate that HA-coated NPs can pass through the TM without 
hindrance and overcome barriers in the TM. Finally, we could demonstrate that 
transfection of HTM cells with siRNA coated HA-NPs led successfully to a reduction in 
CTGF expression. These findings show that HA-coated NPs are the best choice, as they 
successfully internalized by HTM cells in vitro and show an intracellular uptake in 
perfused eyes. Furthermore, we could observe the increase in CD44 in glaucomatous 
tissue specific in the target region, the TM and SC. Therefore, HA coated NPs will have 
a high specificity to the target region in POAG. 
Overall, siRNA delivery to the AH outflow pathway tissue and cells based on HA-coated 
NPs could have a great potential in treatment of POAG.  
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5.5. Outlook 
      In the CTGF deficient mice, the exact role of CTGF during eye development and 
maintenance of different eye structures has to be investigated in detail. Electron 
microscopy will allow for a more detailed analysis, especially of the morphological 
structure of the TM. Compensatory mechanisms like upregulation of other members of 
the CCN protein family to restore CTGF function will be investigated. The morphological 
alterations in the astrocyte network, observed in the conditional CTGF knockdown 
animals, will be investigated regarding cell specificity, using different cell type specific 
conditional knockout mouse model, like endothelial cell, Müller cell and astrocyte specific 
mouse models, currently being bred. To investigate, if morphological changes in retinal 
astrocytes are due to impaired differentiation, specific markers for immature astrocytes, 
like Pax2 will be analyzed.  
 
Concerning a new therapeutic strategy for prevention of POAG progression by reducing 
CTGF, we will investigate the effect of CTGF deficiency on the maintenance of different 
ocular structures in adult conditional CTGF knockout mice. 
 
As astrocyte reactivity was shown to be associated with increased CTGF synthesis in 
vitro and in vivo, we will investigate the impact of CTGF on astrocyte reactivity related to 
increasing substratum stiffness. To this end, murine ON astrocytes are already isolated 
from the CTGFCoin/Coin mice and infected with an Ad-5 virus, expressing a Cre-
recombinase will be used to achieve a CTGF knockout in vitro. To evaluate the possibility 
of CTGF contributing to astrocyte reactivity in the ONH of the murine glaucoma model, 
the βB1-CTGF1 and CTGFCoin/Coin;CAGGCre-ER mice were crossbred, to receive a 
conditional knockout of endogenous CTGF in the CTGF-overexpressing glaucoma 
mouse model. The mechanosensation of TRP-channels and Caveolins will be further 
investigated by blocking of channels and/or downregulation via siRNA. Additionally, the 
Ca2+ signaling in murine ON astrocytes cultured on increasing substratum stiffness will 
be analyzed. For evaluation of the implication of Caveolin1 in the pathological changes 
in ONH during the progression of POAG, we will analyze the glial lamina of Caveolin1 
deficient mice, regarding astrocyte reactivity and CTGF level. 
 
As NPs were successfully delivered to cells of the AH outflow pathway and siRNA coated 
NPs lead to a significant downregulation of CTGF synthesis in HTM cells in vitro, we will 
start to test the delivery in our glaucoma mouse model. We will analyze the distribution 
of NPs in the mouse eye and the knockdown of CTGF by siRNA. Thus, we will be able 
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to investigate the effect of CTGF downregulation in the TM and SC concerning a 
reduction of the IOP in the glaucoma mouse model. 
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6. Conclusion  
In this study, we report that CTGF is expressed in various ocular tissue during 
development and in the adult eye. First analyses point towards the assumption that 
CTGF plays a role in establishment of specific astrocyte structures in the retina and ONH. 
In the pathology of POAG we can state that increased CTGF levels in the ONH are 
associated with astrocyte reactivity related to mechanical stress in vivo and increasing 
substratum stiffness in vitro. Furthermore, our study shows the implication of TRP 
channels, Piezo channels and Caveolin1 in the mechanosensation of murine ON 
astrocytes. 
Finally, with the layer-by-layer coated NP we develop a new tool to deliver siRNA to the 
target tissue in the AH outflow pathway of the eye. These NP provide a new treatment 
strategy to reduce IOP and thereby treat or prevent the progression of POAG. 
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8.1. List of Abbreviations 
ng/µg/g Nanogram/microgram/gram 
µl/ml Microliter/milliliter 
µm/nm/mm Micrometer/nanometer/millimeter 
AGS Astrocyte Growth Supplement 
AH Aqueous humor 
AP Alkaline phosphatase 
APS Ammonium persulfate 
Ax Axon 
BM Basement membrane 
BMP Bone morphogenic protein 
BSA Bovine serum albumin 
c Cornea 
Cav1 Caveolin1 
cb Ciliary body 
CCN Connective Tissue Growth Factor, 
Cystein rich protein, Nephroblastoma 
overexpressed gene 
CD31 Cluster of differentiation 31 
CD44 Cluster of differentiation 44 
CT C-terminal module 
CTGF Connective tissue growth factor 
CWFG Cold water fish gelatin 
Cyr61 Cystein rich protein 61 
DAPI 4',6-diamidino-2-phenylindole 
DCN Decorin 
DMEM Dulbecco's Modified Eagle's medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
E Embryonic day 
ECM Extracellular matrix 
eNOS Endothelial nitric oxide synthase 
ER Endoplasmatic reticulum 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
FGF Fibroblast growth factor 
FN Fibronectin 
GFAP Glial fibrillary acidic protein 
GS Glutamine synthetase 
h Hour 
ha Hyaloid artery 
HA Hyaluron 
HTM Human trabecular meshwork  
HRP Horseradish peroxidase 
IGBP Insulin-like growth factor-binding 
protein 
IGF Insulin-like growth factor  
il Inner layer of the optic cup 
ILM Inner limiting membrane 
INL Inner nuclear layer 
IOP Intraocular pressure 
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IPL Inner plexiform layer 
irs Interretinal space 
JCT Juxtacanalicular tissue 
kPa Kilopascal 
l Lens 
LC Lamina cribrosa 
lv Lens vesicle 
mA Milliampere 
MBP Myelin basic protein 
min Minute 
MGB Minor groove binder 
MP Milk Powder 
MMP2 Matrix metalloproteinase-2  
n number 
NFQ Non-fluorescent quencher 
NO Nitric oxide 
NOV Nephroblastoma overexpressed gene 
NP Nanoparticles 
nr Neuronal layer of the retina 
ol Outer layer of the optic cup 
OLM Outer limiting membrane 
ON Optic nerve 
ONH Optic nerve head 
ONL Outer nuclear layer 
OPL Outer plexiform layer 
os Optic stalk 
ov Optic vesicle 
P Postnatal day 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PDMS Polydimethylsiloxane 
PEI Polycationic polymer 
PFA Paraformaldehyde 
Php Phosphate buffer 
PLGA Poly(D,L-lactide-co-glycolide) 
POAG Primary open angle glaucoma 
pr Pigmented layer of the retina 
PRL Prelaminar region 
PSL Postlaminar region 
RA Retinoic acid 
RNA Ribonucleic acid 
RT Reverse transcriptase 
RT Room temperature 
re Retina 
RPE Retinal pigmented epithelium 
SEM Standard error of the mean 
SC Schlemm’s canal 
scrblsiRNA Scramble small interfering RNA 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
se Surface ectoderm 
sec Seconds 
Shh Sonic hedgehog 
siRNA Small interfering RNA 
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SV-40 Simian-Virus 40 
TBE Tris-borate-EDTA 
TBS Tris-buffered saline 
TGFβ2 Transforming growth factor β2 
TEMED Tetramethylethylenediamine 
TG Transgenic 
TIMP-1 Tissue inhibitors of metalloproteinases-
1 
 
TM Trabecular meshwork 
TRP Transient receptor potential  
Trpc1 Transient receptor potential channel c1 
Trpm7 Transient receptor potential channel v2 
Trpv2 Transient receptor potential channel 
m7 
TSP1 Thrombospondin 1 
UNG Uracil-N glycosylase 
V Volt 
VEGF Vascular endothelial growth factor 
VP Venous plexus 
VWC von Willebrand type c domain 
WISP1 WNT1-inducible-signaling pathway 
protein 1 
WISP2 WNT1-inducible-signaling pathway 
protein 2 
WISP3 WNT1-inducible-signaling pathway 
protein 3 
WT Wildtype 
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Reactive changes in optic nerve astrocytes are mediated by TGFβ2, CTGF and 
increasing substratum stiffness 
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active participation with poster; Title of poster: Reactive changes in optic nerve 
astrocytes are mediated by TGFβ2, CTGF and increasing substratum stiffness 
• 32. Arbeitstagung der Anatomischen Gesellschaft 2017, Würzburg, Germany; 
active participation with talk; Title of talk: Reactive changes in murine optic nerve 
astrocytes are mediated by growth factors and increasing substratum stiffness 
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